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Abstract 
Vaccination against porcine circovirus type 2 (PCV2) has become a standard practice to 
improve pig mortality and growth rate in PCV2-affected herds.  Unfortunately, there has been 
little field-based research evaluating factors which affect circovirus vaccination.  The focus of 
this research was on potential vaccination-affecting factors such as age, dosing strategy, pig 
genetic makeup, and interaction with other vaccines.  A total of 6,275 pigs were used to 
determine factors which affect circovirus vaccination and the effects of vaccination on average 
daily gain (ADG), immune responses, and viral circulation under field conditions.  In the first 
study evaluating circovirus vaccination effects on PCV2 antibody titer, regardless of age and 
dose administration protocol, pigs vaccinated with a 2-dose circovirus vaccine had increased (P 
≤ 0.008) antibody titers compared with non-vaccinates.  In a second study, dosing strategy failed 
(P = 0.31) to affect antibody titers.  However, product and time after vaccination did affect (P = 
0.005) antibody titers.  In another 130-d study across the nursery and finishing phases, pigs 
vaccinated with a 2-dose circovirus vaccine had decreased (P < 0.001) serum PCV2 viral load 
compared with non-vaccinates and ADG of vaccinates was better than non-vaccinates.  
However, the effect was more pronounced (vaccination-by-genetic interaction, P ≤ 0.05) in 
Duroc-based compared to Pietrain-based pigs.  In a study limited to the nursery phase, 
vaccination for PCV2 and Mycoplasma hyopneumoniae independently reduced ADG and 
consumption, but the effect was product-dependent.  In a 155-d study across the nursery and 
finishing phases, vaccination with a 2-dose, 2-vaccine program for PCV2 and Mycoplasma 
hyopneumoniae decreased (P < 0.001) nursery ADG but tended to increase (P = 0.06) finishing 
ADG compared to a 1-dose, 2-vaccine program, with no difference (P = 0.66) observed between 
final pig weights.  Finally, circovirus vaccination affected PCV2-circulation in high-health 
research herds but not in a commercial herd where PCV2 DNA was detected in the environment.  
These results indicate that finishing performance was improved by a 2-dose circovirus vaccine; 
however, nursery performance was negatively affected by the same product.  Circovirus 
vaccination responses of growth, viral load, and antibody titer were affected by pig genetic 
makeup, product, and PCV2-exposure status. 
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Abstract 
Vaccination against porcine circovirus type 2 (PCV2) has become a standard practice to 
improve pig mortality and growth rate in PCV2-affected herds.  Unfortunately, there has been 
little field-based research evaluating factors which affect circovirus vaccination.  The focus of 
this research was on potential vaccination-affecting factors such as age, dosing strategy, pig 
genetic makeup, and interaction with other vaccines.  A total of 6,275 pigs were used to 
determine factors which affect circovirus vaccination and the effects of vaccination on average 
daily gain (ADG), immune responses, and viral circulation under field conditions.  In the first 
study evaluating circovirus vaccination effects on PCV2 antibody titer, regardless of age and 
dose administration protocol, pigs vaccinated with a 2-dose circovirus vaccine had increased (P 
≤ 0.008) antibody titers compared with non-vaccinates.  In a second study, dosing strategy failed 
(P = 0.31) to affect antibody titers.  However, product and time after vaccination did affect (P = 
0.005) antibody titers.  In another 130-d study across the nursery and finishing phases, pigs 
vaccinated with a 2-dose circovirus vaccine had decreased (P < 0.001) serum PCV2 viral load 
compared with non-vaccinates and ADG of vaccinates was better than non-vaccinates.  
However, the effect was more pronounced (vaccination-by-genetic interaction, P ≤ 0.05) in 
Duroc-based compared to Pietrain-based pigs.  In a study limited to the nursery phase, 
vaccination for PCV2 and Mycoplasma hyopneumoniae independently reduced ADG and 
consumption, but the effect was product-dependent.  In a 155-d study across the nursery and 
finishing phases, vaccination with a 2-dose, 2-vaccine program for PCV2 and Mycoplasma 
hyopneumoniae decreased (P < 0.001) nursery ADG but tended to increase (P = 0.06) finishing 
ADG compared to a 1-dose, 2-vaccine program, with no difference (P = 0.66) observed between 
final pig weights.  Finally, circovirus vaccination affected PCV2-circulation in high-health 
research herds but not in a commercial herd where PCV2 DNA was detected in the environment.  
These results indicate that finishing performance was improved by a 2-dose circovirus vaccine; 
however, nursery performance was negatively affected by the same product.  Circovirus 
vaccination responses of growth, viral load, and antibody titer were affected by pig genetic 
makeup, product, and PCV2-exposure status. 
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CHAPTER 1 - A field evaluation of porcine circovirus type 2 
antibody production in pigs following circovirus vaccination using 
different vaccination strategies 
Summary 
Objective(s): To determine the effects of vaccination age, product, and dosing strategy on 
porcine circovirus type 2 (PCV2) indirect fluorescent antibody (IFA) titer and to determine 
important sources of variation when using the PCV2 IFA assay.  
 
Materials and methods:  In experiment one, 125 pigs were assigned to 1 of 4 vaccinated 
treatments or a non-vaccinated treatment (25 pigs per treatment).  Vaccinates received 
Circumvent PCV (Intervet/Schering-Plough Animal Health, Millsboro, DE) at 1 and 3 or 3 and 5 
wk of age, using either 2 mL or 1 mL per dose.   
In experiment two, 90 pigs (15 pigs per treatment) were vaccinated intramuscularly with 
different circovirus vaccines and dosing strategies.  Vaccine treatment designation were: (1) BI: 
CircoFLEX; Boehringer Ingelheim Vetmedica, Inc., St. Joseph, MO, (2) FD: Suvaxyn PCV2; 
Fort Dodge Animal Health, Fort Dodge, IA, or (3) IN: Circumvent PCV.  Dosing strategies 
were: (1) Full Dose: vaccinated at 3 wk (BI, FD, and IN) and 5 wk (IN only) of age with label 
dose (BI: 1 mL per dose, FD and IN: 2 mL per dose), or (2) Split Dose: vaccinated at 3 and 5 wk 
of age (BI: 0.5 mL per dose, FD and IN: 1 mL per dose).   
In experiment three, pigs and their dams were bled at weaning to determine on-farm and within-
laboratory sources of variation to consider when using a PCV2 IFA assay.   
 
Results: Experiment one results indicate that vaccination treatment affected (P < 0.001) PCV2 
IFA titer, but age at vaccination or dose did not affect (P ≥ 0.18) IFA titer. 
Experiment two results indicate that PCV2 IFA titer was affected (P = 0.005) by product and 
time but was not affected (P = 0.31) by dosing strategy. 
Experiment three results indicate that gender and laboratory factors were important sources of 
variation for PCV2 IFA testing.
 2 
Implications: Compared with non-vaccinated pigs, circovirus vaccination increased pig IFA 
titer regardless of vaccination age or dose amount.  Antibody response depended upon the 
vaccine used and sampling time.  Within-day and between-day laboratory factors were sources of 
variation for PCV2 IFA testing and should be considered during experimental design.  
 
Key words: antibody, circovirus, IFA, PCV2, swine, vaccine 
 
Circovirus vaccines can effectively reduce mortality and improve growth performance in 
immunized pigs (Horlen et al., 2008; Jacela et al., 2011).  In general, response to vaccination can 
be determined by an antibody increase following vaccination.  However, detection of an 
antibody rise does not always indicate protective immunity.  In contrast, a lack of antibody 
increase may not always indicate a lack of protective immunity.  Understanding diagnostic 
assays and their limitations and coupling results with clinical observations is important for 
determining efficacy of vaccine products.  Currently several diagnostic tests are performed to 
measure PCV2 antibody levels.  These tests include enzyme-linked immunosorbent assays 
(ELISA) and indirect fluorescent antibody (IFA) assays.  It has been reported that some level of 
maternal-derived, passively-acquired PCV2 antibody as measured by ELISA generally signified 
protection (Opriessnig et al., 2006) but not always (McKeown et al., 2005).  Therefore, some 
production systems have vaccinated pigs earlier than label directions with the intent to immunize 
pigs before pigs were naturally exposed to PCV2 field virus.  Also, some producers have adopted 
a half dose administration protocol to either reduce costs or to extend the vaccine supply across 
more pigs.  There are limited data concerning response to vaccination with different dose 
administration and timing strategies as well as with different circovirus vaccine products.  Thus, 
the objectives of these studies were to: (1) determine effects of vaccinating pigs at younger ages 
on PCV2 antibody response, (2) evaluate the effects of split dose, half dose, or full dose 
strategies on PCV2 IFA titers for different circovirus vaccines, and (3) determine important 
sources of variation to consider when designing studies using PCV2 IFA titer as a response 
criterion.
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Materials and Methods 
Procedures used in all 3 studies were approved by the Kansas State University 
Institutional Animal Care and Use Committee.  Experiments were performed in 3 different multi-
site production systems which had historically been PCV2-positive with evidence of clinical 
circoviral disease. 
In experiment one, a total of 125 pigs were used in a 17-wk trial to evaluate the effects of 
a 2-dose circovirus vaccine on antibody production.  Pigs were selected from 25 litters (5 pigs 
per litter) within a single farrowing group.  Pigs were randomly assigned within litters to 1 of 4 
vaccination treatments or a non-vaccinated control treatment.  Vaccinated treatments were 
arranged in a 2 × 2 factorial with factors of age at vaccination (Young or Old) and dose (Full or 
Half).  A single circovirus vaccine was used.  The circovirus vaccine was a killed, 2-dose, 
baculovirus-expressed, PCV2-capsid protein-derived vaccine (Circumvent PCV; 
Intervet/Schering-Plough, Millsboro, DE).  Vaccine was administered to pigs as an intramuscular 
injection in the neck according to 1 of 2 age treatments.  Age treatments were: (1) Young: 
vaccinated at 1 and 3 wk of age, or (2) Old: vaccinated at 3 and 5 wk of age.  All pigs allotted to 
any vaccinated treatment received 2-doses of circovirus vaccine; however, the amount 
administered was altered according to the dose treatment.  Pigs assigned to the Full treatment 
received 2 mL per dose while pigs assigned to the Half treatment received 1 mL per dose.  Pigs 
were bled at 3 (weaning), 9 (end-of-nursery), and 18 (mid-finishing) wk of age.  Serum was 
tested for PCV2 antibodies using the Kansas State Veterinary Diagnostic Laboratory (KSVDL) 
PCV2 IFA assay. 
In experiment two, a total of 90 pigs were used in a 20-wk trial to evaluate the effects of 
3 different circovirus vaccines and 2 different dosing strategies on PCV2 antibody production.  
Immediately after weaning, pigs were moved into a nursery with 24 pens and 25 to 27 pigs per 
pen.  From each of 6 pens, 15 pigs were randomly selected and assigned to 1 of 6 vaccine 
treatments in a balanced incomplete design so that pigs of different treatments were comingled in 
each pen.  The remaining pigs in the weaning group which were not placed on test were 
vaccinated with Circumvent PCV according to standard farm procedures.  Treatments were 
arranged in a 3 × 2 factorial with vaccine product and dosing strategy as the factors for 
evaluation.  Vaccine treatment designations were: (1) BI: CircoFLEX; Boehringer Ingelheim 
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Vetmedica, Inc., St. Joseph, MO, (2) FD: Suvaxyn PCV2; Fort Dodge Animal Health, Fort 
Dodge, IA, and (3) IN: Circumvent PCV; Intervet/Schering-Plough, Millsboro, DE.  At the time 
of the study, vaccines were labeled as either a 1-dose product (BI and FD) or a 2-dose product 
(IN).  Both BI and IN vaccines were baculovirus-expressed, PCV2-capsid protein-derived 
vaccines while the FD vaccine was a chimeric vaccine derived from PCV1 and PCV2.  All 
vaccines were administered as intramuscular injections in the neck; however, the volume 
administered varied with dosing strategy (Full Dose or Split Dose).  Pigs assigned to the Full 
Dose treatment received each product according to label dose (BI: 1 mL administered at 3 wk of 
age, FD: 2 mL administered at 3 wk of age, and IN: 2 mL per dose administered at 3 and 5 wk of 
age).  Pigs assigned to the Split Dose treatment had volumes split over 2 doses given at 3 and 5 
wk of age (BI: 0.5 mL per dose, FD: 1 mL per dose, and IN: 1 mL per dose).  The Split Dose 
treatment protocol resulted in the pigs assigned to the IN-Split Dose treatment receiving half of 
the total vaccine label volume while pigs in the FD-Split Dose and the BI-Split Dose treatments 
received the total 1-dose administration label volume but split into 2 doses.  Pigs were bled at 3 
(weaning), 5, 11, and 23 wk of age and serum samples were tested for PCV2 antibodies using the 
KSVDL PCV2 IFA assay. 
In experiment three, a total of 312 pigs (17 to 24 d of age) were used to characterize 
passively-acquired, maternal-derived antibody levels in offspring from first parity dams.  A total 
of 146 barrows and 166 gilts were included which represented 52 litters over 4 consecutive wk of 
farrowing (13 randomly selected litters per wk).  If available, a total of 3 barrows and 3 gilts 
from each litter were randomly selected and bled at weaning to measure PCV2 antibody levels.  
If there were less than 3 barrows or gilts available from a litter, then additional barrows or gilts 
were selected to ensure 6 pigs from each litter were bled.  There were 9 litters with less than 3 
barrows and 3 litters with less than 3 gilts available.  There was one litter that had an extra gilt 
sampled and tested while a different litter had 1 less gilt sample tested due to serum tube 
breakage during mail transport.  Serum was collected from the dams at the same time their pigs 
were bled.  Dams in this system were vaccinated at 5 and 8 wk of age with Circumvent PCV (2 
mL per dose) and once with Circumvent PCV (2 mL dose) during gilt-development at 27 wk of 
age.  In addition to characterizing PCV2 antibody levels in the weaned pigs, both on-farm and 
within laboratory factors were identified as sources of variation during PCV2 IFA testing.  This 
was achieved by performing IFA testing of the 312 weanling pig serum samples using a 
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crossover-type study design across 6 days of laboratory testing with 52 samples (1 pig from each 
litter with a total of 24 or 25 barrow and 27 or 28 gilt samples) tested per day.  This design 
allowed measurement of the effects of gender and weaning wk as well as laboratory conditions 
such as IFA day and sample replication. Replication indicated the order of serum loading (first 
dispense or second) for the initial dilution when using an electronic, programmable pipette and 
running duplicate tests.  To load the pipette, a total of 20 µl was drawn into the pipette tip and 
the first dispense of 10 µl was considered replication 1 and the second dispense of 10 µl, which 
emptied the tip, was considered replication 2. 
Diagnostic testing:   
Antibodies against PCV2 were detected using the KSVDL IFA assay.  Diagnostic testing 
methods were accepted and validated according to the American Association of Veterinary 
Laboratory Diagnosticians’ standard requirements necessary for diagnostic laboratory 
accreditation.  Antigen for the IFA assay was obtained by infecting ST cells with a low passage 
PCV2b virus.  The cells were fixed in 80% acetone after 3 days of incubation and plates were 
stored at -20ºC until use.  For each experiment, serum samples were held at -80ºC until all 
samples were collected at which point all serologic testing was performed. 
Serial 1:2 dilutions were performed for the assay beginning with a 1:20 serum to PBS 
dilution.  Plates were incubated for 1 hour at 37ºC and then washed 2 times with PBS.  Bound 
swine antibody was detected with FITC-conjugated goat anti-swine IgG (H+L) (Jackson 
ImmunoResearch Laboratory, West Grove, PA), diluted 1:75 in PBS with added Evan’s Blue 
Dye.  Plates were again incubated for 1 hour at 37ºC and then washed 2 times.  A 50% glycerol 
solution with PBS was added to each of the 96 wells.  All plates were viewed under a 
fluorescence microscope and titers were determined by a single trained technician.  Titration 
endpoints were calculated as the reciprocal of the last serum dilution that gave a positive 
fluorescence result. 
Statistical analysis:  
Prior to analysis, all IFA titers were log2 transformed to approximate a normal 
distribution of titers.  For the IFA analysis, the log2 of 10 was used when serum samples did not 
have PCV2 antibody detected at the most concentrated dilution (1:20).  The log2 of 5,120 was 
used when samples were strongly positive at the least concentrated dilution (1:2,560).  These 
methods allowed those low antibody level (< 1:20) or high antibody level (> 1:2,560) results to 
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be weighted differently than samples with normal-intensity fluorescence detected at dilutions of 
1:20 and 1:2,560.  Log2 transformed antibody titers were transformed back to the original scale 
for presentation as geometric mean titers. 
For experiment one, IFA data were analyzed by repeated measures analysis of variance 
using the MIXED procedure in SAS version 9.1.3 (SAS Institute Inc., Cary, NC) with pig as the 
experimental unit.  The model included fixed effects of vaccination treatment, time of sampling, 
and their interaction and a random effect of litter.  Differences among treatments were 
determined using least squares means (P < 0.05).  Single degree of freedom contrast statements 
were used to determine the main effects of age and dose on IFA titer. 
For experiment two, IFA data were analyzed by repeated measures analysis of variance 
using the MIXED procedure in SAS version 9.1.3 with pig as the experimental unit.  The model 
included fixed effects of vaccine treatment, dosing strategy, time of sampling, and their 
interactions.  Nursery pen was included as a random effect.  Differences between treatments 
were determined using least squares means (P < 0.05). 
For experiment three, factors were analyzed by analysis of variance using the GLIMMIX 
procedure in SAS version 9.1.3 in a 2 × 4 × 6 × 2 factorial arrangement with fixed factors of 
gender (barrow or gilt), weaning wk (1, 2, 3, or 4), IFA laboratory testing day (1, 2, 3, 4, 5, or 6), 
replication (replication 1: first pipette dispense or replication 2: second pipette dispense), and all 
interactions.  Litter was included as a random effect in the statistical model and pig was the 
experimental unit for analysis.  The F-tests reported by type 3 tests of fixed effects in SAS were 
used to determine significant sources of variation (P < 0.05) for weaned pig IFA titer. 
Results 
For experiment one, there was no interaction (P = 0.31; Figure 1.1) observed between 
vaccination treatment and time for PCV2 IFA titer.  In addition, there was no effect (P = 0.80) of 
sampling time for PCV2 IFA titer.  Vaccination treatment affected (P < 0.001; Figure 1.2) the 
mean PCV2 antibody titer with non-vaccinated control pigs having decreased (P ≤ 0.008) mean 
PCV2 antibody levels compared with any vaccinated pig treatment.  Also, there was no effect of 
age at vaccination (P = 0.95) or dose (P = 0.18) for overall PCV2 IFA titer. 
For experiment two, there was no 3-way interaction (P = 0.12; Figure 1.3) observed with 
vaccine treatment, dosing strategy, and time for IFA titer.  There were no 2-way interactions 
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between dosing strategy and time (P = 0.46) or vaccine treatment and dosing strategy (P = 0.15) 
observed for IFA titer.  There was a 2-way interaction (P = 0.005; Figure 1.4) between vaccine 
treatment and time observed for IFA titer.  This interaction was the result of pigs vaccinated with 
IN vaccine having increased (P ≤ 0.04) antibody levels at 3 and 5 wk of age compared with pigs 
vaccinated with BI vaccine with antibody levels of pigs vaccinated with FD vaccine 
intermediate.  At 11 and 23 wk of age, pigs vaccinated with IN vaccine had increased (P ≤ 
0.004) antibody levels compared with pigs vaccinated with either BI or FD vaccines.  As 
measured by the KSVDL PCV2 IFA assay, pigs vaccinated with BI or FD products did not 
demonstrate any PCV2 antibody increase by 11 or 23 wk of age.  Thus, the magnitude of 
antibody response at 11 and 23 wk of age was greater for pigs vaccinated with IN vaccine than 
for pigs vaccinated with either BI or FD vaccine.  Vaccine dosing strategy did not affect (P = 
0.31) PCV2 antibody levels. 
For experiment three, the distribution of PCV2 IFA titers from the 52 first parity dams 
sampled at the time their pigs were weaned was determined (Figure 1.5).  The titers of the dams 
ranged from 80 to greater than 2,560.  Regression analysis of the weanling pig IFA titers with the 
sow IFA titers indicated that sow antibody titer could explain approximately 37% of the variation 
associated with the pig IFA titer data (data not shown).  For the multivariable model of pig IFA 
titer, there were no 4-way or 3-way interactions (P ≥ 0.84; Table 1.1) with gender, weaning wk, 
IFA laboratory testing day, or replication for IFA titer.  There were 2-way interactions between 
gender and IFA day (P = 0.02) and IFA day and replication (P = 0.03; Figure 1.6) observed for 
IFA titer.  There was a trend for a 2-way interaction between gender and wean wk (P = 0.06; 
Figure 1.7) for IFA titer.  There were no other 2-way interactions (P ≥ 0.19) observed for IFA 
titer.  Though also included in higher order interactions, IFA day and replication were highly 
significant (P < 0.001) as individual effects.  In addition, litter accounted for approximately 50% 
of the variability which was not explained by the fixed effects (gender, weaning wk, IFA 
laboratory testing day, replication, and their interactions) in the model for weaned pig IFA titer.   
Discussion 
Since introduction of commercial circovirus vaccines, veterinarians and producers have 
been developing vaccination protocols with the intent to maximize vaccine efficacy and optimize 
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return on investment.  In spite of manufacturers’ label recommendations, age at vaccination, dose 
volume, and dose administration strategy are not consistent between production systems.   
Field reports have suggested that high levels of passively-acquired PCV2 antibody 
interfered with circovirus vaccination and led to a poorer response to vaccination.  Despite these 
reports, results from several studies do not support these suggestions.  Horlen et al. (2008) 
reported increases in antibody titers after vaccination of pigs which were seropositive at the time 
of first vaccination with a 2-dose circovirus vaccine (Circumvent PCV) (Horlen et al., 2008).  
Fachinger et al. (2008) reported that vaccinating pigs with a 1-dose circovirus vaccine 
(CircoFLEX) when passively-acquired antibody levels were greater than 1:1,000 compared with 
vaccinating pigs when passively-acquired antibody levels less than 1:1,000 resulted in similar 
average daily gains.  When comparing vaccinated pigs from both antibody level treatments to 
non-vaccinated pigs in similar antibody categories, average daily gains were increased for 
vaccinated pigs compared with controls (Fachinger et al., 2008).   
Using the same 1-dose circovirus vaccine (CircoFLEX), Kixmöller et al. (2008) reported 
that level of passively-acquired antibody at the time of vaccination (IFA titer categories: less 
than 1:100, 1:100 to 1:1,000, greater than 1:1,000) did not affect overall PCV2 viremia reduction 
associated with circovirus vaccination under field conditions.  However, increased concentration 
of passively-acquired antibody did delay onset of infection and lower overall viral load levels 
(Kixmöller et al., 2008).  Determining that maternal-derived antibody delayed onset of infection 
suggested these passively-acquired antibodies provided some protection.  These findings also 
supported research conclusions from McKeown et al. (2005) who reported that protection was 
dependent upon maternal-derived antibody level as determined by ELISA testing.  In their study, 
high antibody levels were generally protective while low levels were not protective against 
experimental PCV2 infection (McKeown et al., 2005).   
While passively-acquired, maternally-derived PCV2 antibody has been determined to 
provide some protection against PCV2 infection, some field reports also suggest that maternal-
derived antibody inhibits response to some vaccines.  However, association with a reduction in 
vaccine efficacy has not been reliably demonstrated under experimental PCV2-challenge.   
Opriessnig et al. (2010) reported that vaccination of dams with 2 doses (off-label usage; 1 
mL per dose) of a 1-dose circovirus vaccine (CircoFLEX) followed by vaccination of pigs with 
the 1 dose of the same product (1 mL per dose) resulted in no difference after PCV2 challenge 
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for antibody or serum viral load levels in pigs vaccinated and born of vaccinated dams compared 
with those of pigs vaccinated and born of non-vaccinated dams.  Similar results were obtained 
when they performed similar procedures using Circovac (Merial, Lyon, France), a 2-dose (2 mL 
per dose) circovirus vaccine labeled in some countries (not the United States) for use on breeding 
animals (Opriessnig et al., 2010).   
In a different challenge study, Opriessnig et al. (2008) demonstrated that vaccination with 
a 1-dose circovirus vaccine (Suvaxyn PCV2) in the presence of passively-acquired PCV2 
antibody (positive indicating ELISA S/P ratios were equal to or greater than 0.300) resulted in 
similar viral load and histopathologic lesion reduction compared with responses of pigs 
vaccinated without presence of passively-acquired antibody (negative indicating ELISA S/P 
ratios less than 0.300).  In the same study, pigs with passively-acquired antibody present at the 
time of vaccination had reduced severity of microscopic lymphoid lesions and lower PCV2 viral 
load compared with non-vaccinated pigs also having the presence of passively-acquired PCV2 
antibody.  This resulted in the conclusion that vaccination was not affected by presence of 
passively-acquired, maternal-derived PCV2 antibody at the time of vaccination (Opriessnig et 
al., 2008).   
In a different study, vaccination with a 2-dose circovirus vaccine (Circumvent PCV) led 
to improvements in growth performance and mortality compared with non-vaccinated control 
pigs (Jacela et al., 2011).  Using a PCV2 ELISA assay, there was demonstrable PCV2 antibody 
present in both the control (S/P ratio = 0.485) and vaccinated (S/P ratio = 0.364) pig serum at the 
time of vaccination.  This suggests that despite vaccinating pigs with maternal-derived PCV2 
antibodies, improvements are still achieved with vaccination.  They concluded vaccine was 
effective despite the presence of passively-acquired PCV2 antibodies (Jacela et al., 2011). 
Results from experiment one indicate that age did not affect mean antibody titer 
suggesting that a similar antibody level was achieved by pigs vaccinated at 1 wk of age or at the 
label recommended timing of 3 wk of age.  It was not known in this study what the passively-
acquired antibody levels were in the pigs vaccinated at 1 wk of age, but it would be assumed that 
they were similar to or higher than those observed for pigs at 3 wk of age.  Regardless, results of 
our study indicate that overall antibody response to vaccination did not differ between pigs of 
different ages at vaccination.  The lack of an interaction between treatment and wk indicates that 
antibody responses did not differ over time for the different treatments.  However, vaccination 
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treatment affected the mean antibody level (Figure 1.2) as pigs from any vaccinated treatment 
had an increased mean antibody level compared with that of the non-vaccinated control pigs 
under conditions where, based on the antibody response for the control treatment, there appeared 
to be little exposure to field-strain PCV2 virus.   
Although for both experiments one and two there were patterns in PCV2 antibody 
response which were suggestive of differences due to dose of vaccine, there was no effect of 
dose or dosing strategy detected for overall IFA titer.  In experiment two, there were no 
interactions observed between dosing strategy and age or dosing strategy and vaccine treatment 
for PCV2 IFA titer.  Dosing strategy also did not affect the overall antibody titer.  Thus, for 
experiment two, antibody response to circovirus vaccination did not vary with dosing strategy to 
the extent it depended on vaccine product and time of sampling.  Pigs vaccinated with 
Circumvent PCV had a detectable rise in antibody level by 11 wk of age while pigs vaccinated 
with CircoFLEX and Suvaxyn PCV2 did not have a detectable rise in antibody by any of the 3 
post-vaccination sampling times (5, 11, or 23 wk of age; Figure 1.4).  The severity of clinical 
circoviral disease experienced in this commercial herd, prior to the introduction of circovirus 
vaccines, deterred the use of a non-circovirus-vaccinated treatment as a control in our study.  
However, we believe the rise in antibody titer observed for the Circumvent PCV treatment was 
due to vaccination and not a result of natural PCV2 infection.  If natural PCV2 exposure had 
occurred, a rise in antibody titer following natural viral exposure would have been expected in 
the CircoFLEX and Suvaxyn PCV2-vaccinated pigs because of an anamnestic response.  In 
addition, there was no evidence of clinical circoviral disease observed during our trial.  Thus, 
under conditions where there appeared to be little challenge from field strain PCV2 virus, 
antibody responses depended upon the vaccine product used but not necessarily the dosing 
strategy. 
Regardless of the product used in our study, decay in antibody levels was apparent by 23 
wk of age.  In general, gilts are bred once they weigh 136 kg and gestation is approximately 16.5 
wk long.  With PCV2 antibody levels and decay similar to those observed in our study, when the 
time to breeding and subsequent gestation is considered, the amount of vaccine-induced antibody 
that would be passively transferred to piglets would be low.  Therefore, if increased levels of 
vaccine-induced antibody in colostrum are desired then it may be necessary to administer a 
booster vaccine to breeding age females. 
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Although by 23 wk, a decreased in antibody levels was evident in pigs regardless of the 
vaccine used, the antibody responses in the 11 wk following vaccination in our study differed 
from those reported by Opriessnig et al. (2009).  Comparing Circumvent PCV (2 doses; 2 mL per 
dose), Suvaxyn PCV2 (1 dose of 2 mL), Suvaxyn PCV2 (2 doses; 1 mL per dose), and 
CircoFLEX (1 dose of 1 mL) in a PCV2-challenge model and testing for PCV2 antibodies using 
an ELISA assay, they reported significant differences in antibody response at 7.5 wk of age for 
1-dose compared with 2-dose products.  Pigs receiving 1-dose products at 3.5 wk of age had a 
reduced antibody response compared with pigs receiving 2-dose products administered at 3.5 and 
6.5 wk of age.  These differences disappeared by 12.5 wk of age (Opriessnig et al., 2009).  
However, prior to this time, vaccination with any circovirus vaccine product produced a rise in 
antibody levels.  It is unknown why, under experimental conditions and testing for antibody 
using an ELISA test, the circovirus vaccines tested resulted in increased antibody production 
while in our study, under field conditions and testing for antibody using an IFA assay, pigs 
vaccinated with Suvaxyn PCV2 or CircoFLEX failed to have a detectable rise in antibody levels.  
There are little published data comparing PCV2 antibody assays or describing sources of 
variation to consider when performing or analyzing these tests.  There have been comparisons of 
PCV2 ELISA and polymerase chain reaction (PCR) tests performed to evaluate test-to-test or 
laboratory-to-laboratory differences (Harding et al., 2009; Patterson et al., 2008); however, 
limited research has evaluated within-assay sources of variation.  Results from experiment three 
indicate that gender had a tendency to affect antibody levels at weaning and should be 
considered during the design of trials involving IFA testing.  There was a strong litter effect for 
PCV2 IFA titer of pigs which should be considered when designing trials.  Approximately 50% 
of the variability not explained by the fixed effects in the statistical model was explained by the 
litter effect.  This strongly suggests that litter-to-litter effects should be considered when 
selecting animals for use in a PCV2 antibody study because it appeared that the within-litter 
variation tended to be less than or equal to the between-litter variation.  Thus, selecting multiple 
pigs from a single litter and placing more of them on one treatment than another may reduce 
variation associated with the treatment with a higher percentage of littermates and lead to 
detection of differences which may not be true (Type 1 error).  Therefore, it is important to 
represent litters equally among treatments to avoid drawing false conclusions.  In contrast, if the 
effects of litter are not accounted for in the experimental design and analysis, the variation not 
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explained by the fixed or random effects could increase and result in the failure to detect true 
treatment differences (Type 2 error) and require increased sample sizes to detect significant 
treatment effects.   
Results from our third experiment indicate that experimental control should not conclude 
at the field level.  The farm level litter of origin, gender, and potentially wean wk were all 
important sources of variation to consider during experimental design; however, sources of 
variation (IFA testing day and replication) also extended into the diagnostic laboratory.  
Although not a testable factor in our study, changing technicians within a study could add 
another source of variation for IFA testing because of the level of subjectivity in determining 
level of fluorescence.  Of other factors identified as potential sources of variability, replication 
and IFA day explained a significant amount of variability.  In our study, IFA day likely 
represented several factors, one of which was batch of IFA plates.  A different batch of plates 
was used on days 4 and 5 and it appeared the IFA test results obtained on those 2 days were 
lower than on other days (Figure 1.6).  Therefore, we believe that performing testing on serial 
samples not only within a day but also within a batch of plates is important.  If serial samples are 
tested on different days for a single animal then false increases or decreases in antibody titers 
may be observed depending on laboratory conditions and materials.  In randomized trials with 
different treatments, it is important to distribute the number of samples from the treatments 
across the days of testing so every testing day has equal representation across treatments.  
For our experiment, replication also explained a significant amount of variation.  
Although the source of this variation was not known, when performing tests in duplicate and in a 
manner similar to the procedures used in our study, comparing results within replication or 
dispense order is important.  
Laboratory techniques which have potential to influence results must be identified 
because accuracy of diagnostic tests and research results depend upon these procedures.  In a 
research trial, running serial samples for individual pigs on a single IFA plate and blocking by 
testing day would help to account for some of this explainable variation.   
If it is not possible to control within-day and between-day laboratory effects for the IFA 
testing procedures, then these factors should be documented and included in the statistical model 
to determine whether they had a significant effect on the measured response.  Identification of 
conditions under which the responses were different would be important to interpretation and 
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comparison of IFA testing results.  Recognizing that IFA results vary based on many factors 
makes it critical for veterinary clinicians to become actively involved in the diagnostic testing 
process in order to understand the procedures which occur in the laboratory and to be aware of 
the limitations of a diagnostic test.  
Results from our studies indicate that, regardless of age at administration or dose, there 
were differences in antibody responses to circovirus vaccination compared with non-vaccinated 
pigs.  In addition, antibody responses as measured by IFA assay to vaccination were product-
dependent.  Furthermore, our results indicate that IFA testing day, replication, litter of origin, 
gender, and potentially weaning wk all affect pig IFA titers and are important factors to consider 
when designing an experiment with IFA titer as a response variable. 
Implications 
 Circovirus vaccine administration strategy increased geometric mean IFA titer in 
vaccinated pigs regardless of age at injection or dose amount compared with pigs not 
vaccinated.   
 PCV2 antibody response depended on both circovirus vaccine and time of sampling.   
 When performing IFA assays within the diagnostic laboratory, both within-day and 
between-day variation affected results of PCV2 IFA testing.  When designing 
experiments, day of IFA testing, replication, litter of origin, gender, and wean wk were 
important and should be considered as sources of variation for IFA testing.   
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Figure 1.1  Indirect fluorescent antibody (IFA) geometric mean titers (GMT) at 3, 9, and 18 
wk of age for pigs of different vaccination treatments (Exp. 1).   
A total of 125 pigs were randomly assigned within litter (5 pigs per litter) to 1 of 4 
vaccination treatments or a non-vaccinated control.  Vaccination treatments consisted of different 
vaccine doses and ages at administration.  The doses of circovirus vaccine (Circumvent PCV; 
Intervet/Schering-Plough Animal Health, Millsboro, DE) were: (1) Full: 2 mL per dose 
administered twice, (2) Half: 1 mL per dose administered twice.  The ages at vaccination were: 
(1) Young: 1 and 3 wk of age; or (2) Old: 3 and 5 wk of age.  Serum was collected at 3, 9, and 18 
wk of age and tested for antibody by porcine circovirus type 2 IFA assay.  Log2 transformed 
individual pig IFA data were analyzed by repeated measures analysis of variance using the 
MIXED procedure of SAS version 9.1.3 (SAS Institute Inc., Cary, NC).  The model included 
fixed effects of treatment, time of sampling, and their interaction and a random effect of litter.  
Resulting means were transformed back to the original scale for presentation as GMT. 
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Figure 1.2  Average indirect fluorescent antibody (IFA) geometric mean titers (GMT) for 
pigs of different vaccination treatments (Exp. 1). 
A total of 125 pigs were randomly assigned within litter (5 pigs per litter) to 1 of 4 
vaccination treatments or a non-vaccinated control.  Vaccination treatments consisted of different 
vaccine doses and ages at administration.  The doses of circovirus vaccine (Circumvent PCV; 
Intervet/Schering-Plough Animal Health, Millsboro, DE) were: (1) Full: 2 mL per dose 
administered twice, (2) Half: 1 mL per dose administered twice.  The ages at vaccination were: 
(1) Young: 1 and 3 wk of age; or (2) Old: 3 and 5 wk of age.  Serum was collected at 3, 9, and 18 
wk of age and tested for antibody by porcine circovirus type 2 IFA assay.  Log2 transformed 
individual pig IFA data were analyzed by repeated measures analysis of variance using the 
MIXED procedure of SAS version 9.1.3 (SAS Institute Inc., Cary, NC).  The model included 
fixed effects of treatment, time of sampling, and their interaction and a random effect of litter.  
Resulting means were transformed back to the original scale for presentation as GMT. 
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Figure 1.3  Indirect fluorescent antibody (IFA) geometric mean titers (GMT) at 3, 5, 11, 
and 23 wk of age for pigs administered different circovirus vaccines using different dosing 
strategies (Exp. 2). 
A total of 90 pigs (15 randomly selected pigs in each of 6 pens) were assigned to 1 of 6 
vaccination treatments with 3 pens containing 2 treatment replicates and 3 pens containing 3 
replicates.  Vaccination treatments consisted of different circovirus vaccines and dosing 
strategies.  Vaccine treatment designations were: (1) BI: CircoFLEX; Boehringer Ingelheim 
Vetmedica, Inc., St. Joseph, MO, (2) FD: Suvaxyn PCV2; Fort Dodge Animal Health, Fort 
Dodge, IA, and (3) IN: Circumvent PCV; Intervet/Schering-Plough, Millsboro, DE.  Dosing 
strategies were: (1) Full Dose (BI: 1 mL administered at 3 wk of age; FD: 2 mL administered at 
3 wk of age; and IN: 2 mL per dose administered at 3 and 5 wk of age), or (2) Split Dose (BI: 0.5 
mL per dose administered at 3 and 5 wk of age, FD: 1 mL per dose administered at 3 and 5 wk of 
age, and IN: 1 mL per dose administered at 3 and 5 wk of age).  Pigs were bled at 3, 5, 11, and 
23 wk of age and antibody levels were determined in serum samples using a porcine circovirus 
type 2 IFA assay.  Individual pig IFA data were log2 transformed and then were analyzed by 
repeated measures analysis of variance using the MIXED procedure in SAS version 9.1.3 (SAS 
Institute Inc., Cary, NC) with pig as the experimental unit.  The model included fixed effects of 
vaccination treatment, dosing strategy, time of sampling, and their interactions.  Nursery pen was 
included as a random effect.  Resulting means were transformed back to the original scale for 
presentation as GMT. 
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Figure 1.4  Indirect fluorescent antibody (IFA) geometric mean titers (GMT) at 3, 5, 11, 
and 23 wk of age for pigs administered different circovirus vaccines (Exp. 2). 
A total of 90 pigs (15 randomly selected pigs in each of 6 pens) were assigned to 1 of 6 
vaccination treatments with 3 pens containing 2 treatment replicates and 3 pens containing 3 
replicates.  Vaccination treatments consisted of different circovirus vaccines and dosing 
strategies (Full or Split Dose).  Vaccine treatment designations were: (1) BI: CircoFLEX; 
Boehringer Ingelheim Vetmedica, Inc., St. Joseph, MO, (2) FD: Suvaxyn PCV2; Fort Dodge 
Animal Health, Fort Dodge, IA, and (3) IN: Circumvent PCV; Intervet/Schering-Plough, 
Millsboro, DE.  Pigs were bled at 3, 5, 11, and 23 wk of age and antibody levels were determined 
in serum samples using a porcine circovirus type 2 IFA assay.  Individual pig IFA data were log2 
transformed and then were analyzed by repeated measures analysis of variance using the MIXED 
procedure in SAS version 9.1.3 (SAS Institute Inc., Cary, NC) with pig as the experimental unit.  
The model included fixed effects of vaccination treatment, dosing strategy, time of sampling, and 
their interactions.  Nursery pen was included as a random effect.  Resulting means were 
transformed back to the original scale for presentation as GMT. 
Treatment × Time: P = 0.005 
a,b,c,d,e,f,g,h
 P < 0.05  
g
37
ed
289
ed
397
bc
629
g
48
e
307
cd
497
ab
860
f
122
a
1208
bc
807
a
1187
0
500
1000
1500
2000
3 5 11 23
Age, weeks
G
M
T
BI FD IN
 21 
Figure 1.5  Distribution of porcine circovirus type 2 (PCV2) indirect fluorescent antibody 
(IFA) titers from circovirus-vaccinated first parity sows (Exp. 3). 
A total of 52 first parity sows (13 sows per wk over 4 consecutive wk) were randomly 
selected at the time of weaning and had serum collected and tested by PCV2 IFA assay.  In this 
commercial production system, sows were vaccinated as pigs at 5 and 8 wk of age with 
Circumvent PCV (2 mL per dose; Intervet/Schering-Plough Animal Health, Millsboro, DE) and 
once with Circumvent PCV (2 mL dose) during gilt-development at 27 wk of age.   
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Figure 1.6  Indirect fluorescent antibody (IFA) geometric mean titers (GMT) of serum 
samples of weanling pigs tested over 6 days with 2 replications per sample (Exp. 3). 
A total of 312 weanling pigs (146 barrows and 166 gilts) were sampled from 52 litters 
over 4 wk (13 litters per wk).  On-farm and within laboratory factors were evaluated as sources 
of variation in PCV2 IFA testing.  On-farm factors evaluated were gender (barrow or gilt) and 
weaning wk (1, 2, 3, or 4).  Laboratory factors evaluated were IFA testing day (1, 2, 3, 4, 5, and 
6) and sample replication. Replication indicated the dispensing order of serum (first dispense or 
second) from an electronic, programmable pipette for the initial dilution of the IFA testing 
procedure.  Individual pig IFA titers were log2 transformed and analyzed by analysis of variance 
using the GLIMMIX procedure in SAS version 9.1.3 (SAS Institute Inc., Cary, NC).  The model 
used included fixed effects of gender, weaning wk, IFA testing day, replication, and all 
interactions.  Litter was included as a random effect in the model.  Resulting means were 
transformed back to the original scale for presentation as GMT. 
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Figure 1.7  Indirect fluorescent antibody (IFA) geometric mean titers (GMT) of serum 
samples of weanling pigs collected over 4 wean weeks (Exp. 3). 
A total of 312 weanling pigs (146 barrows and 166 gilts) were sampled from 52 litters 
over 4 wk (13 litters per wk).  On-farm and within laboratory factors were evaluated as sources 
of variation in PCV2 IFA testing.  On-farm factors evaluated were gender (barrow or gilt) and 
weaning wk (1, 2, 3, or 4).  Laboratory factors evaluated were IFA testing day (1, 2, 3, 4, 5, and 
6) and sample replication (first dispense or second dispense of serum from an electronic, 
programmable pipette during the dilution procedure).  Individual pig IFA titers were log2 
transformed and analyzed by analysis of variance using the GLIMMIX procedure in SAS version 
9.1.3 (SAS Institute Inc., Cary, NC).  The model used included fixed effects of gender, weaning 
wk, IFA testing day, replication, and all interactions.  Litter was included as a random effect in 
the model.  Resulting means were transformed back to the original scale for presentation as 
GMT. 
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Table 1.1  Factors evaluated for their effects on pig indirect fluorescent antibody (IFA) 
testing (Exp. 3) 
Fixed effect
1-4
 F Value Probability, P < 
Gender × Week × IFA day × Replication 0.39 0.98 
Gender × Week × IFA day 0.64 0.84 
Gender × Week × Replication 0.16 0.92 
Gender × IFA day × Replication 0.27 0.93 
Week × IFA day × Replication 0.35 0.99 
Gender × Week 2.44 0.06 
Gender × IFA day 2.63 0.02 
Week × IFA day 1.30 0.19 
Gender × Replication 0.03 0.86 
Week × Replication 0.17 0.92 
IFA day × Replication 2.46 0.03 
Gender 3.64 0.06 
Week 1.64 0.19 
IFA day 28.66 <0.001 
Replication 28.70 <0.001 
Note: The type 3 test of fixed effects in SAS version 9.1.3 (SAS Institute Inc., Cary, NC) was 
used to obtain these values.
 
1
 Gender was either barrow or gilt. 
2
 Week indicates the wk of weaning for sampling. 
3
 IFA day indicates the day of IFA testing in the laboratory. 
4
 Replication indicates the order of serum loading (first dispense or second) for initial dilution 
when using an electronic, programmable pipette and running duplicate tests. 
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CHAPTER 2 - Genetic makeup influences pig growth rate responses 
to vaccination for porcine circovirus type 2 
Summary 
Objective(s): The objective of this field study was to compare the effect of vaccination for 
porcine circovirus type 2 (PCV2) on the growth rate of pigs with different genetic makeup in a 
high-health herd.  
 
Materials and methods: A total of 454 weanling pigs (20.6 ± 1.98 d of age; 6.1 ± 1.27 kg BW) 
were used in a 130-d trial performed at a genetic multiplication farm in Kansas to determine the 
effect of circovirus vaccination on growth performance of boars and gilts of different genetic 
makeup.  Genetic designations were: A×A (Duroc genotype), B×B (synthetic White Pietrain 
genotype), A×B, and B×A.  Pigs were ranked by birth weight within litter and gender and 
randomly assigned to vaccination treatments (vaccinated or non-vaccinated control).  Pigs 
allotted to the vaccinated treatment received 2 doses (2 mL per dose, intramuscular injection) of 
a circovirus vaccine (Circumvent PCV; Intervet/Schering-Plough Animal Health, Millsboro, DE) 
at 3 and 5 wk of age.  Control pigs were comingled with vaccinated pigs throughout the trial.  
Serum was collected from all pigs on d 0 (weaning), d 40 (end of nursery period), and d 130 (off-
test; approximately 150 d of age) to determine PCV2 viral load and antibody levels.  Pigs were 
individually weighed at these time points to measure ADG.  Measurements of loin and backfat 
depths were collected by real-time ultrasound at off-test.  Data were analyzed on 417 pigs with 
complete growth records at off-test. 
 
Results: Interactions (P ≤ 0.05) between genetic makeup and vaccination treatment were 
observed for d 0 to 40, 40 to 130, and d 0 to 130 growth rates.  On d 130, pigs vaccinated with 
the circovirus vaccine were heavier (genetic makeup-by-vaccination treatment interaction: P = 
0.05) than controls.  However, the magnitude of the mean weight difference between vaccinated 
and control pigs was almost 4 times greater in the A×A pigs than in the B×B pigs with A×B and 
B×A having intermediate weight differences.  Thus, the growth response to circovirus 
vaccination was increased in the A×A population relative to the B×B population. Vaccination 
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reduced (P < 0.001) serum PCV2 viral load levels of vaccinated pigs compared with controls on 
both d 40 and d 130.   
 
Implications: Pig genetic makeup affects growth rate response to circovirus vaccination and 
should be considered a risk factor for PCVD expression. 
 
Key words: circovirus, genetics, growth, PCV2, vaccine 
 
The etiologic agent of porcine circoviral disease (PCVD) (Allan and Ellis, 2000) is 
porcine circovirus type 2 (PCV2).  Risk factors for the development of PCVD include concurrent 
viral or bacterial infections, management factors (Rose et al., 2003), gender, as well as genetics.  
In one study, Landrace pigs were at increased risk for developing clinical PCVD when compared 
with Duroc or Large White pigs (Opriessnig et al., 2006).  In another study, there were 
differences in postweaning mortality between pigs from Pietrain, Large White × Pietrain, and 
Large White × Duroc lines with many mortalities having lesions consistent with PCVD (López-
Soria et al., 2004).  In contrast, yet another study failed to detect differences in PCVD-attributed 
mortality when comparing offspring sired by either Pietrain boars or boars less than 50% Pietrain 
(Rose et al., 2005).  The results from these studies support speculation that varying degrees of 
genetic susceptibility to PCV2 infection or expression of PCVD may exist.  Widespread 
availability of circovirus vaccines, documented to be effective in reducing mortality and 
increasing pig growth rate (Horlen et al., 2008), has promoted research efforts to determine the 
consistency and the magnitude of the effect from circovirus immunization. The limited reports of 
interaction between genetic background and PCVD expression provoke questions regarding the 
impact of response to circovirus immunization between differing genetic makeups.  The focus of 
this study was to compare circovirus vaccination of two genetic populations and their crosses in 
a high-health herd using growth rate as a measure of vaccination response. 
Materials and Methods 
Procedures used in this field trial were approved by the Kansas State University 
Institutional Animal Care and Use Committee.  This 130-d study was performed in a 1,700-sow 
genetic multiplication farm in Kansas.  This farm was of a high-health status, being porcine 
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reproductive and respiratory syndrome virus negative and without evidence of Mycoplasma 
hyopneumoniae infection since stocking in 2000.  In 2006, an increase in morbidity characterized 
by ill-thrift was observed.  Histopathology lesions and gross clinical lesions consistent with 
PCVD were documented, and immunohistochemistry staining for PCV2 antigen and polymerase 
chain reaction (PCR) differentiation of the PCV2 genotype confirmed the presence of PCV2b.   
This study utilized pigs born over a 7 d period.  At birth, all pigs from 72 litters (662 pigs 
total) were weighed and identified by a unique ear-tag number.  As this field study was 
performed in a boar multiplication farm, 128 pigs were eliminated because of low estimated 
breeding values or genetic defects.  In addition, there were 57 pre-weaning deaths and 23 light-
weight pigs which were held back at the time of weaning and thus not included in the study.   
A total of 454 weanling pigs (20.6 ± 1.98 d of age; 6.1 ± 1.27 kg BW) representing 55 
litters from the 4 genetic populations were ranked by birth weight within litter and gender (boar 
or gilt) and randomly assigned to vaccination treatments (vaccinated or non-vaccinated control).  
Genetic designations were: pure-lines of A×A (Duroc genotype) and B×B (synthetic White 
Pietrain genotype) and crossbreds A×B (Duroc sire × synthetic White Pietrain dam) and B×A 
(synthetic White Pietrain sire × Duroc dam).  The circovirus vaccine administered to pigs 
assigned to the vaccinated treatment was a killed, 2-dose vaccine (Circumvent PCV, 
Intervet/Schering-Plough Animal Health, Millsboro, DE). 
At weaning (d 0 of the trial) and again 2 wk later, pigs allotted to the vaccinated 
treatment were injected with the circovirus vaccine according to label dose and route of 
administration (2 mL per dose; IM injection).  In this farm, farrowing and finishing facilities 
were managed all-in, all-out by room; nursery rooms were filled over 2 wk and all-out.  All pigs 
on test were moved from the nursery rooms on d 40, were temporarily housed in a grower 
facility, and then moved to the finishing barn for the remainder of the trial.  Vaccinated and non-
vaccinated control pigs of the different genetic makeup were comingled in single-sex pens 
throughout the trial.   
Serum was collected from all pigs on d 0, 40, and 130 to determine PCV2 viral load in 
serum and PCV2 antibody titers.  Pigs were individually weighed at these time points to measure 
growth rate.  Due to time constraints as pigs were weighed off test, 17% of the pigs (40 control 
pigs and 31 vaccinated pigs) with representation from all treatments were weighed on d 131.  
These 71 pigs had one additional day used in d 40 to 130 and d 0 to 130 growth rate calculations.  
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Backfat and loin depths, measured when pigs were weighed off test, were determined by real 
time ultrasound at the 10
th
 rib P2 location.   
Removals and deaths were recorded throughout the trial.  There were 6 deaths from d 0 to 
40 and 25 deaths from d 40 to 130.  Other animals removed included 1 late castration, 2 with 
missing final weights, 1 with a final data entry error, 1 severe tail bite, and 1 downer pig.  
Statistical analyses were performed on individual records from 417 pigs which had complete 
growth records at the end of the trial.   
Diagnostic testing:   
Serum was stored in -80ºC prior to indirect fluorescent antibody (IFA) and PCR testing. 
Diagnostic testing was performed at the Kansas State Veterinary Diagnostic Laboratory 
(KSVDL) after all samples had been collected.  Diagnostic testing methods were accepted and 
validated in accordance with the American Association of Veterinary Laboratory Diagnosticians’ 
standard requirements necessary for diagnostic laboratory accreditation.  Serum samples were 
assayed for PCV2 antibodies using the 96-well format KSVDL PCV2 IFA assay with serial 1:2 
dilutions beginning with a 1:20 serum to PBS dilution.  Sample sets from control and vaccinated 
pigs were assayed simultaneously, and all samples from an individual pig were tested on the 
same IFA plate.  Serum samples from d 40 and 130 were individually tested for PCV2 nucleic 
acid using the KSVDL PCV2 quantitative PCR assay.  Extraction of PCV2 DNA and PCR 
testing was performed under similar laboratory conditions for individual control and vaccinated 
pig serum samples. 
Analysis:  
The effect of circovirus vaccination on growth response was determined by analysis of 
variance using the GLIMMIX procedure in SAS version 9.1.3 (SAS Institute Inc., Cary, NC) to 
obtain least squares means and standard errors for all response variables.  The statistical model 
included the fixed effects of vaccination treatment, genetic makeup, gender, and all interactions.  
Litter of origin was included as a random effect.  Response variables evaluated were days to 
weaning and off-test, birth weight, d 0 (weaning) weight, and d 130 (off-test) weight.  Individual 
pig growth rate (ADG) was calculated by dividing the period weight gain by the number of days 
in the period.  Growth rate period designations were: d 0 to 40 (nursery period), d 40 to 130 
(grow-finish period), and d 0 to 130 (wean-to-finish period).  Backfat and loin depths were 
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analyzed as unadjusted and adjusted values.  For the adjusted analysis, backfat and loin depths 
were adjusted to a common average off-test body weight. 
Significance tests were performed for comparisons of the means of fixed effect 
combinations and their interactions for all response criteria.  Values of P < 0.05 were considered 
significant. 
Prior to analysis, IFA titers were log2 transformed to approximate a normal distribution.  
For the IFA analysis, the log2 of 10 was used when samples did not have PCV2 antibody 
detected at the most concentrated dilution (1:20).  The log2 of 5,120 was used when samples 
were strongly positive at the least concentrated dilution (1:2,560).  These methods allowed those 
low antibody concentrated (< 1:20) or high antibody concentrated sample (> 1:2,560) results to 
be weighted differently than samples with normal-intensity fluorescence detected at dilutions of 
1:20 and 1:2,560.  The main and interactive effects of genetic makeup, vaccination treatment, 
gender, and time on IFA antibody responses were tested by repeated measures analysis using the 
MIXED procedure in SAS.  The statistical model included the fixed effects of vaccination 
treatment, genetic makeup, gender, time, and all interactions.  The resulting means were 
transformed back to the original scale for presentation as geometric mean titers. 
Viral template quantities were log10 transformed before analysis to achieve normality for 
the PCR data.  Serum samples with any detectable PCV2 nucleic acid were considered to be 
PCV2 DNA-containing samples. Positive quantitative values were included in the analysis for 
these PCV2 DNA-containing samples along with zero-values from samples with no PCV2 DNA 
detected.  The main and interactive effects of genetic makeup, vaccination treatment, and gender 
on d 40 and 130 serum PCV2 nucleic acid load were determined using the GLIMMIX procedure 
in SAS to obtain means and standard errors.  Litter was included as a random effect for the 
analysis of PCR data.  The resulting least squares means were transformed back to the original 
scale for presentation as geometric means. 
The effect of d 40 PCV2 DNA template quantity on growth rate was determined using 
the GLIMMIX procedure in SAS.  Fixed effects in the model included genetic makeup, 
vaccination treatment, d 40 log10 transformed PCV2 template copies, and all interactions.  Litter 
was included as a random effect.  The solutions statement in SAS was used to determine 
intercepts and coefficients for the regression model. 
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Results 
Mortality: 
Postweaning mortality for the control pigs was 7.0% while the vaccinated pig mortality 
was 6.8% despite active PCV2 infection occurring during this trial.  Statistical analysis was not 
performed on these data.  However, there was no discernable difference in mortality between the 
genetic makeups.  
Performance analysis: 
There were no 3-way interactions between genetic makeup, vaccination treatment, and 
gender detected for any responses with the exception of weight-adjusted backfat depth (P = 
0.02). This 3-way interaction was a result of control A×B boars having increased (11.9 ± 0.41 vs. 
10.9 ± 0.41 mm, P = 0.04) backfat depth compared with vaccinated A×B boars. Within all other 
genetic makeup and gender combinations, backfat depth was similar (P ≥ 0.09) between control 
and vaccinated pigs (data not shown).   
There were no 2-way interactions (P ≥ 0.08) observed between vaccination treatment and 
gender for any growth or carcass response criteria (data not shown).  However, there were 2-way 
interactions between genetic makeup and vaccination treatment as well as with genetic makeup 
and gender (Table 2.1) for growth responses.   
Age: 
An interaction between genetic makeup and gender was observed for ages at d 0 (P = 
0.04) and d 130 (P < 0.001).  Resulting from an uneven birth pattern for boars and gilts within 
the A×A genetic makeup during the wk of farrowing, on d 0, A×A boars were 0.3 d younger 
(21.0 ± 0.43 vs. 21.3 ± 0.43 d, P < 0.01) than A×A gilts.  There were no differences (P ≥ 0.40) 
between ages of boars and gilts of B×B (boars: 19.6 ± 0.49 d; gilts: 19.7 ± 0.49 d), A×B (boars: 
20.3 ± 0.47 d; gilts: 20.3 ± 0.47 d), and B×A (boars: 21.2 ± 0.65 d; gilts: 21.3 ± 0.65 d).  The 
interaction at d 130 was a result of A×A boars being 0.2 d younger (151.4 ± 0.46 vs. 151.6 ± 
0.46 d, P < 0.01) than A×A gilts, while B×B boars were 0.6 d younger (149.7 ± 0.52 vs. 150.3 ± 
0.52 d, P < 0.001) than B×B gilts.  There were no differences (P ≥ 0.55) between d 130 ages of 
boars and gilts within A×B (boars: 150.6 ± 0.51 d; gilts: 150.6 ± 0.51 d) and B×A (boars: 151.7 
± 0.69 d; gilts: 150.7 ± 0.69 d).  More importantly for evaluation of vaccination effects there was 
no interaction between genetic makeup and vaccination treatment (P > 0.41) or effect of 
vaccination (P > 0.48) observed for age at weaning or d 130.   
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Weight: 
There were no interactions (P ≥ 0.24) observed between genetic makeup and vaccination 
treatment or genetic makeup and gender for birth or d 0 weights.  In addition, neither genetic 
makeup, vaccination treatment, nor gender affected (P ≥ 0.17) birth or d 0 weights. 
Weight on d 130 depended upon the 2-way interactions between genetic makeup and 
vaccination treatment (P = 0.05) as well as genetic makeup and gender (P = 0.02).  Within A×A, 
gilts weighed less (93.1 ± 2.11 vs. 98.1 ± 2.09 kg BW, P = 0.01) compared with boars.  Within 
B×B, A×B and B×A, boars and gilts had similar (P ≥ 0.07) weights on d 130.   
The 2-way interaction between genetic makeup and vaccination treatment was a result of 
A×A control pigs being lighter (P < 0.001) than vaccinated A×A pigs on d 130 whereas weights 
of control and vaccinated pigs of B×B, A×B, and B×A were similar (P ≥ 0.06).  Regardless, 
within all genetic populations, mean weights of control pigs on d 130 were numerically less than 
those of vaccinated pigs.  Vaccination increased weight compared with that of controls within 
the A×A population (vaccinated pig mean BW: 100.1 kg vs. control pig mean BW: 91.1 kg; 9.0 
kg improvement due to vaccination) almost 4 times that of the effect within B×B population 
(vaccinated pig mean BW: 102.4 kg vs. control pig mean BW: 100.1 kg; 2.3 kg improvement 
due to vaccination).  The vaccination effect on growth rate in the crossbred pigs was intermediate 
to that of pure-lines (A×A and B×B).  
The distribution of off-test weights for control and vaccinated pigs within A×A (Figure 
2.1) and B×B (Figure 2.2) were determined.  These distributions demonstrated the right-shift in 
the d 130 weights of the vaccinated pig population relative to the control pigs. The magnitude of 
the mean weight difference between the control and vaccinated pigs was almost 4 times greater 
in the A×A pigs (9.0 kg difference) compared with the B×B pigs (2.3 kg difference).  
Demonstrated by the population shift within both distributions, vaccination affected the entire 
vaccinated pig population though the extent of the effect of vaccination was different within each 
genetic population.   
Average daily gain: 
There was no interactive effect (P = 0.22) between genetic makeup and gender on d 0 to 
40 ADG; however, gender did affect (P < 0.001) growth rate during this period.  From d 0 to 40, 
gilts grew faster (430 ± 9.4 vs. 403 ± 9.2 g per day) than boars.   
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An interactive effect (P = 0.05) was detected between genetic makeup and vaccination 
treatment for d 0 to 40 ADG.  There was a crossing-interaction for growth rate of control and 
vaccinated pigs within the A×B and B×A populations.  Control pigs of A×B had greater ADG 
compared with A×B vaccinated pigs (P = 0.04), while B×A vaccinated pigs had numerically 
greater ADG compared to B×A controls (P = 0.11).  
There were 2-way interactive effects between both genetic makeup and gender (P = 0.03) 
and genetic makeup and vaccination treatment (P = 0.05) detected for d 40 to 130 ADG.  Boars 
of A×A grew faster (845 ± 17.6 vs. 790 ± 17.8 g per day, P < 0.01) than A×A gilts whereas 
boars and gilts grew at a similar (P ≥ 0.15) rate within B×B, A×B, and B×A.  From d 40 to 130, 
ADG was decreased (P ≤ 0.001) for the A×A controls compared with the growth rates of the 
control pigs of A×B, B×A, and B×B. Controls from the latter 3 genetic populations had similar 
(P ≥ 0.45) d 40 to 130 ADG.  In contrast, A×A vaccinated pigs had similar (P ≥ 0.14) ADG 
compared with vaccinated pigs from the other genetic makeups with the exception of vaccinated 
A×B pigs (P = 0.04).  Thus, the difference between vaccinated and control pig mean growth rate 
was greater within A×A compared with the difference within B×B, A×B, and B×A.  
There were interactive effects between genetic makeup and gender (P = 0.03) and genetic 
makeup and vaccination treatment (P = 0.04) observed for d 0 to 130 ADG.  Boars of A×A grew 
faster (705 ± 15.2 vs. 671 ± 15.3 g per day, P = 0.02) than gilts of A×A whereas within B×B, 
A×B, and B×A, boars and gilts had similar (P ≥ 0.06) d 0 to 130 growth rates.  Growth rate of 
A×A control pigs was reduced (P ≤ 0.002) compared with control pigs from the other genetic 
makeups.  Vaccinated A×A pigs grew slower (P = 0.04) when compared with B×A vaccinated 
pigs, but had similar (P ≥ 0.06) ADG with vaccinated A×B and B×B pigs. These differences in d 
0 to 130 growth rates resulted in the magnitude of the difference between vaccinated and control 
pig mean growth rates being greatest in pigs of A×A.   
Backfat and loin depth: 
There were no 3-way or 2-way interactive effects (P ≥ 0.05) observed for unadjusted 
backfat depth.  Genetic makeup did affect (P = 0.02) backfat depth as A×A (11.7 ± 0.29 mm) 
and A×B (12.0 ± 0.30 mm) pigs had increased (P ≤ 0.02) backfat depth compared with B×B pigs 
(10.7 ± 0.32 mm).  Backfat depth of B×A (11.5 ± 0.42 mm) pigs was intermediate (P ≥ 0.14) to 
measurements of A×A and B×B pigs.   
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There were no 3-way or 2-way interactive effects (P ≥ 0.10) detected for unadjusted loin 
depth; however, loin depth was affected (P < 0.001) by genetic makeup, vaccination treatment, 
and gender.  Loin depth of A×A pigs was decreased (60.7 ± 0.75 vs. 66.3 ± 0.77 mm, P < 0.001) 
compared with that of A×B pigs.  Pigs of A×B had similar (P = 0.28) loin depth compared with 
B×A pigs (67.7 ± 1.06 mm) and increased (P < 0.01) loin depth compared with B×B pigs (69.2 ± 
0.81 mm).  Control pigs had decreased (65.0 ± 0.50 vs. 66.9 ± 0.51 mm; P < 0.01) loin depth 
compared with vaccinated pigs, while boars had decreased (63.9 ± 0.50 vs. 68.0 ± 0.52 mm; P < 
0.01) loin depth compared with gilts.   
As previously explained, after backfat depth measurements were adjusted to a common 
average d 130 weight, there was a 3-way interaction (P = 0.02) observed with genetic makeup, 
gender, and vaccination treatment.  This interaction (P = 0.02) was the result of control A×B 
boars having increased (11.9 ± 0.41 vs. 10.9 ± 0.41 mm; P = 0.04) weight-adjusted backfat depth 
compared with vaccinated A×B boars. Within all other gender by genetic makeup combinations, 
backfat depth was similar (P ≥ 0.09) between control and vaccinated pigs.  The interactive 
effects (P = 0.79) between genetic makeup and vaccination treatment for weight-adjusted backfat 
depth are presented in Figure 2.3.   
After loin depths were adjusted to a common off-test weight, there was no significant 3-
way interaction (P = 0.71) observed.  There was a 2-way interaction (P = 0.01) detected between 
genetic makeup and gender.  Despite loin depths of gilts consistently being increased compared 
with boars, within the A×B makeup the difference was 2.2 mm whereas within A×A, B×B, and 
B×A the difference was 4.3 mm or greater.  Although there was a significant effect of 
vaccination treatment prior to weight-adjustment, after adjustment to a common average d 130 
weight, vaccination treatment failed (P = 0.29) to affect loin depth. The interactive effect (P = 
0.82) of genetic makeup and vaccination treatment for weight-adjusted loin depth are presented 
in Figure 2.4.   
Indirect fluorescent antibody results: 
The IFA geometric mean titers for control and vaccinated pigs on d 0, 40, and 130 are 
presented in Figure 2.5.  These profiles indicate the timing of the PCV2 antibody response due to 
vaccination with the 2-dose circovirus vaccine in contrast with the antibody response produced 
from natural PCV2 exposure. 
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There were 3-way interactions with genetic makeup, vaccination treatment, and time (P = 
0.02), as well as with vaccination treatment, gender, and time (P < 0.01) detected for IFA 
antibody response.  Vaccinated pigs demonstrated an increase in PCV2 antibody titer by d 40 
which decreased by d 130, while control pigs did not have a rise in PCV2 antibody level detected 
until d 130.   
Polymerase chain reaction results: 
There were no 3-way or 2-way interactions (P ≥ 0.15) with genetic makeup, vaccination 
treatment, or gender on d 40 or d 130 PCV2 viral template copy quantity.   
Viral template copy quantity was affected by both genetic makeup (P < 0.01, Figure 2.6) 
and vaccination treatment (P < 0.001).  On d 40, B×B pigs had a decreased (56.8 template copies 
per reaction, P ≤ 0.02) PCV2 DNA load compared with pigs of A×A, A×B, and B×A (420.1 
template copies per reaction or higher).  Vaccinated pigs also had decreased (20.9 viral copies 
per reaction vs. 4582.5 viral copies per reaction, P < 0.001) PCV2 viral template copy quantities 
compared with control pigs (Figure 2.7). 
Only vaccination treatment affected (P < 0.001) d 130 PCV2 viral template copy 
quantity.  Vaccinated pigs had decreased serum viral template quantities (1.3 viral template 
copies per reaction vs. 3.8 viral template copies per reaction) compared with control pigs (Figure 
2.7). 
There was a 3-way interaction (P = 0.04) with genetic makeup, vaccination treatment, 
and d 40 PCV2 DNA template quantity observed for d 40 to 130 ADG.  Growth rate from d 40 
to 130 depended not only on both genetic makeup and vaccine status but also on d 40 viral load.  
As viral load increased, the growth rate response differed depending on the genetic makeup and 
vaccination status.  Growth rate was modeled with the log10 transformed d 40 PCR data and, to 
demonstrate the disparity in growth rates, the models for A×A controls and B×B controls are 
included (Figure 2.8).   
Discussion 
Porcine circovirus disease is a devastating disease affecting multiple organ systems. 
Infection with PCV2 has become endemic in many swine herds. The virus itself is ubiquitous, 
present in nearly all herds, yet the expression of disease (PCVD) pertaining to morbidity and 
mortality varies.  Factors associated with the risk for development of PCVD  disease or lesions 
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have been identified including  genetics (Opriessnig et al., 2006), gender (Corrégé et al., 2001), 
litter of origin (Madec et al., 2000), low birth or weaning weight (Corrégé et al., 2001), and 
management factors (Rose et al., 2003).  Though PCV2 is the necessary etiologic agent of 
PCVD, there is evidence that clinical disease is exacerbated when accompanied by additional 
pathologic agents, also called cofactors (Dorr et al., 2007; Opriessnig et al., 2004).  In general, 
circovirus vaccines have been effective in lessening the severity of or preventing clinical PCVD 
(Desrosiers et al., 2009; Kixmöller et al., 2008).  In development of vaccination programs as 
standard practice for many farms, understanding vaccine limitations and expected responses to 
vaccination has become a focus within the industry. 
Results from our study indicate that growth rate response to circovirus vaccination varies 
with genetic makeup.  To our knowledge, this is the first study demonstrating differential 
responses to circovirus vaccination based on genetic makeup under field conditions.  Genetic 
background, however, had been previously implicated by other researchers as a risk factor for 
expression of PCVD (Opriessnig et al., 2006; Opriessnig et al., 2009b).  Our study supports the 
evidence that PCVD risk is dependent on the genetic makeup of the pig. 
Field reports have suggested pigs from Pietrain background may be less susceptible to 
PCVD (López-Soria et al., 2004); however, some published study results do not support these 
observations (Rose et al., 2005).  In our study, the magnitude of the response was greater in pigs 
of the Duroc genotype compared to pigs of the White Pietrain genotype.  Also, our research adds 
to the body of literature indicating that pig genotype affects responses to vaccination or disease 
expression (Doeschl-Wilson et al., 2009; Reiner et al., 2002; Vincent et al., 2006).   
Performing this study in a high-health status herd with few clinical signs of PCVD other 
than an increase in morbidity provides unique insight on PCVD to the current literature.  
Previous research, evaluating host genetics as a risk factor, has focused on documenting the 
effects of genetic makeup on PCVD-associated mortality, observed clinical disease with wasting, 
or PCV2-lesion severity differences (López-Soria et al., 2004; Opriessnig et al., 2006; Opriessnig 
et al., 2009b; Rose et al., 2005).  Mortality had not increased in the herd used for our study, thus 
mortality was not a primary response of interest.  Nonetheless, mortalities were recorded and 
there was only a 0.2% difference between control and vaccinated pig mortality percentages.   
The effect of circovirus vaccination on growth rate from d 0 to 130 for pigs of A×A was 
about 4 times greater (A×A: 66 g per day vs. B×B: 16 g per day) than the effect of vaccination 
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on growth rate for pigs of B×B.  Although the magnitude of the difference between controls and 
vaccinates was greater in the A×A pigs than in the B×B pigs, the control and vaccinate response 
patterns within the genetic makeups were similar.  Evident from weight distributions for both 
pure-line populations, off-test weights (Figures 2.1 and 2.2) were shifted to the right for the 
vaccinated pigs compared with the control pigs.  It was apparent that all pigs in both populations 
were affected by vaccination, with only the extent of the response being different.  These 
findings support previous reports that circovirus vaccine affected all pigs, even heavy pigs 
(Horlen et al., 2008; Madec et al., 2000).  Detection of the more pronounced right-shift for the 
vaccinated pigs within the weight distribution of the A×A population than in the B×B population 
provided new evidence that genetic makeup affects this circovirus vaccine response.   
Similar to the results from another study (Jacela et al., 2011), vaccination against 
circovirus had little or no influence on carcass composition in our study.  The loin depth 
differences detected initially between pigs of different vaccination treatments resulted from 
differences in d 130 weights.  After weight adjustment to a common off-test weight, no 
difference was detected between loin depths across vaccination treatment.   
Presence of PCV2 virus and active infection was confirmed during this trial by IFA and 
PCR testing.  The IFA results indicate a PCV2 antibody rise in the vaccinated pigs by d 40.  By d 
130, antibody levels in the vaccinated pigs had decreased suggesting the increase by d 40 was 
primarily due to vaccination and not early natural viral exposure.  In contrast, the rise in antibody 
titer between d 40 and 130 for the control pigs indicated natural PCV2 exposure had occurred. 
Active circovirus infection was documented with detection of PCV2 DNA in serum of 
both control and vaccinated pigs.  Viremia was documented by the end of the 40 d nursery phase 
with some pigs still PCV2-viremic on d 130.  Although some nursery pigs were PCV2-viremic, 
the rise in IFA titer after d 40 suggests that many control pigs seroconverted after being moved 
from the nursery.  These results indicate PCV2 circulation and infection during the nursery 
period with subsequent transmission or persistence during the finishing period.  Regardless, 
control and vaccinated pigs were comingled during both the d 0 to 40 and d 40 to 130 periods 
and at both d 40 and 130, PCV2 viral load in vaccinated pigs was markedly decreased compared 
with that of control pigs.  
Under experimental conditions, histopathologic lesion severity, particularly in liver and 
lymphoid tissues, worsened with increased PCV2 viral load detected by immunohistochemistry 
 37 
(Krakowka et al., 2005).  This trial provided data which suggests that growth rate depends upon 
serum viral load.  Pure-line (A×A and B×B) control pig results indicate as d 40 viral load 
increased, d 40 to 130 growth rate decreased; however, the rate at which the change occurred 
was dependent upon genetic makeup.  Growth rate decreased at a faster rate as viral load 
increased for control pigs of A×A compared with controls of the B×B makeup.  Further research 
is needed to comprehensively explain the effects of serum viral load level as it relates to 
performance. Our data provided initial information linking serum viral load and growth 
performance; however, the significance biologically has yet to be fully characterized.  The 
results of this study confirm previous research findings that circovirus vaccination effectively 
decreases serum viral load (Fachinger et al., 2008; Horlen et al., 2008; Opriessnig et al., 2009a), 
even under conditions where vaccinated pigs were housed with control pigs. 
Genetic makeup also affected d 40 PCV2 viral loads.  Pigs of B×B genetic makeup had 
the lowest level of PCV2 DNA detected on d 40.  This genetic population also had the smallest 
response to circovirus vaccination as measured by growth rate.  While these findings support 
observations that growth rate was negatively affected by increasing viral load, they also provide 
evidence that genetic makeup may play a role in the PCV2-infection susceptibility or resistance.   
McIntosh et al. (2006) documented breed differences in PCV2 shedding duration.  A 
survey of PCV2-antibody positive boars in a commercial boar stud revealed detectable PCV2 
DNA in semen from Duroc and Landrace boars.  Throughout the sampling time-frame, there was 
no PCV2 DNA detected in semen from Hamline, Large White maternal or paternal lines, or 
Meishan-synthetic breeds (McIntosh et al., 2006).  While pig genotype has been shown to affect 
expression of other viral diseases (Halbur et al., 1998; Petry et al., 2005; Reiner et al., 2002), 
McIntosh et al. (2006) suggested that genetic makeup may be important for explaining 
differences in PCV2-infection susceptibility and expression.  
Although the responses observed in our study were attenuated by circovirus vaccination, 
these data may indicate that genetic makeup affects PCVD expression.  If the severity of PCV2 
infection was dependent at some level on host genetics, this might explain why vaccination 
affected the genetic makeups differently.  The B×B population was of a White Pietrain genotype 
and the magnitude of the growth difference between control and vaccinated pigs was less than 
that of the A×A pigs of a Duroc genotype.  These findings resulted in additional questions 
regarding differences in susceptibility between these genetic makeups and whether it might be 
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possible to derive animals with improved circovirus-induced disease resistance.  However, the 
primary objective of this trial was to determine whether pigs of different genetic makeups 
differed in their response to circovirus vaccination. With that difference clearly demonstrated, 
further research is needed to address these additional questions. 
Results of this study indicate that pig genetic makeup affects the growth rate response to 
circovirus vaccination.  Thus, pig genetic makeup must be considered as a risk factor relative to 
expression of PCVD and when evaluating performance responses to circovirus vaccination. 
Implications 
 Different genetic makeups respond differently to circovirus vaccination as measured by 
growth rate. 
 This field trial further supports findings of reduced PCV2 viral load levels and improved 
growth rate in vaccinated pigs compared with non-vaccinated control pigs. 
 Genetic makeup should be considered as a risk factor for either PCVD expression or 
response to circovirus vaccine. 
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Figure 2.1  Distribution of pig weights at off-test for control versus vaccinated pigs of 
genetic makeup A×A (Duroc genotype). 
A total of 454 weanling pigs from 4 genetic populations were ranked by birth weight 
within litter and gender (boar or gilt) and randomly assigned to vaccination treatments 
(vaccinated or non-vaccinated control).  Genetic designations were: pure-lines of A×A (Duroc 
genotype) and B×B (synthetic White Pietrain genotype) and crossbreds A×B and B×A.  Pigs 
allotted to the vaccinated treatment were injected (2 mL per dose) at weaning and again 2 wk 
later with a circovirus vaccine (Circumvent PCV, Intervet/Schering-Plough Animal Health, 
Millsboro, DE).  Pigs were weighed on d 0 (weaning), d 40 (end-of-nursery), and approximately 
d 130 (off-test; approximately 150 d of age).  Individual pig records from 417 pigs that had 
complete growth records were used for analysis. 
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Figure 2.2  Distribution of pig weights at off-test for control versus vaccinated pigs of 
genetic makeup B×B (synthetic White Pietrain genotype). 
A total of 454 weanling pigs from 4 genetic populations were ranked by birth weight 
within litter and gender (boar or gilt) and randomly assigned to vaccination treatments 
(vaccinated or non-vaccinated control).  Genetic designations were: pure-lines of A×A (Duroc 
genotype) and B×B (synthetic White Pietrain genotype) and crossbreds A×B and B×A.  Pigs 
allotted to the vaccinated treatment were injected (2 mL per dose) at weaning and again 2 wk 
later with a circovirus vaccine (Circumvent PCV, Intervet/Schering-Plough Animal Health, 
Millsboro, DE).  Pigs were weighed on d 0 (weaning), d 40 (end-of-nursery), and approximately 
d 130 (off-test; approximately 150 d of age).  Individual pig records from 417 pigs that had 
complete growth records were used for analysis.   
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Figure 2.3  Weight-adjusted backfat depth for control and vaccinated pigs of different 
genetic makeups. 
A total of 454 weanling pigs from 4 genetic populations were ranked by birth weight 
within litter and gender (boar or gilt) and randomly assigned to vaccination treatments 
(vaccinated or non-vaccinated control).  Genetic designations were: pure-lines of A×A (Duroc 
genotype) and B×B (synthetic White Pietrain genotype) and crossbreds A×B and B×A.  Pigs 
allotted to the vaccinated treatment were injected (2 mL per dose) at weaning and again 2 wk 
later with a circovirus vaccine (Circumvent PCV, Intervet/Schering-Plough Animal Health, 
Millsboro, DE).  Pigs were weighed on d 0 (weaning), d 40 (end-of-nursery), and approximately 
d 130 (off-test; approximately 150 d of age).  At off-test, backfat and loin depths were measured 
by real time ultrasound at the 10
th
 rib P2 location.  Individual pig records from 417 pigs that had 
complete growth records at off-test were analyzed by analysis of variance using the GLIMMIX 
procedure in SAS version 9.1.3 (SAS Institute Inc., Cary, NC).  The model included the fixed 
effects of vaccination treatment, genetic makeup, gender, and all interactions.  Litter of origin 
was included as a random effect.  Backfat and loin depths were analyzed as unadjusted and 
adjusted (adjusted to a common average off-test body weight) values.   
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Figure 2.4  Weight-adjusted loin depth for control and vaccinated pigs of different genetic 
makeups. 
A total of 454 weanling pigs from 4 genetic populations were ranked by birth weight 
within litter and gender (boar or gilt) and randomly assigned to vaccination treatments 
(vaccinated or non-vaccinated control).  Genetic designations were: pure-lines of A×A (Duroc 
genotype) and B×B (synthetic White Pietrain genotype) and crossbreds A×B and B×A.  Pigs 
allotted to the vaccinated treatment were injected (2 mL per dose) at weaning and again 2 wk 
later with a circovirus vaccine (Circumvent PCV, Intervet/Schering-Plough Animal Health, 
Millsboro, DE).  Pigs were weighed on d 0 (weaning), d 40 (end-of-nursery), and approximately 
d 130 (off-test; approximately 150 d of age).  At off-test, backfat and loin depths were measured 
by real time ultrasound at the 10
th
 rib P2 location.  Individual pig records from 417 pigs that had 
complete growth records at off-test were analyzed by analysis of variance using the GLIMMIX 
procedure in SAS version 9.1.3 (SAS Institute Inc., Cary, NC).  The model included the fixed 
effects of vaccination treatment, genetic makeup, gender, and all interactions.  Litter of origin 
was included as a random effect.  Backfat and loin depths were analyzed as unadjusted and 
adjusted (adjusted to a common average off-test body weight) values. 
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Figure 2.5  Indirect fluorescent antibody (IFA) geometric mean titers (GMT) on d 0, 40, 
and 130 for control and vaccinated pigs. 
A total of 454 weanling pigs from 4 genetic populations were ranked by birth weight 
within litter and gender (boar or gilt) and randomly assigned to vaccination treatments 
(vaccinated or non-vaccinated control).  Genetic designations were: pure-lines of A×A (Duroc 
genotype) and B×B (synthetic White Pietrain genotype) and crossbreds A×B and B×A.  Pigs 
allotted to the vaccinated treatment were injected (2 mL per dose) at weaning and again 2 wk 
later with a circovirus vaccine (Circumvent PCV, Intervet/Schering-Plough Animal Health, 
Millsboro, DE).  Serum was collected from pigs on d 0 (weaning), d 40 (end-of-nursery), and 
approximately d 130 (off-test; approximately 150 d of age).  Statistical analyses were performed 
on data from 417 pigs which had complete growth records at off-test.  Individual pig IFA data 
were log2 transformed and then were analyzed by repeated measures analysis of variance using 
the MIXED procedure in SAS version 9.1.3 (SAS Institute Inc., Cary, NC).  The model included 
the fixed effects of vaccination treatment, genetic makeup, gender, time, and all interactions.  
Resulting means were transformed back to the original scale for presentation. 
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Figure 2.6  Porcine circovirus type 2 (PCV2) viral template quantity determined by PCV2 
polymerase chain reaction (PCR) in serum collected on d 40 from control and vaccinated 
pigs of different genetic makeups. 
A total of 454 weanling pigs from 4 genetic populations were ranked by birth weight 
within litter and gender (boar or gilt) and randomly assigned to vaccination treatments 
(vaccinated or non-vaccinated control).  Genetic designations were: pure-lines of A×A (Duroc 
genotype) and B×B (synthetic White Pietrain genotype) and crossbreds A×B and B×A.  Pigs 
allotted to the vaccinated treatment were injected (2 mL per dose) at weaning and again 2 wk 
later with a circovirus vaccine (Circumvent PCV, Intervet/Schering-Plough Animal Health, 
Millsboro, DE).  Serum was collected from pigs on d 0 (weaning), d 40 (end-of-nursery), and 
approximately d 130 (off-test; approximately 150 d of age).  Statistical analyses were performed 
on data from 417 pigs which had complete growth records at off-test.  Individual pig PCV2 PCR 
data were log10 transformed and then were analyzed by analysis of variance using the GLIMMIX 
procedure in SAS version 9.1.3 (SAS Institute Inc., Cary, NC).  The model included the fixed 
effects of vaccination treatment, genetic makeup, gender, and all interactions.  Litter of origin 
was included as a random effect.  Resulting means were transformed back to the original scale 
for presentation. 
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Figure 2.7  Porcine circovirus type 2 (PCV2) viral template quantity determined by PCV2 
polymerase chain reaction (PCR) of serum samples collected on d 40 and 130 from control 
and vaccinated pigs. 
A total of 454 weanling pigs from 4 genetic populations were ranked by birth weight 
within litter and gender (boar or gilt) and randomly assigned to vaccination treatments 
(vaccinated or non-vaccinated control).  Genetic designations were: pure-lines of A×A (Duroc 
genotype) and B×B (synthetic White Pietrain genotype) and crossbreds A×B and B×A.  Pigs 
allotted to the vaccinated treatment were injected (2 mL per dose) at weaning and again 2 wk 
later with a circovirus vaccine (Circumvent PCV, Intervet/Schering-Plough Animal Health, 
Millsboro, DE).  Serum was collected from pigs on d 0 (weaning), d 40 (end-of-nursery), and 
approximately d 130 (off-test; approximately 150 d of age).  Statistical analyses were performed 
on data from 417 pigs which had complete growth records at off-test.  Individual pig PCV2 PCR 
data were log10 transformed and then were analyzed by analysis of variance using the GLIMMIX 
procedure in SAS version 9.1.3 (SAS Institute Inc., Cary, NC).  The model included the fixed 
effects of vaccination treatment, genetic makeup, gender, and all interactions.  Litter of origin 
was included as a random effect.  Resulting means were transformed back to the original scale 
for presentation. 
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Figure 2.8  Effect of genetic makeup, circovirus vaccination, and d 40 serum PCV2 viral 
template quantity on d 40 to 130 average daily gain (ADG). 
A total of 454 weanling pigs from 4 genetic populations were ranked by birth weight 
within litter and gender (boar or gilt) and randomly assigned to vaccination treatments 
(vaccinated or non-vaccinated control).  Genetic designations were: pure-lines of A×A (Duroc 
genotype) and B×B (synthetic White Pietrain genotype) and crossbreds A×B and B×A.  Pigs 
allotted to the vaccinated treatment were injected (2 mL per dose) at weaning and again 2 wk 
later with a circovirus vaccine (Circumvent PCV, Intervet/Schering-Plough Animal Health, 
Millsboro, DE).  Individual pigs were weighed and serum was collected on d 0 (weaning), d 40 
(end-of-nursery), and approximately d 130 (off-test; approximately 150 d of age).  Individual pig 
d 40 PCV2 PCR data were log10 transformed before analysis.  The effect of d 40 PCV2 DNA 
template quantity on growth rate was determined using the GLIMMIX procedure in SAS version 
9.1.3 (SAS Institute Inc., Cary, NC).  Fixed effects in the model included genetic makeup, 
vaccination treatment, d 40 log10 transformed PCV2 template copies, and all interactions.  Litter 
was included as a random effect.  The solutions statement in SAS was used to determine 
intercepts and coefficients for the regression model. 
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Table 2.1  P-values for age, growth performance, and carcass trait response criteria for the 
interactive effects between genetic makeup and vaccination treatment, and genetic makeup 
and gender, and the main effects of genetic makeup, vaccination treatment, and gender
1
 
Item 
Genetic
2
 × 
Vaccine
3
 
Genetic × 
Gender Genetic Vaccine Gender 
Age, P < 
          D 0 0.71 0.04 0.07 0.48 0.03 
     D 130 0.41 <0.001 0.11 0.65 <0.001 
Weight, P < 
          Birth 0.74 0.41 0.25 0.40 0.29 
     D 0 0.51 0.24 0.32 0.31 0.17 
     D 130 0.05 0.02 0.003 <0.001 0.86 
ADG, P < 
          D 0 to 40 0.05 0.22 0.08 0.72 <0.001 
     D 40 to 130 0.05 0.03 0.003 <0.001 0.20 
     D 0 to 130 0.04 0.03 0.003 <0.001 0.94 
Carcass traits, P  < 
          Backfat 0.46 0.47 0.02 0.13 0.06 
     Loin 0.32 0.10 <0.001 <0.001 <0.001 
     Adj. backfat
4
 0.79 0.47 <0.01 0.62 0.04 
     Adj. loin
4
 0.82 0.01 <0.001 0.29 <0.001 
1 
A total of 454 pigs (boar or gilt) from 4 genetic makeups were assigned to vaccination 
treatment by ranking them by weight within litter and gender and randomly assigning each pig 
to either a vaccinated or non-vaccinated treatment.  Pigs were individually weighed at birth, d 0, 
40, and 130. Backfat and loin depth were measured at the time pigs were weighed off test.  
Analysis was performed by analysis of variance using the GLIMMIX procedure in SAS version 
9.1.3 (SAS Institute Inc., Cary, NC) on records from 417 pigs which had complete growth 
records at off-test.  The statistical model included fixed effects of genetic makeup, vaccination 
treatment, gender, and all interactions.  Litter of origin was included as a random effect. 
2 
Genetic designations were A×A (Duroc genotype), A×B, B×A, and B×B (synthetic White 
Pietrain genotype). 
3 
Vaccination treatments were vaccinated or non-vaccinated control.  Circovirus vaccine 
(Circumvent PCV; Intervet/Schering-Plough Animal Health, Millsboro, DE) was administered 
intramuscularly (2 mL per dose) to vaccinated pigs at 21 and 35 d of age. 
4 
Backfat depth and loin depth were adjusted to a common average off-test weight.  There was a 
3-way interaction (P = 0.02) with genetic makeup, vaccination treatment, and gender for 
weight-adjusted backfat depth. This interaction was a result of control A×B crossbred boars 
having increased (11.9 ± 0.41 vs. 10.9 ± 0.41 mm, P = 0.04) backfat depth compared with 
vaccinated A×B crossbred boars. Within boars or gilts of A×A, B×A, or B×B, weight-adjusted 
backfat depth was similar (P ≥ 0.09) between control and vaccinated pigs. 
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Table 2.2  Means and standard errors for age, growth performance, and carcass trait response criteria for control and 
vaccinated pigs of different genetic makeups
1
 
  Genetic makeup2 
  
A×A  
 
A×B  
 
B×A  
 
B×B  
Item Treatment
3
 Control Vaccinate Control Vaccinate Control Vaccinate Control Vaccinate 
No. of pigs 62 55 60 65 34 32 55 54 
Age, d 
        D 0 21.2±0.43 21.1±0.43 20.3±0.47 20.3±0.47 21.3±0.65 21.3±0.65 19.7±0.49 19.6±0.49 
D 130 151.5±0.46 151.4±0.46 150.6±0.51 150.6±0.51 151.7±0.69 151.7±0.69 150.0±0.52 150.0±0.52 
Weight, kg 
        Birth 1.6±0.07 1.6±0.08 1.7±0.08 1.8±0.08 1.6±0.11 1.6±0.11 1.8±0.08 1.8±0.08 
D 0 5.8±0.23 6.1±0.23 6.3±0.24 6.3±0.24 6.6±0.33 6.5±0.33 5.8±0.25 6.0±0.25 
D 130 91.1±2.03
a
 100.1±2.09
b
 102.8±2.16
bc
 105.6±2.13
bc
 102.8±2.91
bc
 107.5±2.95
c
 100.1±2.22
b
 102.4±2.25
bc
 
ADG, g 
        D 0 to 40 382±15.7
a
 388±16.1
abc
 433±16.9
bd
 409±16.7
ace
 437±22.8
bcde
 463±23.0
de
 417±17.4
abcde
 401±17.6
abc
 
D 40 to 130 772±17.0
a
 864±17.6
b
 873±18.0
b
 915±17.7
c
 867±24.2
bc
 909±24.6
bc
 854±18.5
b
 883±18.8
bc
 
D 0 to 130 655±14.7
a
 721±15.2
b
 741±15.6
bc
 762±15.4
bc
 738±21.1
b
 775±21.4
c
 723±16.1
bc
 739±16.3
bc
 
Carcass traits, mm 
       Backfat 4 11.4±0.34 12.0±0.35 12.1±0.36 12.0±0.35 11.2±0.48 11.7±0.49 10.6±0.37 10.8±0.38 
Loin
5
 59.2±0.87 62.2±0.91 65.6±0.92 66.9±0.90 66.3±1.23 69.0±1.26 68.8±0.95 69.6±0.96 
Adj. backfat
6
 12.2±0.33 12.1±0.33 11.9±0.33 11.6±0.33 11.1±0.45 11.2±0.46 10.7±0.34 10.7±0.35 
Adj. loin
7
 62.3±0.69 62.6±0.69 65.1±0.69 65.4±0.68 65.8±0.92 67.1±0.95 69.2±0.71 69.2±0.72 
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1 
A total of 454 pigs from 4 genetic makeups were assigned to vaccination treatment by ranking them by weight within litter and 
gender and randomly assigning each pig to either a vaccinated or non-vaccinated control treatment. Pigs were individually weighed at 
birth, d 0 (weaning), d 40 (end of nursery period), d 130 (off-test; approximately the end of the finisher period). Backfat and loin depth 
were measured when pigs were weighed off test.  Analysis was performed by analysis of variance using the GLIMMIX procedure in 
SAS version 9.1.3 (SAS Institute Inc., Cary, NC) on records from 417 pigs which had complete growth records at off-test.  The 
statistical model included fixed effects of genetic makeup, vaccination treatment, gender, and all interactions.  Litter of origin was 
included as a random effect.  Results are reported as least squares means±SEM. 
2 
Genetic designations were A×A (Duroc genotype), A×B, B×A, and B×B (synthetic White Pietrain genotype). 
3 
Vaccination treatments included vaccinated and non-vaccinated controls. A circovirus vaccine (Circumvent PCV; Intervet/Schering-
Plough Animal Health, Millsboro, DE) was administered intramuscularly (2 mL per dose) to vaccinated pigs at 21 and 35 d of age. 
4 
Backfat depth was not adjusted to a common weight. 
5 
Loin depth was not adjusted to a common weight. 
6 
Backfat depth was adjusted to a common average off-test weight.  There was a 3-way interaction (P = 0.02) with genetic makeup, 
vaccination treatment, and gender for weight-adjusted backfat depth. This interaction was a result of control A×B crossbred boars 
having increased (11.9 ± 0.41 vs. 10.9 ± 0.41 mm, P = 0.04) backfat depth compared with vaccinated A×B crossbred boars. Within 
boars or gilts of A×A, B×A, or B×B, weight-adjusted backfat depth was similar (P ≥ 0.09) between control and vaccinated pigs. 
7 
Loin depth was adjusted to a common average off-test weight. 
abcde
 Within a row, means without a common superscript letter differ (P < 0.05). 
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CHAPTER 3 - Effects of diet source and vaccination for porcine 
circovirus type 2 and Mycoplasma hyopneumoniae on nursery pig 
performance  
Abstract  
Two experiments were conducted to evaluate the effects of segregated early weaning 
(SEW) and transition diet sources, circovirus and Mycoplasma hyopneumoniae (M. hyo) 
vaccinations, and vaccination timing on pig performance.  In experiment one, a total of 400 pigs 
(5.6 ± 1.03 kg BW) were used in a 20-d study.  Treatments were arranged in a 4 × 2 factorial in a 
randomized complete block design (5 pigs per pen and 10 pens per treatment) with main effects 
of diet manufacturing source (A, B, C, or D) and vaccination timing (d 0 or 8).  Vaccines 
(Circumvent PCV; Intervet/Schering-Plough Animal Health, Millsboro, DE, and RespiSure One; 
Pfizer Animal Health, New York, NY) were administered on d 0 (weaning) or d 8.  A budgeted 
amount of SEW diet (0.45 kg/pig) was fed followed by a transition diet until d 8 and a common 
diet from d 8 to 20.  Diet source affected (P < 0.001) ADG during the first 4 d and affected (P ≤ 
0.02) ADG and ADFI from d 4 to 8.  From d 0 to 4, pigs fed diet B had increased (P ≤ 0.03) 
ADG compared with pigs fed diets A, C, or D.  Growth rate of pigs fed diet D was increased (P 
= 0.02) compared with pigs fed diet C and ADG of pigs fed diet A was intermediate.  From d 4 
to 8, pigs fed diet A had increased (P = 0.04) ADG compared with pigs fed diet B, and had 
increased (P ≤ 0.04) ADG and ADFI compared with pigs fed diets C or D.  Pigs fed diet B had 
increased (P ≤ 0.02) ADFI compared with pigs fed diet C or D.  There were no differences (P ≥ 
0.18) among diet sources once pigs were fed a common diet (d 8 to 20). Overall, diet source did 
not affect ADG; but ADFI tended (P = 0.06) to be decreased for pigs fed diet C compared with 
those fed diets A, B, and D.  Pigs vaccinated on d 0 had decreased (P ≤ 0.01) ADG and ADFI (d 
4 to 8 and d 0 to 8), resulting in lighter (P = 0.003) weights on d 8 than those of pigs not yet 
vaccinated (d 8). However, overall ADG was not affected by vaccination timing.  In experiment 
two, 360 pigs (5.9 ± 0.91 kg BW) were used in a 35-d trial to evaluate the effects of vaccination 
for circovirus and M. hyo using different vaccines. Treatments were arranged in a 3 × 2 factorial 
in a randomized complete block design (5 pigs per pen and 12 pens per treatment). Main effects 
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included circovirus vaccine (none; CircoFLEX, Boehringer Ingelheim Vetmedica, Inc, St. 
Joseph, MO; or Circumvent PCV); with or without a M. hyo vaccine (RespiSure, Pfizer Animal 
Health, New York, NY).  
Overall, pigs vaccinated with Circumvent PCV had decreased (P < 0.02) ADG and ADFI 
compared with pigs vaccinated with CircoFLEX or controls. On d 35, pigs vaccinated with 
Circumvent PCV weighed less (P < 0.01) than CircoFLEX-vaccinated or control pigs. 
RespiSure-vaccinated pigs had decreased (P ≤ 0.05) ADG compared with control pigs from d 14 
to 21 and d 21 to 29. On d 35, RespiSure-vaccinated pigs tended (P = 0.06) to weigh and 
consume less than control pigs. These data indicate diet source and vaccination timing affects pig 
performance after weaning. Vaccination for PCV2 and M. hyo independently reduced ADG and 
ADFI, but the effect was product-dependent. These factors should be considered when managing 
pigs after weaning. 
 
Key words: diet, growth, M. hyo, nursery pig, PCV2, vaccine 
Introduction 
Growth performance of pigs immediately after weaning affects performance throughout 
the growing and finishing phases of production (Tokach et al., 1992).  In addition, increased feed 
intake during the first wk after weaning reduces the risk of development of digestive disorders 
(Madec et al., 1998).  Although weaning is a stressful event known to affect performance, in late 
2007, reports from producers and veterinarians in the field indicated increased difficulty starting 
or maintaining pigs on feed immediately after weaning.  The increase in reports seemed to 
coincide with the widespread adoption of vaccination for porcine circovirus type 2 (PCV2) 
possibly indicating that circovirus vaccination may be contributing to the producer-noted 
difficulty in starting pigs on feed.  These vaccines are labeled for administration at a similar time 
when other growing pig vaccines, such as Mycoplasma hyopneumoniae (M. hyo) vaccines, are 
administered. However, throughout the United States swine industry, timing of circovirus 
vaccination has not been consistent.  In addition,  other  management factors are known to affect 
nursery pig performance, such as diet formulation (Dritz et al., 1996) and weaning age (Main et 
al., 2004).  However, there are limited data on the effects of diet manufacturing source on 
postweaning performance.  Therefore, the objectives of this series of two experiments were to: 
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(1) investigate the effects of diet manufacturing source and vaccination timing for circovirus and 
M. hyo vaccines on nursery pig performance, and (2) determine the effects of 2 commercial 
circovirus vaccines and a M. hyo vaccine on nursery pig performance. 
Materials and Methods 
Procedures used in these experiments were approved by the Kansas State University 
Institutional Animal Care and Use Committee.  Both experiments were performed at the Kansas 
State University Segregated Early Wean facility.  All pens (1.2 m × 1.2 m) were equipped with a 
single cup waterer and a 4-hole, dry, self-feeder providing pigs with ad libitum access to water 
and feed. 
In experiment one, a total of 400 weanling pigs (PIC 1050, PIC, Hendersonville, TN) 
were used in a 20-d growth study to evaluate the effects of segregated early weaning (SEW) and 
transition diet source and timing for circovirus and M. hyo vaccination on nursery pig 
performance.  Pigs (5.6 ± 1.03 kg BW) were blocked by weight and assigned to pens (5 pigs per 
pen) which resulted in 10 blocks of 8 pens with pigs of comparable weight and gender 
characteristics.  A total of 31 gilts and 369 barrows were included in this trial.  Gilts were 
distributed among pens within a single block with 7 pens accommodating 4 gilts and 1 pen 
having 3 gilts.  Treatments were arranged in a 4 × 2 factorial in a randomized complete block 
design (10 pens per treatment) with main effects of diet manufacturing source (A, B, C, or D) 
and vaccination timing (d 0 or d 8).  Within a block, each pen was randomly assigned to 1 of the 
8 treatment combinations.  All SEW and transition diets were formulated to similar nutrient 
specifications (Table 3.1) and were obtained from 4 commercial feed manufacturers.  
At weaning (d 0), a total of 0.45 kg SEW diet was budgeted per pig.  For pens within a 
diet source, after the SEW diet was placed in the feeders, a transition diet was added on top of 
the SEW diet and was fed to pigs until d 8.  On d 8, feeders were emptied prior to feeding a 
common Phase 2 diet until d 20.   
Single doses of circovirus and M. hyo vaccine were administered to pigs during the 20-d 
trial with all pigs receiving a second dose of circovirus vaccine after being weighed off test.  
According to vaccination timing treatment assignment, pigs were vaccinated with 2 mL 
Circumvent PCV (Intervet/Schering-Plough Animal Health, Millsboro, DE) and 2 mL RespiSure 
One (Pfizer Animal Health, New York, NY) on either d 0 or d 8. All vaccines were administered 
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as separate intramuscular injections in the neck according to vaccine label instructions.  Pigs 
were weighed and feed disappearance was determined on d 0, 4, 8, and 20.  From these data, 
pen-level ADG, ADFI, and G:F were calculated.  If a pig was removed from a pen, the date of 
removal and pig weight were recorded for use in performance calculations. 
In experiment two, a total of 360 weanling barrows (PIC 1050; 5.9 ± 0.91 kg BW) were 
used in a 35-d growth trial to evaluate the effects of vaccination for circovirus and M. hyo on 
nursery pig performance.  At weaning (d 0), barrows were blocked by body weight and assigned 
to pens (5 pigs per pen) to create 12 blocks of 6 pens with each pen housing similar weight pigs.  
Within blocks, pens of pigs were randomly allotted to 1 of 6 treatments in a 3 × 2 factorial 
arrangement. Main effects included circovirus vaccine and M. hyo vaccine.  The circovirus 
vaccine treatments were: (1) no circovirus vaccine (non-circovirus-vaccinated control); (2) a 2-
dose vaccine, Circumvent PCV; and (3) a 1-dose vaccine, Ingelvac CircoFLEX (Boehringer 
Ingelheim Vetmedica, Inc., St. Joseph, MO. The M. hyo vaccine treatments were: (1) no M. hyo 
vaccine (non-M. hyo-vaccinated control); and (2) a 2-dose vaccine, RespiSure (Pfizer Animal 
Health, New York, NY). All vaccines were administered as separate intramuscular injections 
according to label directions (Circumvent PCV: 2 mL per dose given on d 0 and 21; CircoFLEX: 
1 mL per dose given on d 0; RespiSure: 2 mL per dose given on d 0 and 21).   
All pigs were phase fed a similar diet within phase throughout the trial. Initially, 0.45 kg 
SEW diet was budgeted per pig, followed a transition diet until d 8.  All pigs were then fed a 
common Phase 2 diet from d 8 to 21 and a common Phase 3 diet from d 21 to 35.  Feeders were 
emptied on d 8 and d 21 prior to switching to Phase 2 and 3 diets, respectively.  Pigs were 
weighed and feed disappearance was determined on d 0, 4, 8, 14, 21, 25, 29, and 35.  From these 
data, pen-level ADG, ADFI, and G:F were calculated.  If a pig was removed from a pen, the date 
of removal and pig weight were recorded for use in performance calculations. 
Data for both experiments were analyzed as a randomized complete block designs using 
the GLIMMIX procedure in SAS version 9.1.3 (SAS Institute Inc., Cary, NC) with pen as the 
experimental unit. For experiment one, fixed effects were diet source, vaccination timing, and 
their interaction.  For experiment two, fixed effects included circovirus vaccine, M. hyo vaccine, 
and their interaction.  Weaning weight, the blocking factor, was included as a random effect for 
both experiments.  Differences between treatments were determined using least squares means 
(P < 0.05).  
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Results 
Experiment one: 
For experiment one, there were no 2-way interactions between diet source and 
vaccination timing for any response criteria with the exception of d 0 to 8 G:F.  The interaction 
(P = 0.05; Table 3.2) resulted from a crossing interaction with pigs fed diets from source B and 
not yet vaccinated having poorer (P = 0.04) G:F compared with vaccinated pigs fed diets from 
source B.  Within all other diet source treatments, pigs not yet vaccinated (d 8) had numerically 
increased or similar (P ≥ 0.07) G:F as pigs vaccinated on d 0.   
For the remainder of the responses, the main effects of diet source (Table 3.3) and 
vaccine timing (Table 3.4) are reported.  From d 0 to 4, approximately the time the budgeted 
amount of SEW diet was consumed, diet source affected (P < 0.001) ADG but not ADFI (P = 
0.22) or G:F (P = 0.28).  Pigs fed diets from source B had increased (P ≤ 0.03) ADG and d 4 
weights compared with pigs fed diets from sources A, C, or D.  Pigs fed diets from source D 
grew faster (P = 0.02) compared with pigs fed diet C and pigs fed diet A had intermediate ADG.   
From d 4 to 8, pigs fed diets from source A had increased (P ≤ 0.04) ADG compared with 
pigs fed diets from sources B, C, or D.  Contributing to this greater ADG was an increase (P ≤ 
0.04) in feed consumption for pigs fed diet A compared with pigs fed diets from sources C or D.  
In addition, pigs fed diets from source B had improved (P ≤ 0.02) ADFI compared with pigs fed 
diets from sources C or D.  Diet source tended (P = 0.07) to affect G:F with pigs fed diets from 
source A having improved G:F than that of pigs fed diets from sources B, C, or D.   
From d 0 to 8, diet source affected (P ≤ 0.001) rate of gain and feed consumption.  Pigs 
fed diets from source C had lower (P ≤ 0.01) ADG and ADFI compared with pigs fed diets from 
sources A or B while pigs fed diets from source D had intermediate ADG and ADFI.  These 
performance differences resulted in pigs fed SEW and transition diets from sources A and B 
being 0.3 kg heavier (P < 0.001) on d 8 compared with pigs fed similarly-formulated diets from 
source C. 
After pigs were placed on a common diet (d 8), diet source did not continue to affect (d 8 
to 20: P ≥ 0.18) pig performance.  Overall (d 0 to 20) ADG and G:F were not affected (ADG: P 
≥ 0.26) by diet source; however, a trend (P = 0.06) was observed for an effect of diet source on 
ADFI.  This suggested that pigs fed diets from source C had lower intake compared with pigs fed 
diets from sources A, B, or D.   
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There was no immediate effect (P ≥ 0.20) of vaccination on pig performance from d 0 to 
4 for pigs vaccinated on d 0 compared with pigs not yet vaccinated.  From d 4 to 8, pigs 
vaccinated with RespiSure One and Circumvent PCV had decreased (P ≤ 0.01) ADG and ADFI 
compared with pigs not yet vaccinated.  Therefore, during the first 8 d after vaccination, pigs 
vaccinated on d 0 had reduced (P ≤ 0.01) ADG and ADFI that resulted in vaccinated pigs 
weighing 0.2 kg less (P = 0.003) on d 8 compared with pigs not yet vaccinated.   
From d 8 to 20, pigs vaccinated on d 8 had decreased (P = 0.05) ADG compared with 
pigs vaccinated on d 0.  There was no effect (P ≥ 0.12) of vaccination timing on ADFI or G:F for 
this period. 
Overall, after all pigs had been vaccinated, vaccination timing did not affect (P ≥ 0.40) 
ADG, ADFI, or G:F.  Pigs had similar (P = 0.78) d 20 weights whether they were vaccinated 
with RespiSure One and Circumvent PCV at weaning or 8-d after weaning. 
Experiment two: 
In experiment two, there were no 2-way interactive effects between circovirus vaccine 
and M. hyo vaccine (P ≥ 0.06) observed for any response criteria, hence main effects of 
circovirus vaccine (Table 3.5) and M. hyo vaccine (Table 3.6) are reported.  Within the first 8 d 
after vaccination (d 0 to 8), circovirus vaccine treatment did not affect (P ≥ 0.26) ADG or G:F.  
However, pigs vaccinated with Circumvent PCV had decreased (P = 0.01) ADFI compared with 
pigs vaccinated with CircoFLEX and intake of non-circovirus-vaccinated pigs was intermediate.  
From d 8 to 14, pigs vaccinated with Circumvent PCV had reduced (P < 0.03) feed intake 
compared with pigs vaccinated with CircoFLEX and non-circovirus-vaccinated pigs.  There was 
no effect (P ≥ 0.12) of circovirus vaccine treatment on ADG or ADFI from d 14 to 21; however, 
G:F was improved (P = 0.02) for pigs vaccinated with Circumvent PCV compared with pigs 
vaccinated with CircoFLEX and non-circovirus-vaccinated pigs had intermediate G:F. 
In the 8-d following the second vaccination for the Circumvent PCV treatment (d 21 to 
29), pigs vaccinated with Circumvent PCV had decreased (P < 0.01) ADG and ADFI compared 
with both CircoFLEX-vaccinated pigs and non-circovirus-vaccinated pigs.  Pigs vaccinated with 
Circumvent PCV tended to have poorer (P = 0.08) G:F compared with pigs vaccinated with 
CircoFLEX or non-circovirus-vaccinated pigs.  From d 29 to 35, pigs vaccinated with 
Circumvent PCV tended to have reduced (P = 0.10) ADFI compared with CircoFLEX-
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vaccinated and non-circovirus-vaccinated pigs; however, ADG and G:F were not affected (P ≥ 
0.13) by circovirus vaccine treatment. 
Overall (d 0 to 35), rate of gain and feed intake were both reduced (P < 0.02) in pigs 
vaccinated with Circumvent PCV compared with pigs either vaccinated with CircoFLEX or 
those not vaccinated for circovirus.  Growth rate and feed consumption were similar (P ≥ 0.34) 
between CircoFLEX-vaccinated pigs and non-circovirus-vaccinated pigs.  Overall G:F was not 
affected (P = 0.30) by circovirus vaccine treatment.  The reduced ADFI and ADG for pigs 
vaccinated with Circumvent PCV resulted in pigs vaccinated with Circumvent PCV weighing 
less (P < 0.01) on d 35 compared with CircoFLEX-vaccinated pigs or non-circovirus-vaccinated 
pigs. 
The M. hyo vaccine treatment results indicate that nursery pig performance was not 
affected (P ≥ 0.40) by vaccination in the first 8-d following initial injection.  From d 14 to 21, 
pigs vaccinated with RespiSure tended to have reduced (P = 0.05) ADG compared with non-M. 
hyo-vaccinated pigs.  There was no difference (P ≥ 0.18) between M. hyo vaccine treatments for 
ADFI or G:F from d 14 to 21.   
Following the second injection of RespiSure (d 21), pigs had reduced (P ≤ 0.02) ADG 
and ADFI from d 21 to 29.  During this period, G:F was not affected (P = 0.85) by M. hyo 
vaccine treatment.  Feed intake was affected by vaccine treatment from d 29 to 35 with pigs 
vaccinated with RespiSure consuming less (P = 0.03) feed than non-M. hyo-vaccinated pigs.  
Overall (d 0 to 35), ADG and feed intake tended (P ≤ 0.10) to be reduced for pigs vaccinated 
with RespiSure compared with non-M. hyo-vaccinated pigs.  These performance differences 
resulted in pigs vaccinated with RespiSure tending (P = 0.06) to weigh less on d 35 compared 
with non-M. hyo-vaccinated control pigs.   
Although there was no 2-way interaction between circovirus vaccine treatments and M. 
hyo vaccine treatments (P = 0.68) observed, analysis of d-35 weights for the circovirus × M. hyo 
vaccine treatments measured against non-vaccinated control pigs demonstrated that 
approximately a 0.7 kg reduction in weight may be due to Circumvent PCV vaccination and an 
additional 0.5 kg reduction in weight may be due to RespiSure vaccination. Therefore, when 
Circumvent PCV and RespiSure vaccines were administered in conjunction, the negative effects 
were additive and resulted in a 1.2 kg lighter mean weight on d 35 (Figure 3.1) compared with 
the mean weight of the non-vaccinated control pigs.  
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Discussion 
Immediately after weaning, nursery pigs are exposed to a variety of stressors such as 
dietary changes, adaptation to a new environment, and alteration in social structure.  In addition, 
vaccines against several pathogens, including PCV2 and M. hyo, are often administered at a 
similar time.  It has been reported that stress effects on growth performance are additive;  thus, 
growth can be affected by removal of non-essential stressors (Hyun et al., 1998). 
Some stressful events are unavoidable as pigs must be weaned from sows, where they 
consumed a milk-only diet, and moved to locations where they are often offered a pelleted diet. 
It is known that diet formulation impacts nursery pig performance; however, there are limited 
reports that describe how variability in diets resulting from factors other than formulation could 
affect pig performance.   
The results from experiment one indicate that commercial source of SEW and transition 
diet should be considered when selecting nursery pigs diets.  Diet sources A, B, and C 
manufactured SEW diets formulated to identical nutrient and ingredient specifications. Growth 
performance of pigs fed diets from source B for the first 4 d after weaning was improved 
compared to that of pigs fed diets from the other sources.  These findings of variable growth 
performance of pigs fed similarly formulated SEW diets suggest that factors other than 
formulation must be evaluated and considered when selecting nursery pigs diets and ingredients.  
For example, use of different lactose sources in diets which are similarly formulated could affect 
pig performance because of product quality differences between the sources (Nessmith et al., 
1997).  
Manufacturing process can affect ingredient and pellet quality which in turn can impact 
the quality of the diet.  Variability between ingredient sources has been demonstrated for 
products such as whey protein concentrate (Gottlob et al., 2005).  In our study, the reason for the 
variability between sources was not determined.  It is also not known whether the characteristics 
responsible for the between-source differences would remain consistent over time.  These diet 
source effects may be dynamic as mills change suppliers for ingredients or buy ingredients over 
time.  Our experiment was designed only to determine at a single time point whether there were 
differences between commercial milling sources for similarly-formulated SEW and transition 
diets which would affect nursery pig performance. 
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Another factor that affected pig performance immediately after weaning was vaccination, 
though the effect appeared to be product-dependent.  In both experiments one and two, 
vaccination of weanling pigs with Circumvent PCV and either RespiSure One or RespiSure 
negatively impacted pig performance after vaccination.  By d 8 in experiment one, pigs 
vaccinated with both Circumvent and RespiSure One had decreased ADG and weighed 0.2 kg 
less on d 8 than pigs not yet vaccinated.  In contrast, in experiment two, the numeric differences 
in d 8 weights of non-vaccinates (6.9 ± 0.30 kg BW) compared to pigs vaccinated with 
Circumvent PCV and RespiSure (6.8 ± 0.30 kg BW, data not shown), indicated there was a 0.1 
kg weight difference by d 8.  Therefore, the magnitude of the growth responses within the first 8 
days after weaning and first injection of Circumvent PCV with an additional M. hyo vaccine 
product was greater in experiment one than in experiment two.   
The differences may have resulted from the different M. hyo vaccines used between the 
experiments.  Additionally, some of the inconsistency may have been due to pigs in experiment 
two experiencing several challenges around the time of weaning.  These challenges consisted of 
heat stress experienced during trucking followed by several pigs exhibiting lameness associated 
with a bacterial infection.  Also, in experiment two, pigs were fed common SEW and transition 
diets which were purchased from the same source as diet source C in experiment one.  Pigs fed 
the SEW and transition diets from source C did not consume those diets well in our first 
experiment.  All of these factors could have contributed to variability in growth rates after 
weaning in experiment two.   
Overall results from experiment one indicate that growth performance and feed intake 
were not different between the vaccination timing treatments.  Thus, vaccination appeared to 
cause a reduction in growth rate of pigs whether they were vaccinated with Circumvent PCV and 
RespiSure One at weaning or 8 d later.  As there was no non-vaccinated control after d 8, the 
severity of the vaccination effect between the timing treatments was not clearly defined.  It was 
also not possible to determine whether vaccinated pigs compensated in subsequent growth rate to 
overcome the negative effects of vaccination on growth performance.  
The experimental design of experiment two allowed the effects of individual vaccine 
products on performance to be determined.  Vaccination with Circumvent PCV alone contributed 
to reduction in feed intake immediately after vaccination.  Interestingly, the majority of the 
negative effect occurred after the second vaccination.  In contrast, vaccination with CircoFLEX, 
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a 1-dose circovirus vaccine, did not affect performance compared with non-circovirus-vaccinated 
pigs. 
By d 35, pigs vaccinated with Circumvent PCV had not compensated with increased 
growth rate to return to a similar weight as the non-circovirus-vaccinated pigs or the CircoFLEX-
vaccinated pigs.  Results from a different field study support these findings as it was determined 
that pigs vaccinated with a 2-dose circovirus vaccine grew slower during the nursery period than 
pigs vaccinated with a 1-dose circovirus vaccine or non-vaccinated control pigs (Vilaca et al., 
2010).   
An immediate negative effect following circovirus vaccination with the 2-dose circovirus 
vaccine has been observed in other studies though the effect has either not been consistent or was 
not maintained.  In one study, circovirus vaccine administered at 9 and 11 wk of age resulted in 
vaccinated pigs being 0.8 kg lighter (P < 0.02)  than non-vaccinated controls just 15 d after 
administration of the first dose and 1 d after the second dose of circovirus vaccine (Jacela et al., 
2011).  In a different study, compared with non-circovirus-vaccinated pigs under commercial 
conditions, Shelton et al. (2009) observed a reduction (P < 0.04) in growth rate and feed intake in 
a 2 wk period following administration of the second dose of circovirus vaccine (Shelton et al., 
2009).  Other studies evaluating the 2-dose circovirus vaccine have failed to detect any 
differences in nursery pig growth rate following circovirus vaccination (Horlen et al., 2008).  
While the effects following vaccination have been variable, the results of some studies have 
indicated that, after pigs are exposed to conditions with field-virus challenge, circovirus 
vaccination was associated with improved growth rates (Horlen et al., 2008; Jacela et al., 2011). 
The effects of the 2-dose M. hyo vaccine (RespiSure) on performance in experiment two 
mirror the effect patterns of the 2-dose circovirus vaccine.  Overall, pigs vaccinated with 
RespiSure tended to weigh less on d 35 with the majority of the negative impacts on feed intake 
and growth rate occurring after administration of the second dose of vaccine.   
The results of experiment two indicate that the effects of the circovirus and M. hyo 
vaccine used were not antagonistic or multiplicative, but were additive.  This is consistent with 
previous research which determined that stress effects were additive in nature (Hyun et al., 
1998).  Thus, the benefit that could be achieved by the removal of a single stressor should be 
predictable.  In experiment two, approximately a 0.7 kg reduction in weight on d 35 was due to 
Circumvent PCV vaccine alone and an additional 0.5 kg reduction in weight was due to 
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RespiSure vaccination (Figure 3.1).  There was no negative effect on d 35 weight associated with 
CircoFLEX vaccination.  Therefore, the effects on nursery pig performance appeared to be 
vaccine product-dependent. 
Reasons for the performance-altering differences among products at this time are not well 
defined.  However, these products vary with respect to adjuvant as well as antigen composition.  
Adjuvants affect growth performance and reproduction rate as well as impact animal comfort or 
carcass quality (Aucouturier et al., 2001).  RespiSure One and RespiSure are manufactured using 
Amphigen, a proprietary oil adjuvant with surfactant (Hoogland et al., 2006; Kuhn, 2004), 
creating an oil-in-water emulsion vaccine.   
Circumvent PCV is made with Microsol Diluvac Forte (Thacker, 2006), a proprietary 
dual oily emulsion adjuvant.  Ingelvac CircoFLEX is manufactured using ImpranFLEX (Roof, 
2010), a proprietary aqueous-based polymer adjuvant.  Although adjuvants without oil may be 
more easily tolerated, the oil phase creates a depot for longer release of antigen leading to 
potential differences in development of or duration of immunity against disease (Aucouturier et 
al., 2001).  Water-in-oil emulsions reportedly induced higher levels of antibody (Jansen et al., 
2006), yet these emulsions have the potential to be damaging to tissues due to the high oil 
content and recruitment of inflammatory cells (Aucouturier et al., 2001).  Although beneficial for 
increased antigen presentation and antibody production, the tissue damage has potential to 
produce a more pronounced inflammatory response that reduces feed intake and growth rate. 
Differences in immune system stimulation by different antigens could contribute to 
differences in performance due to the physiologic cost to development of immunity.  Derting and 
Compton (2003) reported that in white-footed mice more energy was required to produce an 
immune response compared with maintenance of immunity.  They suggested that there were 2 
mechanisms from which energy was obtained: (1) allocating it away from other physiologic 
processes, or (2) increasing feed intake.  Their results indicated that energy was directed away 
from other physiologic systems instead of promoting increased feed intake for the mouse 
(Derting and Compton, 2003).  It is possible that immune system activation caused redirection of 
nutrients from productive growth to development of protective immunity or immune response 
necessary to counteract disease processes (Colditz, 2002).  It was reported that during the height 
of an immune response, metabolic profiles of cells shifted and oxygen consumption and glucose 
utilization increased by two-fold per cell (Colditz, 2002).  Therefore, there was a metabolic cost 
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to development of immunity.  In pigs, Schinckel et al. (1995) determined that immune system 
activation by antigens including numerous vaccines and Escherichia coli lipopolysaccharide 
administered to early-weaned nursery pigs negatively affected growth rate and feed intake 
compared with control pigs not exposed to these same antigens during the nursery period.  Under 
university research conditions, the antigen-exposed pigs took approximately 4 days longer than 
control pigs to reach 120 kg (Schinckel et al., 1995). 
Despite the negative effects associated with administration of some nursery pig vaccines, 
it has been documented that circovirus vaccines and M. hyo vaccines improve pig performance 
or reduce lesion severity under field conditions with notable disease challenge (Dohoo and 
Montgomery, 1996; Horlen et al., 2008; Scheidt et al., 1994).  Therefore, results from these 
experiments should not be interpreted as advocating removal of these vaccines from disease-
affected production systems.  However, the findings in our experiments suggest potential 
negative effects of vaccine usage should be considered when implementing nursery pig 
vaccination strategies.  Altering vaccination timing may delay these effects and may be a 
strategy used if pigs are experiencing multiple stressors within a short period; however, timing of 
vaccination is sometimes dictated by the length of time before natural exposure to the pathogen 
occurs.  Vaccination timing and product factors should be considered when developing 
circovirus and M. hyo vaccination protocols to achieve optimum vaccine efficacy and minimize 
negative effects on the nursery pig. 
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Figure 3.1 The effect of circovirus vaccination and Mycoplasma hyopneumoniae (M. hyo) 
vaccination on d-35 pig weight (Exp. 2). 
A total of 360 weanling barrows (PIC 1050; 5.9 ± 0.91 kg BW) were used in a 35-d trial 
to evaluate the effects of vaccination for circovirus and M. hyo on pig performance.  At weaning 
(d 0), barrows were ranked by body weight and assigned to pens (5 pigs per pen).  Within blocks, 
pens of pigs were randomly allotted treatments in a 3 × 2 factorial arrangement with main effects 
of circovirus vaccine and M. hyo vaccine.  Circovirus vaccine treatments were: (1) Circovirus 
controls: No circovirus vaccine; (2) Circumvent PCV: pigs vaccinated with 2 mL Circumvent 
PCV (Intervet/Schering-Plough Animal Health, Millsboro, DE) administered intramuscularly on 
d 0 and 21; and (3) CircoFLEX: pigs vaccinated with 1 mL Ingelvac CircoFLEX (Boehringer 
Ingelheim Vetmedica, Inc, St. Joseph, MO) administered intramuscularly on d 0. M. hyo vaccine 
treatments were: (1) M. hyo controls: No M. hyo vaccine; and (2) RespiSure (Pfizer Animal 
Health, New York, NY) pigs vaccinated with 2 mL RespiSure administered intramuscularly on d 
0 and 21.  Data were analyzed using the GLIMMIX procedure of SAS version 9.1.3 (SAS 
Institute Inc., Cary, NC) with pen as the experimental unit.  The model included the fixed effects 
of circovirus vaccine, M. hyo vaccine, and their interaction, and a random effect of weight block.   
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Table 3.1 Composition of segregated early wean (SEW) and transition diets (Exp. 1) 
  Diet type 
 SEW  SEW Transition
2
 Transition
2
 Transition 
Ingredient, % 
(sources A, 
B, and C) 
(source D)
1
 (sources A, B, 
and C) 
(sources A, B, 
and C) 
(source D)
1
 
     Corn 33.70 25.60 37.70 37.25 26.35 
     Soybean meal (46.5% CP) 12.55 12.70 20.00 20.00 21.55 
     Spray-dried porcine plasma 6.70 6.70 2.50 2.50 2.50 
     Select menhaden fish meal 6.00 6.00 5.80 5.00 6.00 
     Spray-dried blood cells 1.65 1.65 1.25 1.25 1.25 
     Spray-dried whey 25.00 -- 12.50 25.00 -- 
     Whey permeate 6.00 25.00 11.25 -- 20.00 
     Ground oat groats -- 15.00 -- -- 15.00 
     Choice white grease 5.00 3.00 5.00 5.00 3.00 
     Monocalcium phosphate (21% P) 0.30 0.50 0.60 0.70 0.60 
     Limestone 0.45 0.60 0.45 0.45 0.60 
     Salt 0.25 0.25 0.30 0.30 0.30 
     Zinc oxide 0.36 0.36 0.36 0.36 0.36 
     Vitamin premix with phytase 0.25 0.25 0.25 0.25 0.25 
     Trace mineral premix 0.15 0.15 0.15 0.15 0.15 
     L-lysine HCl 0.15 0.30 0.30 0.26 0.30 
     DL-methionine 0.15 0.23 0.20 0.18 0.19 
     L-threonine 0.08 0.14 0.15 0.13 0.16 
     L-isoleucine -- 0.15 -- -- 0.05 
     Antibiotic
3
  1.00 1.00 1.00 1.00 1.00 
     Acidifier 0.20 0.35 0.20 0.20 0.35 
     Vitamin E, 20,000 IU 0.05 0.05 0.05 0.05 0.05 
     Total 100.00 100.00 100.00 100.00 100.00 
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Calculated analysis      
     Standard ileal digestible amino acids 
               Lysine, % 1.57 1.57 1.50 1.51 1.50 
          Methionine:lysine, % 30 34 35 33 35 
          Met & Cys:lysine, % 55 57 56 55 56 
         Threonine:lysine, % 64 62 62 63 62 
         Tryptophan:lysine, % 17 18 17 17 18 
     Total lysine, % 1.71 1.69 1.63 1.65 1.63 
     ME, kcal/kg 3,499 3,430 3,490 3,472 3,413 
     Protein, % 22.80 22.50 21.80 22.20 22.70 
     Calcium, % 0.82 0.84 0.82 0.83 0.85 
     Phosphorus, % 0.76 0.79 0.75 0.77 0.77 
     Available phosphorus, % 0.59 0.58 0.54 0.55 0.52 
1
 Source D SEW and transition diets were formulated differently from diets supplied by sources A, B, and C due to higher costs of 
whey at the time of formulation. 
2
 Diet sources A, B, and C supplied identically formulated SEW diets, but had the option of using either permeate or whey in their 
transition diets. 
3
 Antibiotics included were tiamulin (35 g/ton) and chlortetracycline (400 g/ton).
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Table 3.2 Means for the effects of diet source and vaccination timing on nursery pig performance
1
 (Exp. 1) 
Diet source: 
 
A  
 
B  
 
C  
 
D  
 
Source × Timing 
Item Timing, d: 0 8 0 8 0 8 0 8 SEM P < 
d 0 to 4 
          
ADG, g 171 188 217 219 162 162 180 203 13.6 0.67 
ADFI, g 107 111 119 133 103 101 137 118 14.8 0.71 
G:F 1.61 1.74 1.83 1.65 1.60 1.57 1.67 1.73 0.084 0.29 
d 4 to 8 
          
ADG, g 232 257 212 220 174 211 176 222 16.0 0.54 
ADFI, g 249 256 245 272 202 226 171 249 20.1 0.25 
G:F 0.94 1.01 0.88 0.81 0.85 0.93 0.60 0.89 0.085 0.22 
d 0 to 8 
          
ADG, g 202 222 215 219 168 187 178 213 11.0 0.43 
ADFI, g 178 183 182 203 152 164 154 183 10.2 0.51 
G:F 1.14
abc
 1.23
a
 1.19
ab
 1.09
c
 1.10
bc
 1.14
abc
 1.16
abc
 1.16
abc
 0.035 0.05 
d 8 to 20 
          
ADG, g 311 308 313 305 333 294 325 320 13.1 0.25 
ADFI, g 422 429 424 417 422 399 429 430 17.4 0.50 
G:F 0.74 0.72 0.74 0.73 0.79 0.74 0.76 0.75 0.022 0.45 
d 0 to 20 
          
ADG, g 267 274 274 271 267 250 266 277 10.4 0.30 
ADFI, g 324 330 327 331 314 304 319 331 13.1 0.57 
G:F 0.83 0.83 0.84 0.82 0.85 0.82 0.84 0.84 0.017 0.61 
Weight, kg 
          
d 0 5.7 5.7 5.7 5.7 5.7 5.7 5.7 5.7 0.27 0.82 
d 4 6.4 6.4 6.6 6.6 6.3 6.4 6.4 6.5 0.30 0.87 
d 8 7.3 7.5 7.4 7.4 7.0 7.2 7.1 7.4 0.33 0.52 
d 20 11.0 11.2 11.0 11.1 10.9 10.8 11.0 11.1 0.44 0.79 
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1
A total of 400 weanling pigs were used in a 20-d growth trial to evaluate the effects of segregated early wean and transition diet 
source (A, B, C, and D) and vaccination timing (d 0 or d 8). There were 5 pigs per pen and 10 pens per diet source and vaccination 
timing treatment combination.  All SEW and transition diets were formulated to similar nutrient specifications but were obtained 
from 4 commercial sources.  A single dose of circovirus and Mycoplasma hyopneumoniae vaccine was administered to pigs during 
20-d trial with a second dose of circovirus vaccine given after pigs were weighed off test.  According to vaccination timing treatment 
assignment, pigs were vaccinated with 2 mL Circumvent PCV (Intervet/Schering-Plough Animal Health, Millsboro, DE) and 2 mL 
RespiSure One (Pfizer Animal Health, New York, NY) on either d 0 or 8.  Data were analyzed using the GLIMMIX procedure of 
SAS version 9.1.3 (SAS Institute Inc., Cary, NC) with pen as the experimental unit.  Fixed effects used in the model were diet source, 
vaccination timing, and their interaction. Weight block was included as a random effect. 
abc 
Within a row, means without a common superscript letter differ (P < 0.05). 
 
 72 
Table 3.3 Means for the effect of diet source on nursery pig performance
1
 (Exp. 1) 
  Diet source     
Item A B C D SEM Probability, P < 
d 0 to 4 
      ADG, g 180
ab
 218
c
 162
a
 191
b
 10.9 < 0.001 
ADFI, g 109 126 102 127 10.7 0.22 
G:F 1.67 1.74 1.59 1.70 0.061 0.28 
d 4 to 8 
      ADG, g 244
a
 216
b
 192
b
 199
b
 12.7 0.002 
ADFI, g 252
a
 259
a
 214
b
 210
b
 15.3 0.02 
G:F 0.97 0.84 0.89 0.75 0.060 0.07 
d 0 to 8 
      ADG, g 212
ab
 217
a
 177
c
 195
bc
 9.0 < 0.001 
ADFI, g 181
ab
 192
a
 158
c
 169
bc
 8.2 0.001 
G:F 1.18 1.14 1.12 1.16 0.026 0.27 
d 8 to 20 
      ADG, g 309 309 314 323 10.9 0.52 
ADFI, g 425 421 410 429 15.8 0.29 
G:F 0.73 0.74 0.77 0.76 0.017 0.18 
d 0 to 20 
      ADG, g 270 272 259 272 8.8 0.26 
ADFI, g 327 329 309 325 11.8 0.06 
G:F 0.83 0.83 0.84 0.84 0.013 0.80 
Weight, kg 
      d 0 5.7 5.7 5.7 5.7 0.27 0.80 
d 4 6.4
a
 6.6
b
 6.3
a
 6.4
a
 0.30 < 0.001 
d 8 7.4
ab
 7.4
a
 7.1
c
 7.2
bc
 0.32 < 0.001 
d 20 11.1 11.1 10.8 11.0 0.43 0.35 
1
A total of 400 weanling pigs were used in a 20-d growth trial to evaluate the effects of 
segregated early wean and transition diet source (A, B, C, and D) and vaccination timing (d 0 
or 8). There were 5 pigs per pen and 20 pens per diet source treatment.  Four commercial diet 
sources produced similarly formulated SEW and transition pelleted diets for this experiment.  
Initially, 0.45 kg SEW diet was budgeted per pig after which transition diets were fed until d 
8 after weaning.  On d 8, feeders were emptied and a common Phase 2 diet was fed until d 20.  
Data were analyzed using the GLIMMIX procedure of SAS version 9.1.3 (SAS Institute Inc., 
Cary, NC) with pen as the experimental unit.  Fixed effects used in the model were diet 
source, vaccination timing, and their interaction. Weight block was included as a random 
effect.  Results are reported as least squares means. 
abc 
Within a row, means without a common superscript letter differ (P < 0.05). 
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Table 3.4 Means for the effect of vaccination timing on nursery pig performance
1
 (Exp. 1) 
  Vaccination timing, d 
  Item 0 8 SEM Probability, P < 
d 0 to 4 
    ADG, g 182 193 9.2 0.20 
ADFI, g 116 116 7.8 0.94 
G:F 1.68 1.67 0.046 0.97 
d 4 to 8 
    ADG, g 199 227 10.6 0.004 
ADFI, g 217 251 12.2 0.01 
G:F 0.81 0.91 0.042 0.12 
d 0 to 8 
    ADG, g 191 210 7.7 0.003 
ADFI, g 167 183 7.0 0.01 
G:F 1.15 1.15 0.020 0.79 
d 8 to 20 
    ADG, g 321 307 9.6 0.05 
ADFI, g 424 419 14.9 0.44 
G:F 0.76 0.74 0.015 0.12 
d 0 to 20 
    ADG, g 269 268 7.9 0.88 
ADFI, g 321 324 11.0 0.60 
G:F 0.84 0.83 0.011 0.40 
Weight, kg 
    d 0 5.7 5.7 0.27 0.46 
d 4 6.4 6.5 0.30 0.15 
d 8 7.2 7.4 0.32 0.003 
d 20 11.0 11.0 0.42 0.78 
1
A total of 400 weanling pigs were used in a 20-d growth trial to evaluate the effects of 
segregated early wean and transition diet source (A, B, C, and D) and vaccination timing (d 0 or 
8). There were 5 pigs per pen and 40 pens per vaccination timing treatment.  Vaccination timing 
refers to the day of vaccination.  On either d 0 or d 8, pigs were vaccinated with 2 mL 
Circumvent PCV (Intervet/Schering-Plough Animal Health, Millsboro, DE) and 2 mL 
RespiSure One (Pfizer Animal Health, New York, NY).  Data were analyzed using the 
GLIMMIX procedure of SAS version 9.1.3 (SAS Institute Inc., Cary, NC) with pen as the 
experimental unit.  Fixed effects used in the model were diet source, vaccination timing, and 
their interaction. Weight block was included as a random effect.  Results are reported as least 
squares means. 
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Table 3.5 Means for the effect of circovirus vaccination on nursery pig growth 
performance, feed intake, and feed efficiency
1
 (Exp. 2) 
  Circovirus vaccine treatment
2
 
 
Probability, 
Item  Control Circumvent PCV CircoFLEX SEM P < 
d 0 to 8 
     ADG, g 127 117 131 7.1 0.26 
ADFI, g 126
ab
 118
a
 133
b
 5.1 0.05 
G:F 0.99 0.99 0.98 0.027 0.94 
d 8 to 14 
     ADG, g 333 309 318 13.0 0.10 
ADFI, g 436
a
 396
b
 432
a
 17.1 0.03 
G:F 0.77 0.78 0.74 0.015 0.13 
d 14 to 21 
     ADG, g 470 467 462 14.1 0.81 
ADFI, g 701 673 698 19.5 0.12 
G:F 0.67
ab
 0.69
a
 0.66
b
 0.011 0.05 
d 21 to 29 
     ADG, g 485
a
 433
b
 498
a
 12.9 < 0.001 
ADFI, g 771
a
 712
b
 781
a
 18.3 < 0.001 
G:F 0.63 0.61 0.64 0.010 0.08 
d 29 to 35 
     ADG, g 680 672 679 19.9 0.88 
ADFI, g 997 980 1,023 26.5 0.10 
G:F 0.68 0.69 0.66 0.008 0.13 
d 0 to 35 
     ADG, g 405
a
 387
b
 407
a
 9.5 0.02 
ADFI, g 587
a
 560
b
 597
a
 13.5 0.003 
G:F 0.69 0.69 0.68 0.005 0.30 
Weight, kg 
     d 0 5.9 5.9 5.9 0.26 0.37 
d 21 12.2 11.9 12.1 0.43 0.29 
d 35 20.1
a
 19.5
b
 20.1
a
 0.54 0.01 
1
A total of 360 barrows were used in a 35-d study.  At weaning (d 0), barrows were ranked by 
body weight and assigned to pens.  Within weight blocks, pens of pigs were randomly allotted 
treatments in a 3 × 2 factorial arrangement with main effects of circovirus vaccine and 
Mycoplasma hyopneumoniae vaccine.  There were 5 pigs per pen and 24 pens per circovirus 
vaccine treatment.  Data were analyzed using the GLIMMIX procedure of SAS version 9.1.3 
(SAS Institute Inc., Cary, NC) with pen as the experimental unit.  The model included the 
fixed effects of circovirus vaccine, M. hyo vaccine, and their interaction, and a random effect 
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of weight block.  Results are reported as least squares means. 
2
Circovirus vaccine treatments were: (1) Control: non-circovirus-vaccinated pigs; (2) 
Circumvent PCV: 2 mL per dose of Circumvent PCV (Intervet/Schering-Plough Animal 
Health, Millsboro, DE) injected intramuscularly on d 0 and 21; and (3) CircoFLEX: 1 mL 
Ingelvac CircoFLEX (Boehringer Ingelheim Vetmedica, Inc, St. Joseph, MO) injected 
intramuscularly on d 0. 
ab 
Within a row, means without a common superscript differ (P < 0.05). 
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Table 3.6 Means for the effect of Mycoplasma hyopneumoniae (M. hyo) vaccination on 
nursery pig growth performance, feed intake, and feed efficiency
1
 (Exp. 2) 
  M. hyo vaccine treatment
2
 
 
Probability, 
Item  Control RespiSure SEM P < 
d 0 to 8 
    ADG, g 128 122 6.1 0.44 
ADFI, g 128 124 4.5 0.40 
G:F 0.99 0.99 0.022 0.91 
d 8 to 14 
    ADG, g 312 327 12.3 0.10 
ADFI, g 420 423 15.9 0.82 
G:F 0.75 0.78 0.012 0.07 
d 14 to 21 
    ADG, g 476 457 13.2 0.05 
ADFI, g 698 684 18.6 0.25 
G:F 0.68 0.67 0.010 0.18 
d 21 to 29 
    ADG, g 485 459 11.6 0.02 
ADFI, g 776 734 17.3 0.001 
G:F 0.62 0.63 0.009 0.85 
d 29 to 35 
    ADG, g 685 670 18.5 0.31 
ADFI, g 1,018 982 25.2 0.03 
G:F 0.67 0.68 0.007 0.28 
d 0 to 35 
    ADG, g 405 395 9.1 0.10 
ADFI, g 589 573 12.8 0.06 
G:F 0.69 0.69 0.004 0.62 
Weight, kg 
    d 0 5.9 5.9 0.26 0.22 
d 21 12.1 12.0 0.42 0.50 
d 35 20.1 19.7 0.53 0.06 
1
A total of 360 barrows were used in a 35-d study.  At weaning (d 0), barrows were ranked by 
body weight and assigned to pens.  Within weight blocks, pens of pigs were randomly allotted 
treatments in a 3 × 2 factorial arrangement with main effects of circovirus vaccine and M. hyo 
vaccine.  There were 5 pigs per pen and 36 pens per circovirus vaccine treatment.  Data were 
analyzed using the GLIMMIX procedure of SAS version 9.1.3 (SAS Institute Inc., Cary, NC) 
with pen as the experimental unit.  The model included the fixed effects of circovirus vaccine, 
M. hyo vaccine, and their interaction, and a random effect of weight block.  Results are 
reported as least squares means. 
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2
M. hyo vaccine treatments were: (1) Control: non-M. hyo-vaccinated pigs; and (2) 2 mL per 
dose of RespiSure (Pfizer Animal Health, New York, NY) injected intramuscularly on d 0 and 
21. 
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CHAPTER 4 - Effect of vaccination program for porcine circovirus 
type 2 and Mycoplasma hyopneumoniae on commercial pig growth 
performance, mortality, and carcass characteristics 
Summary 
Objective(s): To determine, under field conditions, the effect of vaccination program for porcine 
circovirus type 2 (PCV2) and Mycoplasma hyopneumoniae (M. hyo) on commercial pig growth 
performance, mortality, and carcass characteristics.  
 
Materials and methods: A total of 1,993 weanling pigs (25.2 ± 1.24  d of age; 7.4 ± 1.70 kg 
BW) were ranked by birth weight within litter and gender and randomly allotted to different 
vaccination programs (BI: a 1-dose, two vaccine program, or IN: a 2-dose, two vaccine 
program), each consisting of vaccines for PCV2 and M. hyo.  The BI program (Boehringer 
Ingelheim Vetmedica, Inc., St. Joseph, MO) included two, 1-dose vaccines: CircoFLEX and 
MycoFLEX (both 1 mL per dose) administered on d 0.  The IN program (Intervet/Schering-
Plough Animal Health, Millsboro, DE) included two, 2-dose vaccines: Circumvent PCV (2 mL 
per dose) and Myco Silencer ONCE (1 mL per dose) administered on d 0 and 23.  Pigs of both 
vaccination programs were comingled within pens.  Pigs were weighed on d 0 (weaning), 23, 45, 
73, and 155 (off-test) to measure ADG.  Data from 1,993 pigs were used for the mortality 
analysis while data from 1,657 pigs with complete growth records were used for the growth data 
analysis. Carcass data were analyzed from a subsample of 420 pigs harvested on a single day.   
 
Results: Overall, gilts had decreased (P < 0.001) ADG and were lighter (P < 0.001) and leaner 
(P < 0.001) than barrows.  Vaccination program did influence growth patterns.  Pigs vaccinated 
using the 2-dose, two vaccine IN program had decreased (P < 0.001) ADG from d 0 to 73 
(nursery), but tended to have increased (P = 0.06) ADG from d 73 to 155 (finishing) compared 
with pigs vaccinated using the 1-dose, two vaccine BI program.  Overall, ADG, mortality, and 
carcass characteristics were similar (P ≥ 0.14) between the vaccination programs.   
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Implications: Though there were differences in growth pattern, vaccinating pigs using the BI or 
IN vaccination program for PCV2 and M. hyo resulted in similar postweaning mortality 
percentages, growth performance, and carcass characteristics.   
 
Key words: growth, Mycoplasma hyopneumoniae, PCV2, pig, vaccine 
 
Porcine circovirus type 2 and M. hyo are significant pathogens which are endemic in 
many herds.  Porcine circovirus type 2 can cause porcine circoviral disease (PCVD) which 
manifests as a variety of clinical signs and syndromes in nursery and finishing pigs (Segalés et 
al., 2005) including pneumonia, diarrhea, death, porcine dermatitis and nephropathy syndrome, 
and a multi-systemic wasting syndrome.  Primary clinical signs of M. hyo include pneumonia 
and cough (Thacker, 2001) which, if severe, can result in production losses.   
Commercial vaccines have been available for M. hyo for more than 20 years while 
vaccines for PCV2 were licensed for use beginning less than 5 years ago.  Although it is typical 
standard practice in most United States production systems to vaccinate pigs at or around the 
time of weaning with vaccines for M. hyo and PCV2, there has been little research evaluating 
these combinations under field conditions.  Also, while vaccination against PCV2 and M. hyo 
has been effective for attenuation of clinical disease or lesions during finishing, in some studies 
vaccination for PCV2 or M. hyo negatively affected nursery pig performance immediately after 
vaccination (Kane et al., 2009; Shelton et al., 2009).  In a different study, these effects were 
product-dependent with certain vaccines having no negative effects on performance after 
vaccination (Potter et al., 2009).  These studies were limited to the nursery period (Kane et al., 
2009; Potter et al., 2009) or were performed under disease-conditions where vaccination 
improved subsequent performance compared with non-vaccinated controls (Shelton et al., 2009).  
Therefore, it was not determined whether the negative effects on growth rate experienced after 
vaccination with specific products were maintained through finishing or whether finishing 
performance varied with vaccine.  
Therefore, the objective of this field study was to compare the effects of different 
vaccination programs for PCV2 and M. hyo on commercial pig growth performance, mortality, 
and carcass characteristics. 
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Materials and Methods 
Procedures used in this study were approved by the Kansas State University Institutional 
Animal Care and Use Committee.  This study was performed in a commercial farm in northeast 
Kansas.  Nursery and finisher pens were equipped with a dry, self-feeder and a cup waterer 
which allowed all pigs to have ad libitum access to feed and water.  The herd was positive for M. 
hyo and historically had experienced clinical PCVD.  Diagnosis of PCVD had been based on 
evidence of gross abnormalities at necropsy with lesion presence confirmed by histologic 
evaluation. Immunohistochemistry was performed and demonstrated PCV2 antigen in tissues.  
After implementation of a circovirus vaccination program, clinical signs of PCVD were 
mitigated.   
Pigs born over a 22 d period in a single sow farm were used in this 155-d field trial.  At 
birth, all pigs were individually weighed and identified by a unique numbered ear-tag.  Records 
for pre-weaning mortalities were not maintained. 
At weaning (d 0), a total of 1,993 pigs (25.2 ± 1.24  d of age; 7.4 ± 1.70 kg BW) 
representing 213 litters of 2 genetic backgrounds (PIC 327 × Triumph TR24 or PIC 327 × PIC 
1050) were ranked by birth weight within litter and gender (barrow or gilt) and randomly 
assigned to different vaccination programs (BI or IN).  Each program included two vaccines, one 
for M. hyo and the other for circovirus, which were produced by a single manufacturer.   
Vaccination programs were either: (1) BI: a 1-dose, two vaccine program (vaccines 
manufactured by Boehringer Ingelheim Vetmedica, Inc., St. Joseph, MO) with Ingelvac 
CircoFLEX and Ingelvac MycoFLEX, or (2) IN: a 2-dose, two vaccine program (vaccines 
manufactured by Intervet/Schering-Plough Animal Health, Millsboro, DE) with Circumvent 
PCV and Myco Silencer ONCE.  CircoFLEX and Circumvent were the vaccinations for 
circovirus while MycoFLEX and Myco Silencer ONCE were the vaccinations for M. hyo.  For 
the BI vaccination program, unopened bottles of CircoFLEX and MycoFLEX were mixed 
(50:50) on each day of administration (d 0) and a 2 mL volume of the mixed solution (1 mL 
CircoFLEX and 1 mL MycoFLEX) was administered as a single intramuscular injection.  
Vaccines for the IN vaccination program were administered as separate intramuscular injections 
(Circumvent PCV: 2 mL per dose; and Myco Silencer ONCE: 1 mL per dose) on d 0 and 23.   
Pigs were weaned twice a week and were individually weighed and placed consecutively 
into pens in one of four 500-head nursery rooms over 6 weaning days.  There were 25 pigs per 
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pen and a room was filled completely before starting to fill the next nursery room.  Pigs of both 
vaccination programs were comingled within pens.  Pigs were individually weighed by weaning 
group on d 0 (weaning), and then were weighed by nursery and finishing room resulting in 
average weigh days of d 23 (range: d 20 to 28), d 45 (range: d 41 to 49), d 73 (range: d 68 to 79), 
and d 155 (range: d 132 to 163).  Pigs were vaccinated on d 0 (BI and IN) and d 23 (IN only) in 
accordance with their assigned vaccination program.  Immediately after vaccination, pigs were 
monitored for a “fainting” reaction.  This reaction consisted of convulsion-like activity including 
collapsing, immobility, exhibition of involuntary muscle contractions, and irregular respiration.  
Pigs appeared to recover within a short amount of time and there were no pigs that died during 
the reaction period in this study.   
Pigs were moved from the nursery rooms to a single finishing barn with multiple rooms 
and penned with 30 pigs per pen.  Pigs representing both vaccination programs were again 
comingled within pens.  Pigs within a finishing room were weighed off test on a single day.  Pigs 
that weighed 97.5 kg or greater met the minimum weight criteria for the packing plant and were 
marketed in accordance with standard farm procedures.  Carcass data were collected on a 
subsample of 420 pigs from one finishing room.  Pigs were randomly selected to have a similar 
weaning age (24.9 ± 1.32 d of age) and weight distribution (7.5 ± 1.65 kg BW) as the whole 
population.  Pigs for carcass data collection were weighed off test and individually tattooed on a 
single day and then marketed on a single day (d 167).  A total of 101 BI program-vaccinated 
barrows, 113 BI program-vaccinated gilts, 102 IN program-vaccinated barrows, and 104 IN 
program-vaccinated gilts were represented in this subsample.  Carcass data collected on the 
subsample of pigs included hot carcass weight, backfat depth, loin depth, and lean percentage.   
Mortalities were recorded throughout the trial.  Records from these pigs as well as from 
pigs which were unidentifiable because of lost ear tags, or pigs that were missing weight records 
were not used in the growth data analysis.  There were 61 pigs that died, 259 pigs missing ear 
tags, and 16 pigs with incomplete growth records.  Statistical analyses for mortality and pigs 
missing data was performed on individual records from 1,993 pigs while analysis for growth 
performance were performed on individual records from 1,657 pigs which had complete growth 
records at the end of the trial.  Statistical analyses for carcass traits were performed on individual 
records from 420 pigs.
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Analysis:  
Growth, mortality, and carcass data were analyzed by analysis of variance using the 
MIXED procedure in SAS version 9.1.3 (SAS Institute Inc., Cary, NC) to obtain least squares 
means and standard errors for all response criteria.  The statistical model included the fixed 
effects of vaccination program, gender, and their interaction.  Litter of origin was included as a 
random effect.  Individual pig was the experimental unit for all analyses.  Individual pig average 
daily gain (ADG) was calculated by dividing the period weight gain by the number days in the 
period.  For carcass data analysis, loin depth, backfat depth, and lean percentage were adjusted to 
a common average hot carcass weight. 
Significance tests were performed for comparisons of the means of fixed effects and their 
interactions.  Values of P < 0.05 were considered significant for these analyses. 
Results 
There were no 2-way interactions (P ≥ 0.23) between gender and vaccination program 
observed for any age, growth, carcass, or mortality responses.  A similar percentage of barrow 
and gilts died (barrow: 3.6 ± 0.66 % vs. gilt: 3.5 ± 0.64 %; P = 0.92) during the trial.  Similarly, 
vaccination program did not affect mortality (BI: 3.9 ± 0.65 % vs. IN: 3.3 ± 0.65 %; P = 0.49).  
A similar percentage of records were removed from analysis because of lost ear tags and 
incomplete growth records between the genders (barrow: 15.1 ± 1.29 % vs. gilt: 13.6 ± 1.28 %; P 
= 0.33) and the vaccination programs (BI: 15.5 ± 1.27 % vs. IN: 13.2 ± 1.28 %; P = 0.11).   
A similar (P = 0.23) percentage of barrows and gilts exhibited a “fainting” reaction 
following vaccination.  However, vaccination program did affect (P < 0.001; Table 4.1) the 
percentage of pigs that showed signs of the “fainting” reaction (a reaction consisting of 
convulsion-like activity) after vaccination.  The reaction was exhibited by a larger percentage of 
pigs of the IN-vaccination program than that of the BI-vaccination program.   
Mean ages were similar (P = 0.59, data not shown) between barrows and gilts at each of 
the 5 time points when pigs were weighed.  From d 0 to 23, gilts grew faster (P = 0.01) than 
barrows.  From d 23 to 45 and from d 0 to 45 there was no difference (P ≥ 0.24) in growth rates 
between the genders.  Barrows grew faster (P < 0.001) than gilts from d 45 to 73 and from d 0 to 
73 (nursery period). The late nursery increase in ADG for barrows led to heavier (P < 0.001) d 
73 weights for barrows compared with gilts.  
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From d 73 to 155 (finishing period), barrows continued to have increased (P < 0.001) 
ADG compared with gilts.  Thus, overall d 0 to 155 growth rate was increased (P < 0.001) for 
barrows compared with gilts.  On d 155, barrows were 10.6 kg heavier (P < 0.001) than gilts.  A 
greater (P < 0.001) percentage of gilts were unmarketable due to light weight at the end of the 
trial compared with barrows.   
Hot carcass weight was increased (P < 0.001) for barrows compared with gilts.  After 
adjustment to a common average HCW, barrows had increased (P < 0.001) backfat depth, 
decreased (P < 0.001) loin depth, and lower (P < 0.001) percentage lean compared with gilts.   
Mean ages were similar (P = 0.13, data not shown) between pigs of the IN vaccination 
program and those of the BI vaccination program at the 5 time points for weight data collection.  
Following the first vaccination (d 0 to 23), there was no difference (P = 0.48) observed for pig 
growth rate between the 2 vaccination programs.  However, after pigs of the IN vaccination 
program had received the second dose of both vaccines, pigs of the BI vaccination program had 
increased (P < 0.001) ADG compared with IN-program vaccinated pigs from d 23 to 45 and d 0 
to 45.  The difference in growth rate resulted in lighter (P = 0.001) d 45 weights for pigs 
vaccinated using the IN vaccination program compared with pigs vaccinated using the BI 
vaccination program.  Pigs vaccinated using the BI vaccination program continued to have 
increased (P = 0.04) ADG from d 45 to 73 compared with pigs vaccinated using the IN 
vaccination program. For the overall nursery period (d 0 to 73) pigs vaccinated using the BI 
vaccination program had increased (P < 0.001) growth rate compared with that of the pigs 
vaccinated using the IN vaccination program.  On d 73, the end of the nursery period, pigs 
vaccinated using the BI vaccination program were 1.1 kg heavier (P = 0.001) than pigs 
vaccinated using the IN vaccination program.   
Throughout the finishing period, from d 73 to 155, pigs vaccinated using the BI 
vaccination program tended (P = 0.06) to have decreased ADG compared with that of pigs 
vaccinated using the IN vaccination program.  Overall (d 0 to 155) there was no difference (P = 
0.83) in pig growth rate between the vaccination programs.  The similar overall growth rates 
resulted in no difference (P = 0.66) in d 155 (off-test) weights of pigs regardless of whether pigs 
were vaccinated using the BI vaccination program or IN vaccination program.  There was no 
difference (P = 0.67) in cull and light-weight (less than 97.5 kg) pig percentages between 
vaccination programs. 
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There was no difference (P ≥ 0.14) in HCW, adjusted backfat depth, adjusted loin depth, 
or adjusted lean percentage between pigs of either vaccination program. 
Discussion 
Vaccination against circovirus or M. hyo either reduces lesion severity or prevents active 
infection resulting in fewer clinical signs of disease (Baccaro et al., 2006; Horlen et al., 2008; 
Jacela et al., 2011; Jensen et al., 2002; Rapp-Gabrielson et al., 2008).  Despite M. hyo vaccines 
having been commercially available longer than circovirus vaccines, few independent, refereed 
studies have been published which compare 1-dose and 2-dose M. hyo products.   
Considerations when selecting a 1-dose or 2-dose vaccination protocol may be based on 
level of compliance to vaccinate.  With questionable or low compliance, implementing a 2-dose 
vaccination program could help to ensure more pigs are exposed to some amount of vaccine.  
There are limited available data comparing the efficacy of 1-dose and 2-dose M. hyo vaccines.  
However, some studies have indicated that efficacy was, at a minimum, comparable between 1-
dose and 2-dose M. hyo vaccines (Morris and Sanford, 2001; Roof et al., 2001).   
Roof et al. (2001) evaluated lung lesion severity in non-vaccinated control pigs compared 
with pigs vaccinated with 1 of 4 commercial M. hyo vaccines: (1) Ingelvac M. hyo: 1-dose 
(Boehringer Ingelheim Vetmedica, Inc., Canada), (2) Ingelvac M. hyo: 2-dose (Boehringer 
Ingelheim Vetmedica, Inc., Canada), (3) RespiSure One: 1-dose (Pfizer Animal Health, New 
York, NY), and (4) RespiSure: 2-dose (Pfizer Animal Health, New York, NY).  It was reported 
that after M. hyo challenge, with an exception for the 2-dose RespiSure product, all vaccines 
were effective at reducing lung lesion severity in vaccinated pigs compared with non-vaccinated 
controls (Roof et al., 2001).  In a different study performed under field conditions, there was no 
difference in lung lesion severity between pigs vaccinated with a 1-dose M. hyo vaccine 
(Ingelvac M. hyo) and a 2-dose vaccine (RespiSure) (Morris and Sanford, 2001).   
Although lesion severity was often reduced in pigs vaccinated against M. hyo compared 
with non-vaccinates, growth responses to M. hyo vaccines were not consistent between trials 
(Maes et al., 1999; Morrow et al., 1994).  Also, it has not been not well defined whether the 
growth responses previously reported for specific vaccines would be representative of vaccine 
responses achieved under current production practices.   
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Circovirus vaccines have been more recently evaluated than M. hyo vaccines as the first 
circovirus vaccine became available in 2006 for use in the United States.  Despite the initial 
research emphasis on circovirus vaccines, at the time of our trial, there were few side-by-side 
comparisons of 1-dose and 2-dose circovirus vaccine products and their effects on wean-to-finish 
pig performance under field conditions.  In one field study, though there were numeric 
differences, pigs vaccinated with a 2-dose circovirus vaccine (Circumvent PCV) had similar 
growth rates and off-test weights compared with pigs vaccinated with a 1-dose circovirus 
vaccine (Suvaxyn PCV2 One Dose; Fort Dodge Animal Health, Fort Dodge, IA).  Both 
vaccinated groups had improved growth performance compared with controls (Jacela, 2009).  In 
several other separate field studies, 1-dose or 2-dose circovirus vaccines were found to be 
effective at reducing lesions, viremia, mortality, or increasing finishing growth rates in 
vaccinated pigs when compared with non-circovirus-vaccinated control pigs (Fachinger et al., 
2008; Horlen et al., 2008; Jacela et al., 2011; Kixmöller et al., 2008). 
Although finishing performance can be improved by the use of circovirus vaccines, some 
circovirus and M. hyo vaccine products have been shown to negatively affect nursery pig 
performance.  One study indicated that within the 8 d after initial vaccination, pigs vaccinated 
with Circumvent PCV and RespiSure One had decreased ADG, ADFI, and lighter d 8 weights 
compared with non-vaccinated control pigs (Kane et al., 2009).  In a follow-up study, pigs 
vaccinated with Circumvent PCV had reduced ADG and ADFI compared to non-vaccinated 
control pigs or pigs vaccinated with CircoFLEX.  There were no differences in performance 
between the control and CircoFLEX-vaccinated pigs in the 35 d study.  Pigs vaccinated with the 
2-dose RespiSure vaccine had lower ADG compared with non-vaccinated control pigs from d 14 
to 21 and 21 to 25.  On d 35, pigs vaccinated with RespiSure tended to weigh less than control 
pigs (Potter et al., 2009).  Thus, these studies indicated the effects after vaccination were 
product-dependent and these effects should be considered when developing vaccination 
protocols.  However, other factors must also be considered when developing vaccination 
protocols including timing of vaccination in relation to pathogen exposure, labor and product 
costs, and product efficacy for the intended purpose.   
Our study was designed to compare 2 commonly used circovirus and M. hyo vaccination 
programs.  Each program had vaccines supplied by a single manufacturer.  The 1-dose program 
evaluated was the BI program with vaccines: MycoFLEX and CircoFLEX.  Each of these 
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vaccines contained an adjuvant, ImpranFLEX (Roof, 2010), which was a proprietary aqueous-
based polymer.  This adjuvant did not contain mineral oil.  There has been suggestion that an 
adjuvant without mineral oil may be better tolerated by an animal.  At the time of our study, 
MycoFLEX and CircoFLEX had recently received a label for combined administration as a 
single injection.  This increased the convenience of this program as a single 2 mL injection (1 
mL MycoFLEX and 1 mL CircoFLEX) was administered to each pig.   
The 2-dose, two vaccine program evaluated was the IN program with vaccines: Myco 
Silencer ONCE and Circumvent PCV.  Myco Silencer ONCE had a dual label for administration 
as a single 2 mL dose or as a split 2-dose (1 mL per dose) administration.  We administered the 
vaccine using the 2-dose regimen as that was the protocol being used by the production system at 
the time of our study.  Therefore, a total of 2 injections, 1 mL Myco Silencer ONCE and 2 mL 
Circumvent PCV, were administered twice for this second vaccination program.  Each of these 
vaccines contained the adjuvant, Microsol Diluvac Forte (Thacker, 2006), a proprietary dual oily 
emulsion adjuvant.  Results from our study indicate that pigs vaccinated using the 2-dose, two 
vaccine IN program had decreased growth performance from d 0 to 73 compared to the pigs 
vaccinated using the BI program.  The majority of this decrease in performance occurred after 
administration of the second dose of IN vaccines.  Previous reports supported these findings 
(Potter et al., 2009; Shelton et al., 2009).  It could not be determined whether the BI vaccination 
program had any negative effect on the growth rate of the weaned pig as non-vaccinated control 
pigs were not included in the study.  At the time our study was designed, pigs left not vaccinated 
for PCV2 in this commercial system were at risk for PCV2 infection and production loss.  
In contrast to the d 0 to 73 results, from d 73 to 155 growth rates effects were reversed.  
Pigs vaccinated with the 2-dose IN vaccines tended to have improved performance compared 
with pigs vaccinated with BI vaccines.  These growth rate differences resulted in pigs being of 
similar average off-test weight between vaccination programs.  In addition, vaccination program 
did not affect percentage of cull and light-weight pigs.   
Historically M. hyo and PCV2 affected pigs primarily during the finishing period, thus, it 
was our speculation that these late growth rate differences occurred as a result of differences in 
immunity.  It was not possible to separate the effects of the circovirus and M. hyo vaccination 
nor do we know the level of pathogen exposure which occurred during our study.  However, in a 
field study using a M. hyo-free herd, Vilaca et al. (2010) reported growth performance patterns 
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which were similar to those observed in our study which was performed in a M. hyo-positive 
herd.  In their study, pigs were assigned to either a 1-dose circovirus vaccination (1 mL per dose) 
treatment, a 2-dose vaccination (2 mL per dose) treatment, or a saline-injected control treatment.  
Their results indicated a decrease in nursery performance associated with the 2-dose circovirus 
vaccination compared with the 1-dose vaccination treatment and the controls.  During the 
finishing period in their study, growth rates were increased for the pigs vaccinated with the 2-
dose product compared with pigs vaccinated with the 1-dose vaccine or the control pigs.  Growth 
rates were also greater for pigs in the 1-dose vaccinated treatment compared with the control 
pigs.  Viremia was confirmed in the study by PCV2 polymerase chain reaction (Vilaca et al., 
2010).   
For our study, the overall growth performance, mortality, and carcass characteristics were 
not different between the 2 circovirus and M. hyo vaccination programs.  These data would 
suggest that either program would result in the same outcome for producers who own pigs from 
weaning to market.  However, these results may especially be of interest to those who buy or sell 
pigs prior to the finishing period.  Nevertheless, further investigation of different vaccination 
programs may be warranted to fully explain the resulting differences in growth performance 
patterns.  Although growth rates varied by period between the vaccination programs, in this 
commercial herd, the circovirus and M. hyo vaccination program used did not affect overall pig 
performance, mortality, or carcass characteristics.   
Implications 
 The 1-dose, two vaccine (BI; CircoFLEX and MycoFLEX) or 2-dose, two vaccine (IN; 
Circumvent PCV and Myco Silencer ONCE) vaccination program for circovirus and M. 
hyo resulted in similar overall growth performance despite differences in pattern of 
growth rate. 
 Growth performance from d 0 to 73 (nursery period) was improved by the BI vaccination 
program while d 73 to 155 (finishing period) growth performance tended to be improved 
by the IN vaccination program. 
 Mortality and carcass characteristics were not different between the 1-dose, two vaccine 
program or the 2-dose, two vaccine program for vaccination against porcine circovirus 
type 2 and M. hyo. 
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Table 4.1 Effect of gender or vaccination program on reactions, performance, light-weight pig percentages, and carcass traits
1 
  Gender   Vaccination program
2
   Probability, P < 
Item Barrow Gilt   BI IN   Gender Program 
"Fainting" reaction, %
3
 1.1 ± 0.32 0.6 ± 0.31 
 
0.0 ± 0.32 1.7 ± 0.32 
 
0.23 <0.001 
ADG, g 
        D 0 to 23 334 ± 4.4 343 ± 4.3 
 
337 ± 4.3 340 ± 4.3 
 
0.01 0.48 
D 23 to 45 643 ± 5.7 637 ± 5.7 
 
656 ± 5.7 623 ± 5.7 
 
0.24 <0.001 
D 0 to 45 485 ± 4.6 487 ± 4.5 
 
493 ± 4.5 479 ± 4.5 
 
0.68 <0.001 
D 45 to 73 746 ± 6.1 676 ± 6.0 
 
718 ± 6.0 704 ± 6.0 
 
<0.001 0.04 
D 0 to 73
4
 587 ± 4.6 561 ± 4.5 
 
581 ± 4.5 567 ± 4.5 
 
<0.001 <0.001 
D 73 to 155
5
 915 ± 5.3 811 ± 5.3 
 
857 ± 5.3 868 ± 5.3 
 
<0.001 0.06 
D 0 to 155
6
 761 ± 4.2 694 ± 4.2 
 
728 ± 4.2 727 ± 4.2 
 
<0.001 0.83 
Weight, kg 
        D 0 (weaning) 7.6 ± 0.08 7.5 ± 0.08 
 
7.5 ± 0.08 7.5 ± 0.08 
 
0.11 0.57 
D 23 15.2 ± 0.16 15.2 ± 0.16 
 
15.2 ± 0.16 15.2 ± 0.16 
 
0.56 0.92 
D 45 29.1 ± 0.27 29.0 ± 0.27 
 
29.4 ± 0.27 28.7 ± 0.27 
 
0.82 0.001 
D 73 50.3 ± 0.39 48.3 ± 0.38 
 
49.8 ± 0.38 48.7 ± 0.38 
 
<0.001 0.001 
D 155 (off-test) 125.7 ± 0.71 115.1 ± 0.70 
 
120.6 ± 0.70 120.3 ± 0.70 
 
<0.001 0.66 
Culls and < 97.5 kg BW, %
7
 5.9 ± 1.10 11.4 ± 1.08 
 
8.3 ± 1.08 8.9 ± 1.08 
 
<0.001 0.67 
Carcass characteristics
8
 
        HCW, kg 97.4 ± 0.84 91.2 ± 0.83 
 
93.9 ± 0.82 94.7 ± 0.83 
 
<0.001 0.41 
Backfat depth, mm
9
 19.8 ± 0.47 17.1 ± 0.47 
 
18.2 ± 0.46 18.7 ± 0.47 
 
<0.001 0.14 
Loin depth, mm
9
 55.5 ± 0.49 58.4 ± 0.48 
 
56.7 ± 0.47 57.2 ± 0.48 
 
<0.001 0.41 
Lean percentage, %
9
 51.8 ± 0.18 53.3 ± 0.18   52.6 ± 0.18 52.5 ± 0.18   <0.001 0.59 
1
 A total of 1,993 weanling pigs (initially 25.2 ± 1.24 d of age; 7.4 ± 1.70 kg BW)  were used in a wean-to-finish growth trial to 
evaluate the effects of gender (barrow or gilt) and circovirus and Mycoplasma hyopneumoniae vaccination program (BI: a 1-dose, 
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two vaccine program, or IN: a 2-dose, two vaccine program) on pig performance.  Weaning occurred twice a week and pigs 
consecutively placed in 4 nursery rooms were started on test over 6 weaning days.  Pigs were then weighed by nursery or finishing 
room resulting in average weigh days of d 23, 45, 73, and 155 (off-test).  Growth data analysis was performed on records from 1,657 
pigs (initially 25.1 ± 1.22 d of age) which had complete growth records at off-test.  Data for the gender effect were from 805 barrows 
and 852 gilts while data for the effect of vaccination program were from 820 BI-program vaccinated pigs and 837 IN-program 
vaccinated pigs.  Results were reported as least squares means ± SEM. 
2
 Pigs assigned to the 1-dose, two vaccine BI vaccination program received 1 mL Ingelvac CircoFLEX (Boehringer Ingelheim 
Vetmedica, Inc., St. Joseph, MO) and 1 mL Ingelvac MycoFLEX (Boehringer Ingelheim Vetmedica, Inc., St. Joseph, MO) as a 
single intramuscular injection on d 0.  Pigs assigned to the 2-dose, two vaccine IN vaccination program received 2 mL Circumvent 
PCV (Intervet/Schering-Plough Animal Health, Millsboro, DE), and 1 mL Myco Silencer ONCE (Intervet/Schering-Plough Animal 
Health, Millsboro, DE) as separate intramuscular injections on d 0 and 23. 
3
 "Fainting" reaction exhibited after vaccination characterized by immediate convulsion-like activity. 
4
 Nursery ADG. 
5
 Finisher ADG. 
6 
Wean-to-finish ADG. 
7
 Percentage of pigs considered to be culls or weigh less than 97.5 kg (minimum weight for the packing plant) on d 155. 
8
 Carcass data were collected on a subset of 420 pigs (203 barrows and 217 gilts; 214 BI-program vaccinated and 206 IN-program 
vaccinated pigs) harvested on a single day from a single finishing room.  Pigs were randomly selected to have a similar weaning age 
(24.9 ± 1.32 d of age) and weight distribution (7.5 ± 1.65 kg BW) as the whole population. 
9
 Carcass traits were adjusted to a common average HCW. 
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CHAPTER 5 - Utilizing vaccination for porcine circovirus type 2 
(PCV2) as a tool to aid elimination of PCV2 from swine populations 
Abstract 
Objective: To determine whether circovirus vaccination influenced porcine circovirus type 2 
(PCV2) circulation within a herd and could be used as a tool to eliminate PCV2 from PCV2-
positive swine herds.   
 
Design: Phases 1 and 5 used a cross-sectional and phases 2, 3, and 4 used a longitudinal design.  
 
Animals: A total of 928 pigs from the Michigan State University (MSU) Swine Teaching and 
Research Center, Kansas State University (KSU) Swine Teaching and Research Center, and a 
Kansas commercial farm were used during a 3-year monitoring study. 
 
Procedures: Infection with PCV2 was confirmed by polymerase chain reaction (PCR) and 
indirect fluorescent antibody (IFA) testing in both university herds before introduction of 
circovirus vaccine.  After vaccination implementation, vaccinated barrows were selected from 
consecutive weaning groups and serially bled for detection of viremia.  Follow-up testing with 
circovirus-vaccinated and non-vaccinated pigs was performed at the KSU farm.  Pigs were 
individually weighed and a subsample bled 4 times for antibody detection.  In a circovirus-
vaccinated commercial herd, serial-bleeding and PCV2 PCR testing on serial serum samples 
from 85 non-circovirus-vaccinated pigs was completed.  Testing by PCV2 PCR was performed 
on environmental swab samples collected from facilities at the KSU and commercial farms. 
 
Results: Sera from 0 of 9 MSU vaccinated-cohorts and 3 of 10 KSU vaccinated-cohorts had 
detectable PCV2 DNA.  Of the three KSU cohorts that had detectable PCV2 DNA, only one 
group had more than one sample with detectable PCV2 DNA.  From follow-up testing, a PCV2 
antibody rise after vaccination was detected for vaccinated pigs with no detectable rise in 
antibody for the non-vaccinated pigs.  Overall growth rate of non-vaccinated pigs tended (P = 
0.07) to be increased compared with vaccinated pigs.  Antibody and growth results indicate a 
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lack of PCV2 exposure at the KSU farm.  In contrast, non-vaccinated pigs did become PCV2 
viremic at the commercial farm.  Viral DNA was detected in the environment of the commercial 
farm but not from the KSU facilities. 
 
Conclusions and Clinical Relevance: Circovirus vaccination affected PCV2 circulation in the 
university herds that appeared to have low initial viral exposure. However, viral circulation was 
unaffected in a commercial herd where environmental PCV2 viral sources were detected.  
Circovirus vaccine provided a tool to affect viral circulation on farms but would need to be used 
in conjunction with other management practices to eliminate PCV2 from most swine 
populations. 
Introduction 
Porcine circovirus type 2 (PCV2) is a necessary agent for causing porcine circovirus 
disease (PCVD), a multi-syndrome, production-damaging disease (Segalés et al., 2005).  
Identified in diagnostic laboratory samples back to the early 1990’s, PCV2 has affected most 
United States swine herds.  Despite a long history of PCV2 circulation within the swine 
population, vaccines against PCV2 have only been commercially-available since 2006 
(Opriessnig et al., 2009).  Initial studies evaluating the effects of circovirus vaccination on 
production parameters in PCV2-affected herds indicated that vaccination was effective at 
reducing finishing phase mortality and increasing pig growth rate (Fachinger et al., 2008; Horlen 
et al., 2008; Kixmöller et al., 2008).  In single-cohort studies, vaccination with commercial or 
experimental vaccines against PCV2 reduced viremia (Fachinger et al., 2008; Kixmöller et al., 
2008) and decreased viral shedding in nasal secretions and feces (Fort et al., 2008; Fort et al., 
2009).  However, there are limited data evaluating the effects of vaccination on PCV2 viral 
circulation within a herd over time.  Our goal was to monitor PCV2 viral circulation in swine 
herds after implementing a circovirus vaccination program for growing pigs.  The short-term 
objective of this project was to determine whether circovirus vaccination could be used to affect 
viral circulation within 2 farrow-to-finish herds. The long-term objective for the project was to 
understand whether use of circovirus vaccines over time in PCV2-positive swine herds could 
provide a tool to eliminate PCV2 from these herds.  
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Materials and Methods 
Procedures used in these studies were approved by the Kansas State University and 
Michigan State University Institutional Animal Care and Use Committees. 
Herd History: 
The Michigan State University (MSU) and Kansas State University (KSU) Swine 
Teaching and Research Centers were single-location farrow-to-finish operations. Pigs were 
moved through the KSU farm in an all-in, all-out manner in nursery, grower, or finisher rooms.  
In the MSU farm, about half of the pigs placed in a nursery, grower, or finisher room were 
moved in and out at a time.  Pigs were born (farrowed) at each farm approximately every 4 
(MSU) or 5 (KSU) wk which resulted in growing pig populations of about 300 pigs in each age 
group.  Both herds were negative for porcine reproductive and respiratory syndrome virus and 
the MSU herd was negative for Mycoplasma hyopneumoniae (M. hyo).  Pigs at the KSU farm 
were vaccinated at weaning for M. hyo (RespiSure-ONE; Pfizer Animal Health, New York, NY) 
which, along with other management procedures, contributed to low levels of clinical disease.  
Prior to the start of our study, both farms had been closed to live animal introductions; however, 
semen was introduced from outside sources.  In October 2007, the KSU farm began to bring 
replacement gilts from an outside source into the herd approximately every 9 wk.   
Clinical History: 
The KSU farm did not have any clinical signs of PCVD noted before the baseline testing 
and subsequent implementation of a circovirus vaccination program. Although prior to baseline 
testing, histopathologic evaluation on tissues of one pig documented lymphoid depletion lesions 
consistent with PCVD.  The MSU farm had evidence of moderate clinical PCVD (10 to 15% 
nursery mortality) prior to baseline testing.  
Phase 1: Baseline testing procedures 
In early 2007, a cross-sectional survey was conducted of each university herd to verify 
the presence of PCV2 and to characterize patterns of PCV2 infection and seroconversion.  At the 
MSU farm, blood was collected from 101 pigs across a total of 5 growing pig populations (6 to 
10, 11 to 15, 16 to 20, 21 to 25, and 26 to 30 wk of age).  Within the KSU farm, 141 pigs were 
sampled across 5 growing pig populations (4, 9, 14, 19, and 24 wk of age).  Serum was pooled 
(MSU: 21 pools, and KSU: 27 pools) within age group and analyzed using the Kansas State 
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Veterinary Diagnostic Laboratory (KSVDL) PCV2 PCR assay for detection of PCV2 nucleic 
acid.  Viral template quantities for each serum pool were log10 transformed and transformed 
results were averaged for pools within each age range to characterize the changes in viral load.  
For the detection of PCV2 antibodies, individual serum samples were tested using the 96-well 
format KSVDL PCV2 IFA assay with serial 1:2 dilutions beginning with a 1:20 serum to 
phosphate-buffered saline dilution and ending with a 1:2,560 ratio.  The titration endpoint was 
calculated as the reciprocal of the last serum dilution that gave a positive result. Diagnostic 
testing methods were accepted and validated in accordance with the American Association of 
Veterinary Laboratory Diagnosticians’ standard requirements necessary for diagnostic laboratory 
accreditation. 
All IFA titers were log2 transformed to approximate a normal distribution prior to 
descriptive analysis.  For samples which did not have antibody detected at the most concentrated 
dilution (1:20), the log2 of 10 was used in the analysis.  For samples which were considered by 
the trained IFA technician to be strongly positive at the least concentrated dilution (1:2,560), the 
log2 of 5,120 was used.  This allowed these results to be weighted differently than samples with 
antibody detected with a normal level of fluorescence at the 1:20 and 1:2,560 dilutions.   
Infection and antibody profiles obtained from the baseline testing were considered when 
deciding on sampling times for the Phase 2 study on each farm. 
Phase 2: Trial procedures 
In the spring of 2007, both MSU and KSU initiated circovirus vaccination programs.  A 
2-dose circovirus vaccine (Circumvent PCV; Intervet/Schering-Plough, Millsboro, DE) was 
administered as an intramuscular injection (2 mL per dose) to all growing pigs in each weaning 
group with 3 to 5 wk between vaccine doses.  Pigs were weaned and vaccinated with the first 
dose of circovirus vaccine at approximately 3 wk of age at the KSU farm while at the MSU farm 
there was some variation within weaning age or timing of first vaccination (range: 2 to 6 wk).   
From 2007 to 2008, barrows from consecutive weaning cohorts at the MSU (9 groups) 
and KSU (10 groups) farms were monitored for PCV2 viremia.  A minimum of 12 barrows per 
group from different litters were randomly selected, ear-tagged, and serially-bled at 4 time-
points: weaning or just before vaccination, entry-to-finishing, mid-finishing, and end-of-
finishing.  After completion of data collection in 2008, individual serum samples for pigs with 
complete serum sets (4 serum samples per pig) were tested by the KSVDL PCV2 PCR assay for 
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detection of PCV2 nucleic acid.  An average of 40 cycles was run with a cycle time threshold of 
0.05 for classification of PCV2 nucleic acid-containing (positive) samples. 
Phase 3: Follow-up monitoring procedures 
Beginning in the spring of 2009, a total of 372 pigs (186 non-vaccinated control pigs and 
186 circovirus-vaccinated pigs) across 3 weaning groups were used in a Phase 3 growth and 
PCV2 antibody follow-up study at the KSU farm.  At the start of the Phase 3 study, the KSU 
farm had been vaccinating pigs against PCV2 for the previous 2 years.  During that time there 
had been no evidence of clinical disease.  A first objective of this follow-up study was to 
document the effects of circovirus vaccination on PCV2 antibody titers and to determine whether 
there was evidence of PCV2 exposure.  A second objective of this Phase 3 study was to evaluate 
the effects of circovirus vaccination on growth rate of pigs in the KSU herd.   
Three groups of pigs were used in the Phase 3 study.  For groups 1 and 2, there were 7 
pigs per nursery pen.  A total of 18 barrow pairs (36 pigs; 1 pair in each of 18 pens) for group 1 
and 30 barrow pairs (60 pigs; 1 pair in each of 30 pens) for group 2 were utilized. Within a pen, a 
pair of barrows was selected with one barrow per pair randomly allotted to a vaccinated 
treatment and the pen-mate barrow assigned to the non-vaccinated control treatment.  Barrows 
assigned to the vaccinated treatment were injected intramuscularly with a 2-dose circovirus 
vaccine (Circumvent PCV) at approximately 3 and 6 wk of age.  All other pigs in the weaning 
group not enrolled in the follow-up study were vaccinated with the same 2-dose circovirus 
vaccine.  
Throughout the entire study, pairs of barrows remained penned together thereby ensuring 
the same diets were fed to both vaccinated and non-vaccinated barrows.  Each pair also 
experienced the same environmental and pig exposures.  Barrows were individually weighed and 
bled at 4 time-points: d 0 (pre-vaccination), entry-to-finisher, mid-finishing, and end-of-
finishing.  From these data, average daily gain (ADG) was calculated for 3 periods: nursery and 
grower, finisher, and overall nursery to finisher.  Removals and mortalities were recorded and 
weighed and their gain and time on test were included in performance calculations. 
For group 3, 138 barrow or gilt pairs (276 pigs) were randomly allotted to treatments 
(vaccinated or non-vaccinated control) at the time of weaning with procedures similar to those 
used for groups 1 and 2.  However, for group 3, there were 6 or 8 pig per nursery pen (3 of 4 
pairs within a pen) and all pigs were placed on test.  Pigs assigned to the vaccinated treatment 
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were injected intramuscularly with a 2-dose circovirus vaccine (Circumvent PCV) at 
approximately 3 and 9 wk of age.  Weighing and penning procedures for each pair were similar 
to those used for groups 1 and 2.  A subset of 20 barrow pairs (40 pigs) from 20 different pens 
distributed throughout the nursery were bled at the time of weighing.  Pairs of barrows were 
selected and, within each pair, one barrow was randomly assigned to a vaccinated treatment and 
the pen-mate barrow assigned to the non-vaccinated control treatment.  For group 3, removals 
and mortalities were recorded and weighed and their gain and time on test were included in 
performance calculations. 
Once all serum had been collected, individual serum samples for groups 1, 2, and 3 were 
tested for PCV2 antibodies using the KSVDL IFA assay.  Test procedures used were similar to 
those used in Phase 1; however, an initial serum to phosphate-buffered saline dilution of 1:40 
was used with subsequent serial 1:3 dilutions for groups 1, 2, and 3 samples.  To account for 
variability due to IFA plate, all samples for each pair of pigs were tested on the same IFA plates 
with the exception of 1 pair which had samples from each bleed tested across 4 IFA plates 
because of sample space availability.  Samples were randomly assigned to plate wells and 
negative and positive controls were run on each IFA plate.  Testing was performed over 7 days 
(2 days for group 1, 3 days for group 2, and 2 days for group 3) and pairs of pigs were balanced 
across IFA days within each study.   
Group 1, 2, and 3 IFA titers were log3 transformed to approximate a normal distribution 
prior to statistical analysis.  For samples which did not have antibody detected at the most 
concentrated dilution (1:40) the log3 of 13.3 was used in the analysis while the log3 of 262,440 
was used for analysis for samples which were considered by a single trained IFA technician to be 
strongly positive at the least concentrated dilution (1:87,480). This allowed these samples to be 
weighted differently than positive samples with normal level fluorescence at 1:40 and 1:87,480. 
Group 1, 2, and 3 IFA data were analyzed by repeated measures analysis using the 
GLIMMIX procedure in SAS version 9.1.3 (SAS Institute, Inc., Cary, NC).  Fixed effects in the 
model included treatment, time, and their interaction.  Group and IFA day were used as random 
effects.  Differences between treatments were determined using least squares means (P < 0.05).  
Log3 transformed least squares means were transformed back to the original scale for 
presentation as geometric mean titers (GMT). 
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Growth data were analyzed using the GLIMMIX procedure in SAS version 9.1.3.  The 
interaction with gender and treatment was determined to be non-significant for group 3, and 
growth data was pooled across the genders for subsequent analysis of the treatment effect.  Thus, 
growth data for all 3 groups were analyzed using a single model.  Treatment was a fixed effect 
and group was included as a random effect.  Differences between treatments were determined 
using least squares means (P < 0.05). 
Phase 4: Monitoring for PCV2 under commercial conditions 
A commercial farm in Kansas, determined to have had severe PCVD before circovirus 
vaccine became available, was selected as a herd for an additional monitoring study (Phase 4) 
because of proximity and clinical history.  Prior to the introduction of circovirus vaccine, 
postweaning mortality had ranged from 5% to 19%.  After implementation of a circovirus 
vaccination program (Circumvent PCV) the herd had less apparent clinical disease (mortality: 
4% to 9%).  The circovirus vaccination program had been in place for a year before our Phase 4 
study began.  In addition to the history of PCV2 infection, porcine reproductive and respiratory 
syndrome virus and M. hyo also contributed to the health challenges in the nursery and finishing 
phases of production.  Pigs were weaned from a sow farm in western Kansas and moved to 
eastern Kansas to be placed at a nursery-finishing site.  There were 2 nursery barns with 4 rooms 
each and 8 finishing barns at the site.  Pigs were moved all-in, all-out by nursery room and 
finishing barn. 
A total of 85 pigs (1.7 to 3.1 wk of age) from a 1,100 pig weaning group were ear-tagged 
and bled just prior to weaning.  These 85 pigs were not vaccinated against PCV2 and were 
monitored for 9 wk.  All other pigs in the weaning group were vaccinated according to standard 
farm protocol with a 2-dose circovirus vaccine (Circumvent PCV).  The 85 non-vaccinated 
sentinel pigs were initially penned in 4 pens in the nursery room which also contained pens of 
circovirus-vaccinated pigs.  If pigs were removed from their initial pens because of illness or 
injury, they were moved to a sick pig pen but were still monitored.  After approximately 8 weeks 
in the nursery, pigs were moved to a single finisher barn at the same farm location and were 
placed in pens according to their vaccination status.  Pigs were bled approximately every 3 wk 
for a total of 4 sampling times (sampling time age ranges: 1.7 to 3.1, 4.9 to 6.3, 7.9 to 9.3, 10.9 to 
12.3 wk of age).  The objective of this monitoring effort was to determine whether non-
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vaccinated pigs housed in barns with pigs vaccinated against PCV2 became viremic with PCV2 
after circovirus vaccine was used in the herd for a year. 
Serum samples were pooled (5 samples per pool) within age range and were analyzed by 
the KSVDL PCV2 PCR assay for presence of PCV2 nucleic acid.  Genotype of PCV2 (PCV2a 
or PCV2b) was determined for samples with detectable PCV2 nucleic acid. 
Phase 5: Monitoring for PCV2 in the environment of swine barns 
As pigs involved in all previous phases of this study were exposed to different 
environments and pigs over time, it was of interest to determine whether there were 
documentable sources of PCV2 exposure.  The objective for this phase of monitoring was to 
demonstrate applicability of swabbing and PCV2 PCR testing as a method for monitoring PCV2 
levels on environmental surfaces in swine production facilities.   
Swab samples were collected from the nursery and finisher rooms at both the KSU farm 
and the commercial farm in eastern Kansas which was used in the Phase 4 study.  Cotton swabs 
were used to sample the floor slats, gating, waterers, feeders, fans and heaters in the nursery or 
finishing rooms.  Swabs were placed in vials containing enriched media.  For each farm, samples 
were pooled within nursery or finishing production phases (2 KSU nursery or finishing pools and 
16 commercial farm nursery or finishing pools).  A uniform amount of this pooled suspension 
was tested by KSVDL PCV2 PCR for detection of PCV2 nucleic acid.   
Results  
Phase 1: 
Baseline PCV2 IFA testing of the serum collected from pigs from the MSU herd 
demonstrated that passively-acquired antibody declined by 15 wk of age (Figure 5.1).  Higher 
levels of antibody were apparent in pigs 16 to 20 wk of age or older.  There was PCV2 nucleic 
acid detected by PCR in serum samples from pigs 11 to 15 wk of age and older (Figure 5.2).   
In the baseline analysis of the KSU herd (Phase 1), passively-acquired antibody in 
growing pigs declined by 19 wk of age with higher levels of antibody detected following this 
decline (Figure 5.3).  Viremia was detectable only in populations consisting of pigs which were 
19 and 24 wk of age (Figure 5.4).  The 19-wk old pigs were viremic but did not have antibody 
levels suggestive of seroconversion.
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Phase 2: 
After introduction of circovirus vaccination, PCV2 PCR testing of serum samples 
collected over time from 9 MSU and 10 KSU cohort groups showed a different infection pattern 
on each farm compared with baseline PCR profiles.  From the MSU farm, PCV2 PCR testing on 
sera collected from 86 barrows at 4 sampling points (pre-vaccination, entry-to-finishing, mid-
finishing, and end-of-finishing) failed to detect PCV2 nucleic DNA (Table 5.1).   
From the KSU farm, testing by PCV2 PCR on serum samples from 111 barrows failed to 
detect nucleic acid (PCV2 PCR negative) in samples collected at any time from pigs in groups 1, 
2, 4, 7, 8, 9, and 10 (Table 5.2).  Serum samples with detectable PCV2 DNA (PCV2 PCR 
positive) were found in group 3 (10%, 1/10 samples from mid-finishing), group 5 (25%, 3/12 
samples from weaning; 25%, 3/12 samples from entry-to-finishing; 8.3%, 1/12 samples from 
mid-finishing; and 8.3%, 1/12 samples from end-of-finishing), and group 6 (8.3%, 1/12 samples 
from entry-to-finishing).  For serum samples with detectable DNA, viral template quantity 
ranged from 5 to 379 viral template copies per reaction.  In only 1 (group 5) of the 10 groups 
(10%) did a pig remain viremic for longer than 1 testing interval.  Overall, no PCV2 viral DNA 
was detected in samples from 7 of the 10 groups (70%) monitored over a time period of greater 
than 1 year.   
Phase 3: 
After 2 years of vaccinating growing pigs against PCV2 at the KSU farm, subsamples of 
pigs were allocated to a circovirus-vaccinated treatment or a non-vaccinated control treatment in 
a growth and PCV2 antibody follow-up study (Phase 3).  There was an interaction (P < 0.001) 
between treatment and time for antibody level (Table 5.3).  With the exception of the initial 
bleed (d 0; during the wk of weaning) when control and vaccinated pig antibody levels were 
similar (P = 0.41), vaccinated pigs had increased (P < 0.001) PCV2 antibody levels compared 
with controls at all other sampling times.  The magnitude of the antibody responses varied over 
time for control and vaccinated pigs as did the pattern of antibody production or decay.  By the 
time the pigs were placed into the finisher, control pig antibody levels had declined (P < 0.001) 
compared with their respective d 0 levels; however, throughout the finishing period control pig 
antibody levels remained similar (P ≥ 0.61).  In contrast, compared with their respective d 0 
antibody levels, vaccinated pigs had an increase (P < 0.001) in PCV2 antibody titer by the time 
of entering the finisher which decreased (P < 0.001) by each of the subsequent sampling points. 
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During the nursery and grower periods, vaccinated pigs had decreased (P = 0.005; Table 
5.4) ADG compared with non-vaccinated control pigs.  Vaccinated and control pigs had similar 
(P = 0.30) finishing ADG though growth rates for vaccinated pigs continued to be numerically 
less than control pig growth rates.  Overall, there was a tendency (P = 0.07) for vaccinated pigs 
to have decreased ADG compared with control pigs.  These growth rate differences resulted in 
control pigs entering the finisher being 1.2 kg heavier (P = 0.03) than vaccinated pigs.  When 
pigs were taken off test at the end of the finishing period, control pigs had a numeric weight 
advantage (P = 0.16) of 2.0 kg over vaccinated pigs.   
Phase 4: 
Results obtained from the commercial farm with a 1-year history of circovirus-
vaccination were different than those observed in the KSU farm.  From a serial sampling of 85 
non-vaccinated sentinel pigs, there was no PCV2 DNA detected in the weaning pools (0/17 
pools; Table 5.5).  In contrast, PCV2 nucleic acid was detected in pooled samples at each 3 
subsequent sampling ages (4.9 to 6.3 wk of age: 1/17 pools; 7.9 to 9.3 wk of age: 6/16 pools; and 
10.9 to 12.3 wk of age: 12/16 pools).  Genotype was reported for each pool.  There was PCV2a 
detected in all but 1 pool (4.9 to 6.3 wk of age: 1/17 pools; 7.9 to 9.3 wk of age: 6/16 pools; and 
10.9 to 12.3 wk of age: 11/16 pools).  However, PCV2b was not detected in any of the pools 
until 10.9 to 12.3 wk of age (2/16 pools).   
Phase 5: 
Environmental swabbing and testing by PCV2 PCR (Figure 5.5) detected PCV2 DNA in 
samples from 8 commercial nursery and 8 commercial finisher barns.  In contrast, the presence 
of PCV2 DNA was not detected by PCV2 PCR testing of environmental swab samples from the 
KSU farm. 
Discussion 
Porcine circovirus disease is considered to be a leading viral disease in the swine industry 
(Opriessnig et al., 2009).  Circovirus vaccines are available as an aid for prevention of viremia 
but these vaccines are costly to production systems.  In addition, concern that the field viral 
strains may mutate thereby reducing the effectiveness of vaccines demands consideration of 
other options such as PCV2 elimination.   
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This was a first study to evaluate the effects of circovirus vaccination on viral circulation 
at the herd level.  Determining whether vaccination could be used as a tool in viral elimination 
efforts was a focus for our study because it was known that vaccination against PCV2 reduced 
viremia (Fachinger et al., 2008) and viral shedding (Fort et al., 2009).  Our study was designed to 
begin to evaluate the hypothesis that circovirus vaccination programs in herds would affect 
viremia and subsequent viral shedding into the environment.  Over time, a reduction in 
environmental contamination coupled with continued use of circovirus vaccine to build 
immunity in growing pigs prior to viral exposure, would aid derivation of PCV2-free herds.   
The MSU and KSU herds and management served as models for commercial multi-site 
swine production systems.  Based on the Phase 1 baseline testing, PCV2 was detected in both 
swine populations though viremia was not increased until after the nursery period.  This provided 
evidence for primarily horizontal rather than vertical transmission.  Both herds had PCV2-
viremic pigs during finishing and had evidence that pigs likely seroconverted after the 
documented time for onset of viremia (Figures 5.1, 5.2, 5.3, and 5.4).   
Although both farms had viral circulation evident during finishing, the MSU pigs 
experienced an earlier onset of viremia than the KSU pigs.  Both herds were considered good 
models in which to monitor the effects of circovirus vaccination long-term because baseline 
results from both non-vaccinated populations indicated viral presence and seroconversion-
supporting antibody profiles. 
Circovirus vaccination programs were started in each herd in the spring of 2007 and 
monitoring of barrows from each farrowing group began.  Barrows were selected for monitoring 
because some reports have indicated that barrows were at increased risk for development of 
disease (Corrégé et al., 2001; Rodríguez-Arrioja et al., 2002).  In the MSU herd, viremia was not 
detected in serum collected at any sampling point from circovirus-vaccinated barrows (Table 
5.1).  During the same time, there were no reports of clinical PCVD from the farm.  Still, it is 
possible that some pigs may have become transiently viremic between sampling points.  In a 
study under field conditions, compared with non-vaccinated control pigs, circovirus vaccination 
reduced (P < 0.001) average duration of viremia by almost 50% (non-vaccinated control pigs: 
34.3 d vs. vaccinated pigs: 17.4 d) (Fachinger et al., 2008).  However, the MSU farm baseline 
testing indicated onset of viremia early in the finishing phase and infection appeared to be 
detectable in a portion of the population throughout finishing.  Thus, the MSU vaccinated pig 
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PCR data demonstrates that vaccination appeared to have an effect on the viral circulation within 
this farm by either shortening the duration of viremia or preventing it altogether. 
In the KSU herd, there were 3 groups which had at least 1 pig with detectable PCV2 
DNA in the serum.  These groups (3, 5, and 6; Table 5.2) were not consecutive groups, nor were 
the ages at the time of detectable viremia consistent among groups.  In addition, there was only 1 
group with pigs testing positive for PCV2 at more than 1 sampling point.  Although the viral load 
levels between sampling points were not known, the PCV2 viral loads detected in the positive 
serum samples among the 4 bleeding times were 379 template copies per reaction or less.  The 
biologic significance of these numbers is not yet known: however, viral burden has been 
positively correlated with histologic lesion severity in non-vaccinated and PCV2-challenged pigs 
(Krakowka et al., 2005).  In our study, none of the viremic vaccinated pigs or their group-mates 
had been identified as being PCVD-suspects.  Evidence of PCV2-problems was restricted to 
PCR detection of transient viremia.  Though PCV2 was intermittently detected among 
vaccinated pigs, because there were no naïve pigs in the population the virus was not able to 
transmit readily, propagate within groups, and establish widespread infection within the herd.  
Therefore, these KSU herd results indicate immunization by circovirus vaccination affected viral 
circulation by controlling the spread of virus and shortening the duration of viremia or by 
preventing the infection entirely. 
The follow-up study (Phase 3) was performed at the KSU farm to verify circovirus 
vaccination had affected within-in farm viral circulation patterns and to determine the farm’s 
new PCV2-status.  Results indicate a change in the herd PCV2 antibody profile.  Pigs for this 
follow-up study were born primarily from dams that were vaccinated against circovirus as 
weaned pigs; however, gilts or sows were not vaccinated against circovirus prior to breeding or 
during gestation.  Whereas before vaccine introduction into the herd, pigs had antibody decay 
until mid-finishing followed by high levels of antibody in late-finishing, the pattern after 2 years 
of continuous vaccination was different.  Antibody levels at the time of weaning were similar 
and low for pigs assigned to the control or vaccinated treatments (Table 5.3).  After vaccination, 
vaccinated pigs had a rise in antibody by the beginning of the finishing period which then 
decreased throughout finishing.  In contrast, control pigs had decay in antibody levels through 
the beginning of finishing and never had a rise in antibody levels.  The lack of antibody rise 
suggests that control pigs were not exposed to the PCV2 virus during the time period for 
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sampling.  Residual PCV2 virus shed from previous infected pigs and present in the environment 
did not appear to stimulate an immune response in these control pigs, nor did it appear that there 
was exposure to PCV2 virus transmitted from vaccinated but infected pigs within the groups.  
These follow-up KSU results indicate that the virus had either been eliminated from the herd and 
farm facilities, or had fallen below a threshold which could trigger stimulation of the immune 
system. 
Growth rate had been previously used as an indicator of disease and therefore was 
included as a response for this study.  Previous field studies with natural PCV2-challenge 
indicated that pigs vaccinated against PCV2 had improved overall growth rates compared with 
non-vaccinated control pigs with the largest improvements in ADG detected during finishing 
(Fachinger et al., 2008; Horlen et al., 2008; Jacela et al., 2011).  Although usually beneficial for 
finishing performance, some studies have demonstrated negative effects on nursery pig growth 
performance with vaccination programs involving the 2-dose circovirus vaccine (Potter et al., 
2009; Shelton et al., 2009; Vilaca et al., 2010). 
In our study, circovirus vaccination negatively affected growth rate during the nursery 
and grower periods (Table 5.4).  This resulted in vaccinated pigs being 1.2 kg lighter than non-
vaccinated control pigs at the beginning of the finishing period.  These results are consistent with 
other work which indicated that pigs vaccinated with the 2-dose circovirus vaccine (Circumvent 
PCV) have reduced growth rates after vaccination compared with either non-vaccinated control 
pigs or pigs vaccinated with the 1-dose circovirus vaccine (CircoFLEX; Boehringer Ingelheim 
Vetmedica, Inc., St. Joseph, MO) (Potter et al., 2009).   
During the finisher phase and for the overall study, vaccinated pigs had numerically 
reduced ADG compared with control pigs.  At the time pigs were taken off test, compared with 
vaccinated pigs, control pigs had a 2.0 kg numeric weight advantage.  However, the lack of 
positive growth rate response due to vaccination may be explainable by low or no natural PCV2 
challenge in the KSU herd.  We believe that the level of PCV2 viral exposure had been reduced 
or eliminated on this farm due to the circovirus vaccination program and the management 
practices used during the previous 2 years.  However, other researchers have found that under 
conditions where there was a natural PCV2 challenge, vaccination improved finishing pig 
performance compared with that of non-vaccinates (Horlen et al., 2008; Jacela et al., 2011).   
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In our study, during finishing, vaccinated pigs did not demonstrate greater ADG 
compared with non-vaccinated control pigs.  Vaccinated pigs were not able to compensate for or 
overcome the negative effects of vaccination in the nursery. Thus, the immunity built in the 
nursery and grower period did not provide any benefit during finishing as PCV2 was not present 
as a challenge to the immune system of the pigs. Therefore, the lack of serologic evidence for 
PCV2 exposure coupled with the tendency for vaccinated pigs to have poorer overall growth 
performance than control pigs suggests that PCV2 was not a pathogenic threat for growing pigs 
in the KSU herd during the follow-up testing.   
The results which indicated that PCV2 was no longer an apparent natural challenge for 
pigs in the KSU farm could not be replicated in a commercial farm in Kansas despite both farms 
having implemented long-term circovirus vaccination programs.  At the time the data were 
collected, the commercial farm had been continuously vaccinating pigs for a 1 year—slightly 
less time than the KSU farm.  Clinical disease had been decreased during the time when the 
vaccine was being used in the commercial herd.  The commercial farm moved pigs all-in, all-out 
from their nursery and finisher rooms and used a similar disinfectant to that of the KSU farm. 
However, the period of down-time between batches of pigs for cleaning and disinfection of 
rooms was longer at the KSU farm compared to the commercial farm.   
In the commercial farm, the non-vaccinated pigs did become viremic after movement into 
the nursery (Table 5.5) and exhibited clinical signs of PCVD.  The clinical disease in these pigs 
was apparent even though they constituted a relatively low percentage of the population and herd 
immunity did not appear to prevent propagation of the infection. Therefore, the belief that 
housing environment contributed a significant source of PCV2 virus in this population led us to 
perform the environmental evaluation. We acknowledge that pig-to-pig transmission from 
viremic pigs could also play a role in the dynamics of the infection. However, we believe this 
was less likely. At each time point, more serum pools had detectable DNA, which indicated that 
more pigs were becoming infected.  In addition, PCV2a was first detected followed by PCV2b, 
thus over time, the infection profile also changed.  Whether this differential pattern has biologic 
significance is yet to be determined. 
To understand why non-vaccinated pig results differed between the KSU herd and the 
commercial farm, it was important to identify sources of viral exposure.  Seemingly pigs at both 
farms were being weaned free of PCV2 implicating PCV2 in the environment as a primary 
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source of exposure.  Swabs were collected in all nursery and finishing rooms at the commercial 
farm.  Nursery and finishing rooms at the KSU farm which had housed study pigs at some point 
through the 3 year study were also sampled.  Though PCR detection of PCV2 nucleic acid does 
not provide any information about whether the viral material is infectious, it does allow 
measurement of environmental viral loads which could potentially contain infectious material.   
In the commercial facility, PCV2 DNA was found in every room and barn.  In contrast, at 
the KSU farm, PCV2 nucleic acid was not detected in either the nursery or finishing facility.  
Although the infectivity status of the PCV2 DNA detected at the commercial site was not known, 
any residual infectious material present in the environment could explain why non-vaccinated 
pigs placed in this facility became viremic shortly after movement into the facility.  Complete 
inactivation of PCV2 was difficult by disinfection under laboratory conditions (Royer et al., 
2001).  Therefore, in our study, with viral material detected in the environment, it was likely that 
some infectious virus remained.  To our knowledge, this was the first report of detection of 
PCV2 DNA in the environment of swine barns.   
This was the also first report which has documented presence of PCV2 in the 
environment of a facility where non-vaccinated sentinel pigs became viremic.  In contrast, at the 
KSU farm where presence of PCV2 was not detected in the environment, non-vaccinated pigs 
were not exposed to the virus.  Further investigation of this environmental virus-based route of 
transmission is warranted to determine the importance of this potential risk. 
In conclusion, results from this 3 year investigation indicate that circovirus vaccination 
did affect viral circulation in swine herds.  Success in lowering levels or eliminating the virus as 
a pathogenic threat was achieved at a university research herd.  However, under commercial 
conditions, there appeared to be other exposure risk factors, such as residual PCV2 in the 
environment, which inhibited viral elimination efforts.  Therefore, circovirus vaccination 
provides a tool to affect viral circulation on farms but must be used in conjunction with other 
management practices to address additional exposure risk factors in order to eliminate the PCV2 
virus from most swine populations. 
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Figure 5.1 Characterization of the porcine circovirus type 2 (PCV2) antibody profile of the 
Michigan State University (MSU) Swine Teaching and Research Center herd prior to 
implementation of a circovirus vaccination program. 
At the MSU farm, a total of 101 pigs were sampled across 5 growing pig populations (6 
to 10, 11 to 15, 16 to 20, 21 to 25, and 26 to 30 wk of age) using a cross-sectional design.  Serum 
samples from individual pigs were tested by the Kansas State Veterinary Diagnostic Laboratory 
PCV2 indirect fluorescent antibody (IFA) assay for detection of PCV2 antibodies.  All IFA titers 
were log2 transformed to approximate a normal distribution prior to descriptive analysis.  
Resulting transformed means were transformed back to the original scale for presentation as 
geometric mean titers (GMT). 
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Figure 5.2 Characterization of the porcine circovirus type 2 (PCV2) infection profile of the 
Michigan State University (MSU) Swine Teaching and Research Center herd prior to 
implementation of a circovirus vaccination program. 
Serum was pooled (MSU: 21 pools) within age group and analyzed using the Kansas 
State Veterinary Diagnostic Laboratory (KSVDL) PCV2 polymerase chain reaction assay for 
detection of PCV2 nucleic acid.  Pooled results were log10 transformed and transformed results 
were averaged within age ranges to characterize patterns for viral load. 
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Figure 5.3 Characterization of the porcine circovirus type 2 (PCV2) antibody profile of the 
Kansas State University (KSU) Swine Teaching and Research Center herd prior to 
implementation of a circovirus vaccination program. 
At the KSU farm, a total of 141 pigs were sampled across 5 growing pig populations (4, 
9, 14, 19, and 24 wk of age) using a cross-sectional design.  Serum samples from individual pigs 
were tested by the Kansas State Veterinary Diagnostic Laboratory PCV2 indirect fluorescent 
antibody (IFA) assay for detection of PCV2 antibodies.  All IFA titers were log2 transformed to 
approximate a normal distribution prior to descriptive analysis.  Resulting transformed means 
were transformed back to the original scale for presentation as geometric mean titers (GMT). 
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Figure 5.4 Characterization of the porcine circovirus type 2 (PCV2) infection profile of the 
Kansas State University (KSU) Swine Teaching and Research Center herd prior to 
implementation of a circovirus vaccination program. 
Serum was pooled (KSU: 27 pools) within age group and analyzed using the Kansas 
State Veterinary Diagnostic Laboratory PCV2 polymerase chain reaction assay for detection of 
PCV2 nucleic acid.  Pooled results were log10 transformed and transformed results were 
averaged within age ranges to characterize patterns for viral load. 
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Figure 5.5 Detection of porcine circovirus type 2 (PCV2) nucleic acid in the environment of 
nursery and finisher facilities at the Kansas State University (KSU) Swine Teaching and 
Research Center and a commercial farm. 
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Note.  Porcine circovirus type 2 (PCV2) polymerase chain reaction (PCR) results for 
environmental swabs of Farm A (KSU farm) and Farm B (commercial farm) nursery and finisher 
locations. Cycle time (Ct) values are reported as 0.0 (no PCV2 DNA detected) or greater than 0.0 
(PCV2 DNA detected) with the lower positive Ct values indicative of more PCV2 viral DNA. 
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Table 5.1 Detection of porcine circovirus type 2 (PCV2) nucleic acid in serum samples 
serially-collected from barrows across 9 consecutive weaning groups enrolled in a post-
circovirus-vaccination implementation monitoring program at the Michigan State 
University Swine Teaching and Research Center
1
 
    Sampling
2
 
Item 
Pigs, 
no.
3
 
d 0  
(wean 
wk) 
Entry-to-
finishing 
Mid-
finishing 
End-of-
finishing 
Group 1 10 
    Interval, wk
4
 
 
--- 6.1 14.0 17.1 
PCV2 DNA detected
5
 
 
no no no no 
Group 2 9 
    Interval, wk
4
 
 
--- 7.1 15.1 18.0 
PCV2 DNA detected
5
 
 
no no no no 
Group 3 9 
    Interval, wk
4
 
 
--- 5.9 12.0 18.0 
PCV2 DNA detected
5
 
 
no no no no 
Group 4 9 
    Interval, wk
4
 
 
--- 7.0 13.0 18.1 
PCV2 DNA detected
5
 
 
no no no no 
Group 5 11 
    Interval, wk
4
 
 
--- 5.9 12.9 16.9 
PCV2 DNA detected  
 
no no no no 
Group 6 10 
    Interval, wk
4
 
 
--- 6.0 11.1 18.0 
PCV2 DNA detected
5
 
 
no no no no 
Group 7 10 
    Interval, wk
4
 
 
--- 8.1 15.0 20.0 
PCV2 DNA detected
5
 
 
no no no no 
Group 8 9 
    Interval, wk
4
 
 
--- 6.3 13.1 18.0 
PCV2 DNA detected
5
 
 
no no no no 
Group 9 9 
    Interval, wk
4
 
 
--- 6.0 13.0 18.0 
PCV2 DNA detected
5
   no no no no 
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1
 A total of 86 barrows (4 samples per barrow) were serially-bled and serum was analyzed by 
polymerase chain reaction (PCR) for detectable PCV2 DNA.  All pigs were vaccinated 
intramuscularly with 2 doses (2 mL per dose) of Circumvent PCV (Intervet/Schering-Plough 
Animal Health, Millsboro, DE) after the d 0 blood sample was collected (during the wk of 
weaning). 
2
 Sampling points were during wean wk (d 0; single pre-vaccination serum sample), after entry 
to the finisher, during mid-finishing, and at the end of the finishing period.   
3
 An average of 12 barrows were randomly selected across 9 consecutive farrowing groups, ear-
tagged, and monitored for their lifetime.  Serum samples from barrows with complete serum 
sets (4 serum samples per pig) only were tested by PCR for detectable PCV2 nucleic acid.  
Number of pigs reported in the table represents the number of pigs with complete serum sets. 
4
 Interval indicates the amount of time in wk which had elapsed since the previous sampling 
point.  The d 0 sample was collected during weaning wk. 
5
 All serum samples were individually tested by PCR for presence of PCV2 nucleic acid.  
Results are reported as yes if there was a sample with detectable PCV2 nucleic acid for the 
indicated group and sampling point, and no if there were no samples with detectable PCV2 
nucleic acid. 
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Table 5.2 Detection of porcine circovirus type 2 (PCV2) nucleic acid in serum samples 
serially-collected from barrows across 10 consecutive weaning groups enrolled in a post-
circovirus-vaccination implementation monitoring program at the Kansas State University 
Swine Teaching and Research Center
1 
    Sampling
2
 
Item 
Pigs, 
no.
3
 
d 0  
(wean 
wk) 
Entry-to-
finishing 
Mid-
finishing 
End-of-
finishing 
Group 1 11 
    Interval, wk
4
 
 
--- 8.7 15.0 21.9 
PCV2 DNA detected
5
 
 
no no no no 
Group 2 10 
    Interval, wk
4
 
 
--- 9.9 14.9 20.0 
PCV2 DNA detected
5
 
 
no no no no 
Group 3 10 
    Interval, wk
4
 
 
--- 9.3 14.4 19.1 
PCV2 DNA detected
5.6
 
 
no no yes no 
Group 4 8 
    Interval, wk
4
 
 
--- 10.1 14.9 20.0 
PCV2 DNA detected
5
 
 
no no no no 
Group 5 12 
    Interval, wk
4
 
 
--- 9.9 15.0 19.9 
PCV2 DNA detected
5.6
 
 
yes yes yes yes 
Group 6 12 
    Interval, wk
4
 
 
--- 10.3 15.3 19.8 
PCV2 DNA detected
5.6
 
 
no yes no no 
Group 7 12 
    Interval, wk
4
 
 
--- 10.2 14.0 19.5 
PCV2 DNA detected
5
 
 
no no no no 
Group 8 12 
    Interval, wk
4
 
 
--- 9.7 14.7 17.1 
PCV2 DNA detected
5
 
 
no no no no 
Group 9 12 
    Interval, wk
4
 
 
--- 9.7 15.0 19.6 
PCV2 DNA detected
5
 
 
no no no no 
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Group 10 12 
    Interval, wk
4
 
 
--- 10.3 14.9 20.3 
PCV2 DNA detected
5
   no no no no 
1
 A total of 111 barrows (4 samples per barrow) were serially-bled and serum was analyzed by 
polymerase chain reaction (PCR) for detectable PCV2 DNA.  All pigs were vaccinated 
intramuscularly with 2 doses (2 mL per dose) of Circumvent PCV (Intervet/Schering-Plough 
Animal Health, Millsboro, DE) after the d 0 blood sample was collected (during the wk of 
weaning). 
2
 Sampling points were during wean wk (d 0; single pre-vaccination serum sample), after entry 
to the finisher, during mid-finishing, and at the end of the finishing period.   
3
 An average of 12 barrows were randomly selected across 10 consecutive farrowing groups, 
ear-tagged, and monitored for their lifetime.  Serum samples from barrows with complete serum 
sets (4 serum samples per pig) only were tested by PCR for detectable PCV2 nucleic acid.  
Number of pigs reported in the table represents the number of pigs with complete serum sets. 
4
 Interval indicates the amount of time in wk which had elapsed since d 0 (day of vaccination).  
The d 0 sample was collected during weaning wk and was collected before the vaccine was 
administered. 
5
 All serum samples were individually tested by PCR for presence of PCV2 nucleic acid.  
Results are reported as yes if there was a sample with detectable PCV2 nucleic acid for the 
indicated group and sampling point, and no if there were no samples with detectable PCV2 
nucleic acid. 
6
 Viral template quantities ranged from 5 to 379 template copies per reaction across serum 
samples with detectable PCV2 nucleic acid.  Within group 5 pigs, there were 2 barrows with 
serum samples which had detectable nucleic acid at more than 1 sampling point. 
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Table 5.3 Effect of circovirus vaccination and time on indirect fluorescent antibody (IFA) geometric mean titer (GMT) in pigs 
produced at a farm which had been vaccinating growing pigs against porcine circovirus type 2 (PCV2) continuously for 2 
years
1
 
 
Treatment
2
 
  
 
Control 
 
Vaccinate 
 
Probability, P < 
Item     Time: 
d 0 
(wean 
wk) 
Entry-to-
finishing 
Mid-
finishing 
End-of-
finishing   
d 0 
(wean 
wk) 
Entry-to-
finishing 
Mid-
finishing 
End-of-
finishing   
Treatment × 
time 
Samples, no. 68 68 68 68 
 
68 66 66 66 
 
--- 
Titer, GMT
3
 35.9
a
 15.2
b
 14.8
b
 13.6
b
 
 
43.6
a
 52789.3
c
 13841.2
d
 3729.8
e
 
 
<0.001 
1
 A total of 136 barrows (68 control and 68 vaccinated pigs) across 3 farrowing groups were ear-tagged and monitored from weaning 
through finishing at the Kansas State University Swine Teaching and Research Center.  Pigs were serially-bled on d 0 (within a wk of 
weaning), after entering the finisher (time elapsed since d 0 range: 8.4 to 8.9 wk), mid-finishing (time elapsed since d 0 range: 13.4 to 
13.9 wk), and at the end of the finishing period (time elapsed since d 0 range: 18.0 to 19.4 wk).  Antibody levels against PCV2 were 
determined by IFA testing on individual serum samples.  Individual pig IFA titer data were log3 transformed and were analyzed by 
repeated measures analysis using the GLIMMIX procedure in SAS version 9.1.3 (SAS Institute, Inc., Cary, NC).  Fixed effects in the 
model included treatment, time, and their interaction.  Group and IFA day were included as random effects.   
2
 Treatments were non-vaccinated control or vaccinated.  Vaccinated pigs were injected intramuscularly with 2 doses (2 mL per dose) 
of Circumvent PCV (Intervet/Schering-Plough Animal Health, Millsboro, DE) after the d 0 blood sample was collected (during the 
wk of weaning). 
3
 Geometric mean titers were calculated by taking the mean of the log3 transformed IFA titer values then converting the resulting 
transformed mean back to the original scale for presentation. 
a,b,c,d,e 
Means without a common superscript letter differ (P < 0.05). 
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Table 5.4 Effect of circovirus vaccination on growth rate of pigs produced at a farm which 
had been vaccinating growing pigs against porcine circovirus type 2 (PCV2) continuously 
for 2 years
1
 
  Treatment
2
     
Item Control Vaccinate SEM Probability, P < 
Pigs started on test, no. 186 186 --- --- 
ADG, g 
    Nursery-grower
3
 561 537 6.1 0.005 
Finisher
4
 1,095 1,083 13.1 0.30 
Overall
5
 853 838 10.6 0.07 
Weight, kg 
    d 0 6.3 6.3 0.20 0.97 
Entry-to-finishing 40.4 39.2 0.90 0.03 
End-of-finishing (off test) 119.2 117.2 2.42 0.16 
1
 A total of 372 weanling pigs (186 control and 186 vaccinated pigs) across 3 farrowing groups 
were ear-tagged and monitored from weaning through finishing at the Kansas State University 
Swine Teaching and Research Center.  Pigs were individually weighed on d 0 (within the 
weaning wk and the day of vaccination), after entering the finisher, and at the end of the 
finishing period to calculate average daily gain.  Growth and on test time data from mortalities 
and removed pigs were included in growth and period length calculations.  Individual pig 
growth data were analyzed using the GLIMMIX procedure in SAS version 9.1.3 (SAS Institute, 
Inc., Cary, NC).  The interaction with gender and treatment was determined to be non-
significant for group 3, and growth data was pooled across the genders for subsequent analysis.  
Growth data for all 3 groups was analyzed using a model which included treatment as a fixed 
effect and group as a random effect. 
2
 Treatments were non-vaccinated control or vaccinated.  Vaccinated pigs were injected 
intramuscularly with 2 doses (2 mL per dose) of Circumvent PCV (Intervet/Schering-Plough 
Animal Health, Millsboro, DE). 
3
 Nursery-grower ADG and period length include data from mortalities and removed pigs.  The 
nursery period length was not different (P = 0.15) between control (59.7 ± 1.48 d) and 
vaccinated (59.1 ± 1.48 d) pigs.
 
4
 Finisher ADG and length include data from mortalities and removed pigs.  The number of 
days for the finisher period was not different (P = 0.94) between control (71.7 ± 1.13 d) and 
vaccinated (71.6 ± 1.14 d) pigs.
 
5
 Overall ADG and length include data from mortalities and removed pigs.  The number of days 
for the overall trial was not different (P = 0.96) between control (132.1 ± 2.67 d) and vaccinated 
(132.1 ± 2.67 d) pigs.
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Table 5.5 Detection of porcine circovirus type 2 (PCV2) nucleic acid in serum samples 
serially-collected from pigs not vaccinated for PCV2 in a monitoring program at a 
commercial farm
1
 
  Age, wk
2
 
Item 
1.7 to 3.1  
(wean wk) 
4.9 to 
6.3 
7.9 to 
9.3 
10.9 to 
12.3 
Pig survival, % 100.0 97.6 91.8 91.8 
Interval, wk
3
 --- 3.2 6.2 9.2 
PCV2 PCR results 
    Pools for PCR, no.
4
 17 17 16 16 
PCV2 DNA detected
5,6
 no yes yes yes 
Pools with detectable PCV2 DNA, % 0 5.9 37.5 75.0 
1
 A total of 85 pigs were serially-bled and serum was analyzed by polymerase chain reaction 
(PCR) for detectable PCV2 DNA.  Pigs were not vaccinated for PCV2 at any time during this 
monitoring period on this commercial farm. 
2
 Pigs were bled initially during the wk of weaning when pig ages ranged from 1.7 to 3.1 wk of 
age.  Pigs were serially-bled every 3 wk (on average) thereafter until pigs were 10.9 to 12.3 wk 
of age.   
3
 Interval indicates the amount of time in wk which had elapsed since the initial sampling point.  
The initial sample was collected during weaning wk. 
4
 A total of 5 serum samples were included in a single pool for testing by PCV2 PCR. 
5
 All serum samples were individually tested by PCR for presence of PCV2 nucleic acid.  
Results are reported as yes if there was a sample with detectable PCV2 nucleic acid for the 
indicated group and sampling point, and no if there were no samples with detectable PCV2 
nucleic acid. 
6
 For serum pools with PCV2 DNA detected, cycle time (Ct) values ranged from 27.7 to 40.7.  
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CHAPTER 6 - Effect of vaccination with a subunit vaccine for 
porcine reproductive and respiratory syndrome virus on mortality 
and finishing pig performance under field conditions 
Summary 
Objective(s): The objectives of this trial were to evaluate the effect of vaccination with a  
subunit porcine reproductive and respiratory syndrome virus vaccine (PRRSV-RS; Sirrah Bios, 
Ames, IA) on cumulative mortality and finishing performance of pigs under field conditions.   
 
Materials and methods: A total of 140 litters of pigs (1,561 pigs) were allotted to different 
vaccination treatments (vaccinated or non-vaccinated control) at the time of processing (4 d of 
age).  Treatment groups were formed by randomly assigning one of the vaccination treatments to 
the first litter processed at each of 5 sow farms.  Vaccination treatment assignments were then 
alternated on subsequently processed litters.  The non-vaccinated control group consisted of 780 
pigs, from a total of 70 litters, while the vaccinated group included a total of 781 pigs, also 
representing 70 litters.  Pigs assigned to the vaccinated treatment were injected with 1 mL 
PRRSV-RS vaccine intramuscularly at processing (4 d of age) and again at weaning 
(approximately 24 d of age).  Mortality was recorded from the day of processing through 
finishing.  Pigs were weaned into a common nursery and control and vaccinated pigs were 
comingled within pens.  Upon movement to the finishing barn, pigs were penned by gender and 
vaccine status (25 control pig pens; 24 vaccinated pig pens).  Pigs were first weighed 2 wk after 
placement into the finishing barn (d 0) and approximately every two weeks until d 112 (off-test).  
On d 90, 168 heavy pigs (84 control pigs and 84 vaccinated pigs) were weighed, taken off test, 
and sold as top pigs.  Mortality data were analyzed using chi-square analysis while growth data 
were analyzed by analysis of variance using a mixed model.   
 
Results: Cumulative mortality risks (processing through nursery and overall) were not affected 
(P ≥ 0.23) by vaccination treatment.  There were no 2-way interactions (P ≥ 0.10) between 
gender and vaccination treatment for any d 0 to 112 performance responses.  Two weeks into the 
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finishing period (d 0), mean weights of control (26.5 kg) and vaccinated pigs (26.6 kg) were not 
different (P = 0.90).  Control and vaccinated pigs had similar (P ≥ 0.13) mean ADG, ADFI, and 
G:F throughout the finishing period.  Average off-test mean BW of control and vaccinated pigs 
were not different (P = 0.95).   
 
Implications: The subunit PRRSv vaccine (PRRSV-RS) used in this study failed to affect 
overall mortality or finishing growth performance of commercial pigs.   
 
Key words: growth, mortality, pig, PRRSv, vaccine 
 
Porcine reproductive and respiratory syndrome has been recognized in the United States 
since 1987 (Christianson and Joo, 1994).  This economically-destructive disease is caused by 
porcine reproductive and respiratory syndrome virus (PRRSv) a member of the family 
Arteriviridae.  Modified-live and whole virus inactivated PRRSv vaccine products have been 
produced for commercial use (Hill et al., 2004); however, success with these vaccines to control 
or prevent PRRSv infection has been limited.  Modified live vaccines tended to reduce lesions 
and clinical signs when used with a homologous virus strain; however, with heterologous PRRSv 
strains the vaccines were less effective (Labarque et al., 2003).  In general, inactivated PRRSv 
vaccines work poorly in naïve animals; yet, they may have a functional role in boosting antibody 
titers (Hill et al., 2004).  Porcine reproductive and respiratory syndrome virus strains can mutate 
(Chang et al., 2002) which, combined with the capability of the virus to evade some immune 
functions (Pol and Steverink, 2000), has challenged vaccine development.  To date a consistently 
effective vaccine has not been identified.  In addition, the attenuated vaccine virus from 
modified-live PRRSv vaccines is shed after vaccine administration and can transmit to 
unvaccinated pigs (Botner et al., 1997; Nielsen et al., 2001). With vaccine virus being shed, there 
is concern that further transmission of the PRRSv vaccine virus may increase the potential for 
reversion to a more virulent viral form (Opriessnig et al., 2002).  
Subunit vaccines, a class of second generation vaccines which are developed using 
specific viral proteins, have been effective for prevention of other diseases such as porcine 
circovirus disease (Fachinger et al., 2008; Horlen et al., 2008).  Subunit products have some 
properties desirable in a vaccine.  Made from specific proteins, no vaccine virus is shed after 
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administration.  Subunit vaccines also allow the development of differential diagnostic tests 
which, based on antibody detection, characterize origins of antigen as either field virus or 
vaccine.  In 2008, a subunit PRRSv vaccine, PRRSV-RS (Sirrah-Bios, Ames, IA), was made 
available in Kansas for use on sows or growing pigs.  There were limited data demonstrating 
subunit PRRSv vaccine efficacy under field conditions. Thus, the objectives of this trial were to 
evaluate the effects of a subunit PRRSv vaccine (PRRSV-RS) vaccine on cumulative mortality, 
growth performance, and feed efficiency of commercial finisher pigs.  
Materials and Methods 
Procedures used in this study were approved by the Kansas State University Institutional 
Animal Care and Use Committee.  The study was performed in a commercial multi-site 
production system in Kansas.  Pigs were born over a 7 d period at 5 sow farms, weaned into a 
single nursery, and then moved to a commercial research finishing barn in northeast Kansas. 
A total of 140 litters (1,561 pigs) were allotted to different vaccination treatments 
(vaccinated or non-vaccinated control) at the time of processing (4 d of age).  Treatment groups 
were formed by randomly assigning the first litter processed at each of 5 sow farms to one of the 
vaccination treatments and then alternating treatment assignments on subsequently processed 
litters until each treatment was composed of pigs from 70 litters.  At the time of processing, all 
pigs were ear-tagged with a unique colored ear-tag identifying the treatment assignment.  After 
pigs were individually tagged, litter of origin records were not maintained.  A total of 780 pigs 
were assigned to the non-vaccinated control treatment while 781 pigs were assigned to the 
vaccinated treatment.  Pigs assigned to the vaccinated treatment were injected with 1 mL PRRSv 
vaccine (PRRSV-RS; Sirrah Bios, Ames, IA) intramuscularly at processing (4 d of age) and 
again at weaning (approximately 24 d of age; range: 20 to 26 d of age).  Control pigs were not 
injected at processing or weaning. 
In general, mortality was calculated by subtracting ending inventories from beginning 
inventories for specific periods.  Mortality totals were verified by counting ear tags collected 
from pigs that died or were humanely euthanized in accordance with farm criteria for euthanasia.  
Within-period mortality was determined for the periods of processing to weaning, weaning to the 
end of the nursery, and throughout the finishing period until pigs were taken off test.  Cumulative 
mortality was calculated by determining the number of pigs from each vaccination treatment 
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surviving at the end of the study and subtracting this value from the initial number of pigs 
assigned to each treatment. 
Pigs from all 5 sow farms were weaned into a single nursery room and were phase-fed 
similar diets within phase throughout the nursery period.  All pigs were allowed to have ad 
libitum access to feed and water throughout the trial.  Pigs were penned in single-sex (barrow or 
gilt) pens with control and vaccinated pigs commingled within each nursery pen.  All pigs were 
vaccinated with a 2-dose commercial circovirus vaccine (Circumvent PCV, Intervet/Schering-
Plough Animal Health, Millsboro, DE) and a Mycoplasma hyopneumoniae vaccine (Myco 
Silencer ONCE, Intervet/Schering-Plough Animal Health, Millsboro, DE) during the nursery 
period according to routine nursery procedures.   
Pigs (age range: 60 to 66 d of age) were moved to a single curtain-sided finisher barn 
equipped with a dual-nipple swinging drinker (Trojan Plastic Waterswing; Trojan Specialty 
Products, Dodge City, KS) and a single-sided, dry, 3-hole, stainless-steel feeders (AP-3WFS-
QA; Automated Production Systems, Assumption, IL) in each pen.  Feeder holes were 35.6 cm 
wide.  There were 49 test pens which were 3.0 m × 5.5 m.  The barn was equipped with an 
automated feeding system (FeedPro; FeedLogic Corp., Willmar, MN) that recorded feed delivery 
to each individual pen feeder.  All pigs were allowed to have ad libitum access to feed and water 
throughout the finishing period.   
All test pigs were moved from the nursery to the finishing barn on a single day.  While 
control and vaccinated pigs had been comingled within pens during the nursery phase, after 
being moved to the finishing barn, pigs were penned based on vaccination treatment (vaccinated 
or non-vaccinated control) and gender (barrow or gilt).  Treatments were randomly assigned to 
pens.  There were 12 pens of each treatment and gender combination with the exception of 
vaccinated barrows, for which there were 13 pens.   
Pigs were weighed by pen and feed intake was recorded on d 0 (2 wk after placement into 
the finishing barn), and again on d 14, 28, 41, 56, 70, 90, and either d 111 or 112.  From these 
data, ADG, ADFI, and G:F were calculated.  According to routine farm procedures, on d 90, a 
total of 168 of the heaviest pigs (84 control pigs and 84 vaccinated pigs) were weighed, taken off 
test, and sold as top pigs.  Data from these heavy pigs were included all calculations.  Remaining 
pigs were taken off test over 2 consecutive days with the last pigs being weighed off test on d 
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112.  A total of 24 pens (6 pens per gender and vaccination treatment) were weighed off test on 
the first day with the remaining pens weighed off test on the second day. 
Analysis:  
Mortality data were analyzed using the FREQ procedure in SAS version 9.1.3 (SAS 
Institute Inc., Cary, NC).  Differences in mortality between treatments were determined using 
chi-square analysis (P < 0.05). Mortality data both within production period (processing to 
weaning, nursery, and finisher) and cumulatively were analyzed.  
Finisher growth and feed performance data were analyzed as a completely randomized 
design using the GLIMMIX procedure of SAS version 9.1.3.  Pen was the experimental unit for 
all performance data analysis.  Vaccination treatment was the fixed effect of interest; however, 
gender and the interaction between vaccination treatment and gender were added to the model to 
control for expected differences in growth rate between barrows and gilts.  Differences between 
treatments were determined by using least squares means (P < 0.05).   
Results 
Mortality results: 
From processing (4 d of age) until weaning, there was a trend for control pigs to have 
increased (P = 0.08; Table 6.1) mortality compared with vaccinated pigs.  There was no 
difference (P ≥ 0.20) observed for mortality risks between control and vaccinated pigs during the 
nursery or finishing periods.  Cumulative mortality from processing through the end of the 
nursery period was similar (P = 0.23) for controls and vaccinates.  In addition, cumulative 
mortality from processing through off-test did not differ (P = 0.67) due to vaccination treatment.   
Growth results: 
There were no 2-way interactions (P ≥ 0.10) observed between gender and treatment for 
any of the d 0 to 112 performance responses.   
On d 0, the mean initial BW for barrows and gilts were similar (P = 0.67; Table 6.2).  As 
expected, barrows had increased (P < 0.001) overall mean ADG and ADFI and poorer (P < 
0.001) G:F than gilts.  Mean off-test BW of barrows was 6.2 kg heavier (P < 0.001) than gilts. 
Mean initial BW on d 0 were not different (P = 0.90; Table 6.3) for control and 
vaccinated pigs.  Mean growth rate, ADFI, and G:F during finishing (d 0 to 112) did not differ (P 
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> 0.13) between vaccination treatments.  There was no difference (P = 0.95) in mean off-test BW 
of control and vaccinated pigs. 
Discussion 
Control of PRRSv has been a challenge to the swine industry.  Safe and effective 
vaccines which cross-protect against multiple PRRSv strains are needed to help control the 
problem.  Commercial vaccines are available; however, to date a safe, proven vaccine which 
cross protects against multiple strains of PRRSv has not been identified. A PRRSv subunit 
vaccine (PRRSV-RS; Sirrah-Bios, Ames, IA) was recently developed for use on growing pigs or 
sows.  The PRRSV-RS subunit vaccine has some characteristics, including differential potential, 
which would be appealing for use in a vaccination program focused on PRRSv elimination.  
Subunit vaccines are formed by using specific viral proteins to target an immune 
response. Typically, these proteins are expressed using a vector that can support expression of a 
portion of viral immunogenic proteins (Levine and Sztein, 2004).  Thus, like a whole virus 
inactivated vaccine product, a subunit vaccine will not propagate or revert to virulence.  
However, unlike a whole virus inactivated vaccine which would contain whole viral components, 
subunit vaccines are created from proteins of specific viral genes.  Diagnostic tests to 
differentiate a vaccinated from a non-vaccinated but infected animal can be developed for use 
with subunit vaccines.  Not all viral genes expressing immunogenic proteins are used in the 
production of a subunit vaccine, allowing a non-vaccinated but infected animal to produce an 
immune response against a greater number of proteins than were included in the subunit vaccine.  
Therefore, testing for antibodies against different vaccine and field-virus-only expressed proteins 
would determine whether an animal had mounted an immune response only to the vaccine or the 
field virus. However, an animal which was vaccinated and then exposed to a field virus would 
have antibodies against both antigens and not be able to be classified as vaccinated by the 
differential test alone. 
The PRRSV-RS vaccine was developed using 2 PRRSv structural proteins in heterodimer 
form.  This heterodimer form consists of the proteins linked by a disulfide bond (Mardassi et al., 
1996).  These proteins, glycoprotein 5 and the matrix protein, were those encoded by open 
reading frames 5, a highly variable region, and open reading frame 6, a more conserved region 
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among PRRSv strains (Dea et al., 2000).  Both proteins were expressed using a replicon vector 
prior to combination with the adjuvant.   
In a mouse model a heterodimer of specific proteins promoted development of 
neutralizing antibodies against equine arteritis virus (Balasuriya et al., 2000), also a member of 
the family Arteriviridae.  Using horses in a second study, Balasuriya et al. (2002) evaluated 
subunit vaccines produced with a recombinant alphavirus, a vaccine strain of Venezuelan equine 
encephalitis, and compared responses in vaccinated horses with those from non-vaccinated 
horses.  Vaccines used in this challenge study were derived of replicons expressing either 
individual equine arteritis virus proteins or the heterodimer of proteins.  Horses vaccinated with 
the expressed heterodimer of proteins developed neutralizing antibodies, had a shorter duration 
shedding, and showed fewer clinical signs of disease than the other horses (Balasuriya et al., 
2002).  For reasons previously described, it has been suggested that the GP5-M heterodimer, a 
combination of proteins from both variable and conserved gene regions, may induce neutralizing 
antibodies against PRRSv infection in the pig which also may be cross-protective.   
The herd used for this trial historically has pigs exposed to the PRRSv and clinical 
disease during the nursery period.  In our study, during the nursery period there was no 
difference in mortality.  It was during this period that the pigs on our study exhibited clinical 
signs consistent with both PRRSv and influenza. Serum was collected from different nursery 
pigs from the same herd during the time our trial was in progress.  Diagnostic testing performed 
at the Kansas State Veterinary Diagnostic Laboratory confirmed presence of PRRSv by 
polymerase chain reaction and PRRSv antibodies by enzyme-linked immunosorbent assay.  In 
our study, total of 9.3% of the control pigs and 9.2% of the vaccinated pigs which entered the 
nursery died during the nursery period.  Therefore, the vaccine failed to affect on mortality 
during the period when control of PRRSV infection was most needed.   
Once pigs were placed in the finishing barn, there was no difference in finishing 
mortality between control pigs (4.4%) and vaccinated pigs (5.9%).  Overall, from processing 
through finishing, there was no difference in mortality between the vaccination treatments 
(control pigs: 21.5% vs. vaccinated pigs: 20.6%).  Although diagnostics were not performed on 
trial pigs to detect viremia with PRRSv or seroconversion, pigs did exhibit clinical signs and 
have overall mortality consistent with other confirmed PRRSV-positive groups in this system.   
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Two weeks after entry into the finishing barn, there was no difference in mean pig 
weights between control and vaccinated pigs.  Therefore, if control and vaccinated pigs weighed 
similarly at 4 days of age, vaccination treatment likely did not affect growth rate before the 
finishing period.  During the 112-d finishing trial, there were no differences in ADG, ADFI, or 
G:F.  These results indicate the PRRSV-RS vaccine did not affect performance of finishing pigs.  
Mean off-test weight between controls and vaccinates was similar.  Thus, the PRRSV-RS 
vaccine failed to affect mortality, pig performance, or mean off-test weight. 
Although use of the vaccine did not result in improved pig performance, it also did not 
negatively affect performance.  Some research has indicated that a number of vaccines, with 
representation from subunit, inactivated, and modified-live vaccine types, can negatively impact 
performance after administration (Kane et al., 2009; Potter et al., 2009; Pretzer et al., 1996; 
Shelton et al., 2009).  In a field study, nursery pig growth rate and feed intake was decreased 
compared with non-vaccinated controls following vaccination with a 2-dose circovirus vaccine 
(vaccinated on d 1 and 22 of the study).  All pigs were inoculated on d 30 of the study with a live 
PRRRS virus just 8 d after administration of the second dose of circovirus vaccine.  In the period 
following inoculation (d 29 to 50), feed efficiency was improved and growth rate tended to be 
increased in the circovirus-vaccinated pigs compared with the non-vaccinated pigs.  In addition, 
the percentage of pigs that were able to remain on test was improved for pigs vaccinated against 
circovirus (Shelton et al., 2009).  In our study, all pigs had been vaccinated against circovirus 
during the nursery period.  It was not determined whether the circovirus vaccination had any 
effect on disease presentation during our study, though the pigs still appeared to exhibit clinical 
signs consistent with both PRRSv and influenza.  Despite vaccination with the PRRSV-RS 
having no positive effects on performance or mortality percentages, there also appeared to be no 
additional cost associated with loss of performance with use of this vaccine.  Thus, the total cost 
of vaccination would be due to product, labor, and supply expenses. 
Therefore, in this herd, which had historical PRRSv-associated challenge, the subunit 
PRRSv vaccine (PRRSV-RS) failed to affect overall mortality or finishing pig performance. 
Implications 
 There were no differences between control and vaccinated pig mortality during any 
production phase or for cumulative mortality. 
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 Control and vaccinated pigs had similar mean ADG, ADFI, G:F, and off-test weights. 
 The subunit PRRSv vaccine administered to growing pigs failed to affect mortality or 
finisher pig performance in this commercial herd. 
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Table 6.1 Effect of PRRSV-RS vaccine on within-period and cumulative mortality
1,2
 
Item Control Vaccinate Probability, P < 
Inventory 
   
Processing
3
 781 780 --- 
Weaning
4
 707 725 --- 
Entry-to-finisher
5
 641 658 --- 
Off-test
6,7
 529 535 --- 
Within-period mortality 
   Processing to weaning, % 9.5 7.1 0.08 
Nursery, % 9.3 9.2 0.95 
Finisher, % 4.4 5.9 0.20 
Cumulative mortality 
   Processing to end-of-nursery, % 17.9 15.6 0.23 
Processing to off-test, %
6
 21.5 20.6 0.67 
1 
A total of 1,561 pigs (barrows or gilts) from 140 litters across 5 sow farms were assigned to 
vaccination treatments at processing (4 d of age) by randomly assigning entire litters to either a 
vaccinated treatment or a non-vaccinated control treatment. Control and vaccinated pigs were 
comingled in the nursery and then separated by vaccination treatment and gender in the 
finishing barn. Mortality was tracked for controls and vaccinates from processing to the end of 
the finishing portion of the trial. 
2 
Vaccination treatments were: Non-vaccinated (control) or vaccinated (vaccinate).  Vaccinated 
pigs were injected intramuscularly with a 2-dose (1 mL per dose) porcine reproductive and 
respiratory syndrome virus subunit vaccine (PRRSV-RS; Sirrah-Bios, Ames, IA) at processing 
and weaning.  
3 
4 d of age.  
4 
Weaning age range was 20 to 26 d of age. 
5 
Entry-to-finisher age range was 60 to 66 d of age. 
6 
Off-test age range was 187 to 193 d of age. 
7 
Inventory at off-test excludes pigs sold as top pigs (84 controls and 84 vaccinates) on d 90 of 
the trial. 
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Table 6.2 Means and standard errors for growth performance responses for barrows and 
gilts
1
 
Item Barrow Gilt Probability, P < 
Initial BW on d 0, kg 26.3 ± 0.77 26.8 ± 0.79 0.67 
d 0 to 112 
   ADG, kg 0.911 ± 0.0119 0.850 ± 0.0121 < 0.001 
ADFI, kg 2.561 ± 0.0361 2.297 ± 0.0368 < 0.001 
G:F 0.356 ± 0.0026 0.370 ± 0.0027 < 0.001 
Mean off-test BW, kg 129.9 ± 1.06 123.7 ± 1.08 < 0.001 
Note. Results are reported as least squares mean ± standard error of the mean.
 
1 
A total of 1,561 pigs (barrows or gilts) from 140 litters across 5 sow farms were randomly 
assigned by litter to vaccination treatments at processing (4 d of age).  Barrows and gilts were 
housed in single-sex pens in the nursery with vaccinated and non-vaccinated pigs comingled 
within each pen.  In the finishing barn, pigs were separated by vaccination treatment and gender 
and a 112-d growth study was performed.  There were 24 pens of gilts and 25 pens of barrows. 
All pens of pigs (1,292 pigs total) were initially weighed 2 wk after placement in the finishing 
barn (d 0).  On d 90, a total of 168 of the heaviest pigs (83 barrows and 85 gilts) were weighed, 
taken off test, and sold as top pigs.  Data from these heaviest pigs were included in pen data and 
accounted for in calculations.  Pen-level performance data were analyzed by analysis of 
variance using the GLIMMIX procedure of SAS version 9.1.3 (SAS Institute, Inc., Cary, NC).  
The model included fixed effects of vaccination treatment, gender, and their interaction.   
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Table 6.3 Means and standard errors for growth performance responses for non-
vaccinated control and vaccinated finisher pigs
1,2
 
Item Control Vaccinate Probability, P < 
Initial BW on d 0, kg 26.5 ± 0.79 26.6 ± 0.77 0.90 
d 0 to 112 
   
ADG, kg 0.887 ± 0.0121 0.874 ± 0.0119 0.44 
ADFI, kg 2.427 ± 0.0368 2.431 ± 0.0361 0.93 
G:F 0.366 ± 0.0027 0.361 ± 0.0026 0.13 
Mean off-test BW, kg 126.8 ± 1.08 126.8 ± 1.06 0.95 
Note. Results are reported as least squares mean ± standard error of the mean. 
1 
A total of 1,561 pigs (barrows or gilts) from 140 litters across 5 sow farms were assigned to 
vaccination treatments at processing (4 d of age) by randomly assigning entire litters to either a 
vaccinated treatment or a non-vaccinated control treatment. Control and vaccinated pigs were 
comingled in the nursery and then separated by vaccination treatment and gender in the 
finishing barn. Treatment pens were randomly distributed throughout the barn. There were 24 
pens of control pigs and 25 pens of vaccinated pigs. All pens of pigs (1,292 pigs total) were 
initially weighed 2 wk after placement in the finishing barn (d 0) and again every 2-wk until d 
112.  On d 90, a total of 168 of the heaviest pigs (84 control pigs and 84 vaccinated pigs) were 
weighed, taken off test, and sold as top pigs.  Data from these heaviest pigs were included in 
pen data and accounted for in calculations.  Pen-level performance data were analyzed by 
analysis of variance using the GLIMMIX procedure of SAS version 9.1.3 (SAS Institute, Inc., 
Cary, NC).  The model included fixed effects of vaccination treatment, gender, and their 
interaction.   
2 
Vaccination treatments were: Non-vaccinated (control) or vaccinated (vaccinate).  Vaccinated 
pigs were injected intramuscularly with a 2-dose (1 mL per dose) porcine reproductive and 
respiratory syndrome virus subunit vaccine (PRRSV-RS; Sirrah-Bios, Ames, IA) at processing 
and weaning.   
 
 
